Aminotriazine derivative and pharmaceutical composition comprising the same

ABSTRACT

The present invention provides novel compounds having a P2X 3  and/or P2X 2/3  receptor antagonistic activity. 
     A compound of Formula (I): 
                         
wherein R a  and R b , and R d  and R e  are taken together to form oxo or the like; R 4a  and R 4b  are hydrogen or the like; n is 1 or the like; R 2  is aryl or the like; s and s′ is 0 or the like; R 9  and R 9 ′ are halogen or the like; R 20a  and R 20b  are hydrogen, alkyl or the like; u is 1 to 4; R 13  is hydrogen or the like, or its pharmaceutically acceptable salt.

CROSS REFERENCE TO RELATED APPLICATIONS

This application is a national phase application based on PCT/JP2014/065678, filed Jun. 13, 2014, which claims the priority of Japanese Patent Application No. 2013-125134, filed Jun. 14, 2013, the content of each application being incorporated herein by reference.

TECHNICAL FIELD

The invention relates to a compound useful for the treatment of diseases or conditions associated with P2X receptor, specifically to P2X₃ and/or P2X_(2/3) receptor, and a pharmaceutical composition comprising such compound.

BACKGROUND ART

Adenosine triphosphate (ATP) is known to serve as a source of energy in cells and a substrate of phosphorylation, as well as an extracellular messenger. It is known that ATP is released from a cell by various stimulation such as cellular injury, inflammation, nociceptive stimulus, reduced blood oxygen level, and also known to be released together with another messenger from a primary sensory nerve terminal. ATP thus released mediates various extracellular signal transductions through an ATP receptor (Non-Patent Document 4, Non-Patent Document 5).

ATP receptor is categorized into ionotropic P2X family and G protein-coupled P2Y family. For P2X family, seven subtypes have been reported, and a member of this family forms a homo-trimeric structure or a hetero-trimeric structure together with another member of this subtype and functions as a non-specific cation channel (Non-Patent Document 6).

ATP is known to cause pain, and studies with P2X₃ knockout and knockdown methodologies have shown that P2X₃ receptor mediates transmission of chronic pain. P2X₃ receptors are expressed in a specific manner on peripheral sensory nerve to form a homo-complex or hetero-complex with P2X₂ (P2X_(2/3)) (Non-Patent Document 1).

Later, the compound A-317491 was reported as a specific antagonist to P2X₃ and P2X_(2/3) receptors. A-317491 is tri-substituted-N-[(1S)-1,2,3,4-tetrahydro-1-naphthalenyl]benzamide derivative represented by the formula:

(Patent Document 1). It was reported to exhibit an antagonist activity to P2X₃ and P2X_(2/3) receptors and analgesic action in neuropathic pain model and inflammatory pain model in rats (Non-Patent Document 7). This indicates that pain sensation is transmitted via P2X₃ or P2X_(2/3) receptor and that a compound having a P2X₃ or P2X_(2/3) receptor antagonistic activity is useful as an analgesic. Also, compounds that exhibit P2X₃ or P2X_(2/3) receptor antagonistic activity are described in Patent Documents 2-7.

Additionally, it was recently reported that vesical reflex was strongly reduced in P2X₃ knockout mouse (Non-Patent Document 2), suggesting that a compound having P2X₃ antagonistic activity is useful in the treatment of diseases caused by overactive bladder. Also, compounds that exhibit P2X₃ or P2X_(2/3) receptor antagonistic activity arc described, in Patent Documents 2-7.

In addition, P2X₃ receptor is expressed in neuroepithelial bodies (NEB) of the lung (Non-Patent Document 9), ATP induces cough (Non-Patent Document 10), and the like, therefore it is suggested that P2X₃ receptor participates in signal transduction in the respiratory system (Non-Patent Document 11). These reports suggest the possibility that compounds that exhibit P2X₃ receptor antagonistic activity are useful in the treatment of respiratory diseases.

Later, the compound A-317491 known as a specific antagonist to P2X₃ and P2X_(2/3) receptors was reported inhibiting an activity of afferent vagal A fiber in pulmonary diseases (Patent Document 16). Additionally, biphenyl and phenyl-pyridine derivatives were reported as a specific antagonist to P2X₃ and P2X_(2/3) receptors, and it is suggested that the biphenyl and phenyl-pyridine derivatives exhibit improving effect on respiratory diseases in asthma and lung model (Patent Document 17). Also, compounds that exhibit P2X₃ or P2X_(2/3) receptor antagonistic activity are described in Patent Documents 2-7.

Patent Documents 8, 9, 10, 11, and 15 and Non-Patent Document 14 disclose compounds having similar structure to the compounds of the present invention but they do not disclose analgesic effect and P2X₃ or P2X_(2/3) receptor antagonistic activity. Non-Patent Document 8 discloses compounds having similar structure to the compounds of the present invention and having analgesic effect, but it does not discloses P2X₃ nor P2X_(2/3) receptor antagonistic activity. Patent Document 12 and Non-Patent Documents 12 and 13 disclose compounds having P2X₃ receptor antagonistic activity but the structures are different with those of the compounds of the present invention. Patent Documents 13, 14, and 18 disclose compounds having P2X₃ or P2X_(2/3) receptor antagonistic activity with a triazine structure.

PRIOR ART Patent Document

[Patent Document 1] WO02/094767

[Patent Document 2] WO2005/095359

[Patent Document 3] U.S.2007/0037974

[Patent Document 4] U.S.2007/0049758

[Patent Document 5] U.S.2007/0049610

[Patent Document 6] U.S.2007/0049609

[Patent Document 7] U.S.2007/0049534

[Patent Document 8] JP12-072757A

[Patent Document 9] WO2006/104713

[Patent Document 10] WO2006/104715

[Patent Document 11] WO2006/102112

[Patent Document 12] WO2010/051188

[Patent Document 13] WO2010/092966

[Patent Document 14] WO2012/020749

[Patent Document 15] WO2011/017347

[Patent Document 16] WO2006/012639

[Patent Document 17] WO2010/149578

[Patent Document 18] WO2013/089212

Non-Patent Document

[Non-Patent Document 1] Neuroscientist (2005), 11, pp.345-356

[Non-Patent Document 2] J. Physiol. 567.2 (2005), pp.621-639

[Non-Patent Document 3] Expert Opin. Ther. Patens (2006), 16(8), pp.113-1127

[Non-Patent Document 4] J. Physiology (2003), 554(2), pp.301-308

[Non-Patent Document 5] J. Physiology (2003), 553(3), pp.683-694

[Non-Patent Document 6] Pflungers Arch Eur J physiol (2006), p.452, 513-537

[Non-Patent Document 7] PNAS (2002), 99(26), pp.17179-17184

[Non-Patent Document 8] Journal of Medicinal Chemistry (2008), 51(23), pp.7885-7639

[Non-Patent Document 9] Brouns et al. Am J Respir Cell Mol Biol (2000), 23, pp.52-61

[Non-Patent Document 10] Basoglu et al. Chest. (2005), 128(4), pp.1905-9

[Non-Patent Document 11] Adriaensen et al. THE ANATOMICAL RECORD PART A (2003), 270A, pp.25-40

[Non-Patent Document 12] Cantin, L.-D. et al. Bioorg. Med. Chem. Lett. (2012), 22(7), pp.2565-2571

[Non-Patent Document 13] Jahangir, A. et al. Bioorg. Med. Chem. Lett. (2009), 19, pp.1632-1635

[Non-Patent Document 14] Chemistry—A European Journal (2012), 18(5), pp.1476-1486

SUMMARY OF THE INVENTION Problems to be Solved by the Invention

The present invention provides a novel compound having a P2X₃ and/or P2X_(2/3) receptor antagonistic activity. It also provides a pharmaceutical composition having a P2X₃ and/or P2X_(2/3) receptor antagonistic activity.

Means for Solving the Problem

Through their extensive research to solve the aforementioned problems, the inventors have found novel compounds that bind specifically to P2X₃ and/or P2X_(2/3) receptor and exhibit an antagonistic activity, and novel compounds that bind specifically to P2X₃ and/or P2X_(2/3) receptor. Additionally, they have discovered pharmaceutical compositions that have P2X₃ and/or P2X_(2/3) antagonistic activity.

The compounds and pharmaceutical compositions encompassed by the present invention produced excellent results of P2X₃ receptor inhibitory effect, P2X₃ receptor inhibitory effect in the presence of rat serum albumin (hereinafter referred to as RSA) and the like. The compounds encompassed by the present invention or the pharmaceutical compositions encompassed by the present invention also produced excellent results in CYP enzyme inhibition assay, FAT assay, solubility assay, metabolic stability assay, hERG inhibitory activity assay, pharmacokinetic assay (bioavailability assay, total body clearance assay, etc.) and/or protein binding assay and the like.

This invention relates to the following (1) to (44):

-   (1) A compound of Formula (I):

wherein,

R^(a) and R^(b) are both hydrogen atoms, or R^(a) and R^(b) are taken together to form oxo, thioxo or ═N—R^(x);

R^(d) and R^(e) are both hydrogen atoms, or R^(d) and R^(e) are taken together to form oxo, thioxo or ═N—R^(y);

R^(x) and R^(y) are each independently a hydrogen atom, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkenyl, a substituted or unsubstituted non-aromatic heterocyclic group, substituted or unsubstituted aryl or substituted or unsubstituted heteroaryl;

R^(4a) is each independently a hydrogen atom or substituted or unsubstituted alkyl; R^(4b) is each independently a hydrogen atom or substituted or unsubstituted alkyl; or R^(4a) and R^(4b) attached to the same carbon atom are taken together to form oxo or thioxo;

n is an integer of 1 to 4;

R² is substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkenyl, a substituted or unsubstituted non-aromatic heterocyclic group, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl;

R⁹ is each independently halogen, hydroxy, carboxy, cyano, nitro, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted alkyloxy, substituted or unsubstituted alkenyloxy, substituted or unsubstituted alkynyloxy, substituted or unsubstituted alkylthio, substituted or unsubstituted alkenylfhio, substituted or unsubstituted alkynylthio, substituted or unsubstituted acyl, substituted or unsubstituted alkyloxycarbonyl, substituted or unsubstituted alkenyloxycarbonyl, substituted or unsubstituted alkynyloxycarbonyl, substituted or unsubstituted carbamoyl, substituted or unsubstituted amino, substituted or unsubstituted sulfamoyl, substituted sulfonyl, substituted sulfinyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkenyl, a substituted or unsubstituted non-aromatic heterocyclic group, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted cycloalkyloxy, substituted or unsubstituted cycloalkenyloxy, substituted or unsubstituted non-aromatic heterocyclyloxy, substituted or unsubstituted aryloxy or substituted or unsubstituted heteroaryloxy;

R^(9′) is each independently halogen, hydroxy, carboxy, cyano, nitro, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted alkyloxy, substituted or unsubstituted alkenyloxy, substituted or unsubstituted alkynyloxy, substituted or unsubstituted alkylthio, substituted or unsubstituted alkenylthio, substituted or unsubstituted alkynylthio, substituted or unsubstituted acyl, substituted or unsubstituted alkyloxycarbonyl, substituted or unsubstituted alkenyloxycarbonyl, substituted or unsubstituted alkynyloxycarbonyl, substituted or unsubstituted carbamoyl, substituted or unsubstituted amino, substituted or unsubstituted sulfamoyl, substituted sulfonyl, substituted sulfinyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkenyl, a substituted or unsubstituted non-aromatic heterocyclic group, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted cycloalkyloxy, substituted or unsubstituted cycloalkenyloxy, substituted or unsubstituted non-aromatic heterocyclyloxy, substituted or unsubstituted aryloxy or substituted or unsubstituted heteroaryloxy;

s and s′ are each independently an integer of 0 to 3;

R^(20a) is each independently a hydrogen atom, hydroxy, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, or substituted or unsubstituted alkyloxy;

R^(20b) is each independently a hydrogen atom, hydroxy, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, or substituted or unsubstituted alkyloxyl;

or R^(20a) and R^(20b) attached to the same carbon atom or the different carbon atoms are taken together to form substituted or unsubstituted cycloalkane, substituted or unsubstituted cycloalkene, or a substituted or unsubstituted non-aromatic heterocyclic ring; provided that all R^(20a) and R^(20b) are not hydrogen atoms at the same time;

u is an integer of 1 to 4; and

R¹³ is a hydrogen atom or substituted or unsubstituted alkyl,

provided that the following compounds:

are excluded, or its pharmaceutically acceptable salt.

-   (2) The compound according to the above (1), wherein the group     represented by the formula:

is a group represented by the formula:

or its pharmaceutically acceptable salt,

-   (3) The compound according to the above (1), wherein the group     represented by the formula:

is a group represented by the formula:

or its pharmaceutically acceptable salt.

-   (4) The compound according to the above (1), wherein the group     represented by the formula:

is a group represented by the formula:

or its pharmaceutically acceptable salt.

-   (5) The compound according to the above (1), wherein the group     represented by the formula:

is a group represented by the formula:

or its pharmaceutically acceptable salt.

-   (6) The compound according to the above (1), wherein the group     represented by the formula:

is a group represented by the formula:

or its pharmaceutically acceptable salt.

-   (7) The compound according to any one of the above (1) to (6),     wherein n is 1, R^(4a) and R^(4b) are both hydrogen atoms, and R² is     substituted or unsubstituted phenyl or substituted or unsubstituted     cycloalkyl, or its pharmaceutically acceptable salt. -   (8) The compound according to any one of the above (1) to (7),     wherein n is 1, R^(4a) and R^(4b) are both hydrogen atoms, and R² is     substituted or unsubstituted phenyl, or its pharmaceutically     acceptable salt. -   (9) The compound according to any one of the above (1) to (8),     wherein n is 1, R^(4a) and R^(4b) are both hydrogen atoms, and R² is     phenyl substituted with chloro or methyl, or its pharmaceutically     acceptable salt. -   (10) The compound according to any one of the above (1) to (9),     wherein n is 1, R^(4a) and R^(4b) are both hydrogen atoms, and R² is     phenyl substituted with methyl, or its pharmaceutically acceptable     salt. -   (11) The compound according to any one of the above (1) to (8),     wherein n is 1, R^(4a) and R^(4b) are both hydrogen atoms, and R² is     phenyl substituted with halogen, or its pharmaceutically acceptable     salt. -   (12) The compound according to any one of the above (1) to (8),     wherein n is 1, R^(4a) and R^(4b) are both hydrogen atoms, and R² is     4-methylphenyl, 4-chlorophenyl, 2,4-dichlorophenyl, or     4-methylcyclohexyl, or its pharmaceutically acceptable salt. -   (13) The compound according to any one of the above (1) to (10) and     (12), wherein n is 1, R^(4a) and R^(4b) are both, hydrogen, atoms,     and R² is 4-methylphenyl, or its pharmaceutically acceptable salt. -   (14) The compound according to any one of the above (1) to (9), (11)     and (12), wherein n is 1, R^(4a) and R^(4b) are both hydrogen atoms,     and R² is 4-chlorolphenyl, or its pharmaceutically acceptable salt. -   (15) The compound according to any one of the above (1) to (14),     wherein R^(a) and R^(b) are taken together to form oxo, or its     pharmaceutically acceptable salt. -   (16) The compound according to any one of the above (1) to (15),     wherein R^(d) and R^(e) are taken together to form oxo, or its     pharmaceutically acceptable salt. -   (17) The compound according to any one of the above (1) to (16),     wherein s is 0, or its pharmaceutically acceptable salt. -   (18) The compound according to any one of the above (1) to (16),     wherein s is 1 or 2, and R⁹ is each independently halogen,     unsubstituted alkyl, haloalkyl, unsubstituted alkenyl, or     unsubstituted alkynyl, or its pharmaceutically acceptable salt. -   (19) The compound according to the above (18), wherein s is 1, R⁹ is     fluoro, chloro or methyl, or its pharmaceutically acceptable salt. -   (20) The compound according to any one of the above (1) to (19),     wherein s′ is 0, or its pharmaceutically acceptable salt. -   (21) The compound according to any one of the above (1) to (19),     wherein s′ is an integer of 1 to 3, or its pharmaceutically     acceptable salt. -   (22) The compound according to the above (21), wherein s′ is 1 or 2,     and R^(9′) is each independently halogen, carboxy, cyano,     substituted or unsubstituted alkyl, substituted or unsubstituted     alkyloxy, substituted or unsubstituted alkyloxycarbonyl, or     substituted or unsubstituted aryl, or its pharmaceutically     acceptable salt. -   (23) The compound according to the above (21) or (22), wherein s′ is     1, and R^(9′) is fluoro, chloro, bromo, iodo, carboxy, cyano,     methyl, ethyl, propyl, isopropyl, hydroxymethyl, fluoromethyl,     difluoromethyl, trifluoromethyl, methyloxy, ethyloxy, propyloxy,     isopropyloxy, methyloxycarbonyl, or ethyloxycarbonyl, or its     pharmaceutically acceptable salt. -   (24) The compound according to any one of the above (21) to (23),     wherein s′ is 1, and R^(9′) is fluoro, chloro, carboxy, cyano,     methyl, hydroxymethyl, trifluoromethyl, methyloxy, isopropyloxy,     difluoromethyl, methyloxycarbonyl, or ethyloxycarbonyl, or its     pharmaceutically acceptable salt. -   (25) The compound according to the above (1), wherein -   R^(a) and R^(b) are taken together to form oxo; -   R^(d) and R^(e) are taken together to form oxo; -   R^(4a) and R^(4b) are both hydrogen atoms; -   n is 1; -   R² is phenyl substituted with methyl; -   s is 0; and -   s′ is 1, -   or its pharmaceutically acceptable salt. -   (26) The compound according to the above (1), wherein -   R^(a) and R^(b) are taken together to form oxo; -   R^(d) and R^(e) are taken together to form oxo; -   R^(4a) and R^(4b) are both hydrogen atoms; -   n is 1; -   R² is phenyl substituted with halogen; and -   s and s′ are both 0, -   or its pharmaceutically acceptable salt. -   (27) The compound according to the above (26), wherein R¹³ is a     hydrogen atom and the group represented by the formula:

is a group represented by the formula:

or its pharmaceutically acceptable salt,

-   (28) A compound of formula:

or its pharmaceutically acceptable salt.

-   (29) A pharmaceutical composition comprising the compound according     to any one of the above (1) to (28), or its pharmaceutically     acceptable salt. -   (30) The pharmaceutical composition according to the above (29),     wherein the composition has a P2X₃ and/or P2X_(2/3) receptor     antagonistic activity. -   (31) The pharmaceutical composition according to the above (30),     wherein the composition has an effect of treatment for and/or     prevention of chronic pain, urination disorder, or respiratory     disease. -   (32) A compound according to any one of the above (1) to (28), or     its pharmaceutically acceptable salt, for use in a method for     treating and/or preventing a disease related to P2X₃ and/or     P2X_(2/3) receptor. -   (33) The compound according to the above (32), or its     pharmaceutically acceptable salt, for use in a method for treating     and/or preventing chronic pain, urination disorder, or respiratory     disease. -   (34) A method for treating and/or preventing a disease related to     P2X₃ and/or P2X_(2/3) receptor comprising administering the compound     according to any one of the above (1) to (28), or its     pharmaceutically acceptable salt. -   (35) The method according to the above (34), for treating and/or     preventing chronic pain, urination disorder, or respiratory disease, -   (36) Use of the compound of any one of the above (1) to (28), or its     pharmaceutically acceptable salt, in the manufacturing of an agent     for treating and/or preventing a disease related to P2X₃ and/or     P2X_(2/3) receptor. -   (37) The use according to the above (36), in the manufacturing of an     agent for treating and/or preventing chronic pain, urination     disorder, or respiratory disease. -   (38) A pharmaceutical composition comprising the compound of any one     of the above (1) to (28), or a pharmaceutically acceptable salt     thereof, for oral administration. -   (39) The pharmaceutical composition of the above (38), which is a     tablet, powder, granule, capsule, pill, film, suspension, emulsion,     elixir, syrup, lemonade, spirit, aromatic water, extract, decoction     or tincture. -   (40) The pharmaceutical composition of the above (39), which is a     sugar-coated tablet, film-coated tablet, enteric-coated tablet,     sustained-release tablet, troche tablet, sublingual tablet, buccal     tablet, chewable tablet, orally dispersing tablet, dry syrup, soft     capsule, micro capsule or sustained-release capsule. -   (41) A pharmaceutical composition comprising the compound of any one     of the above (1) to (28), or a pharmaceutically acceptable salt     thereof, for parenteral administration. -   (42) The pharmaceutical, composition of the above (14), for dermal,     subcutaneous, intravenous, intraarterial, intramuscular,     intraperitoneal, transmucosal, inhalation, transnasal, ophthalmic,     inner ear or vaginal administration. -   (43) The pharmaceutical composition of the above (41) or (42), which     is injection, infusion, eye drop, nose drop, ear drop, aerosol,     inhalation, lotion, impregnation, liniment, mouthwash, enema,     ointment, plaster, jelly, cream, patch, cataplasm, external powder     or suppository. -   (44) A pharmaceutical composition comprising the compound of any one     of the above (1) to (28), or a pharmaceutically acceptable salt     thereof, for a pediatric or geriatric patient.

Effect of the Invention

The compound of the invention has a P2X₃ and/or P2X_(2/3) receptor antagonistic activity and is useful in the treatment of diseases or conditions associated with a P2X₃ and/or P2X_(2/3) receptor.

Mode for Carrying Out the Invention

As used throughout the specification, the following terms have the following meaning unless specifically indicated.

The term “halogen” means fluoro, chloro, bromo and iodo.

The halogen moiety in said “haloalkyl”, “haloalkylcarbamoyl” and “haloalkyloxy” is as defined above for “halogen”.

The term “alkyl” includes a straight or branched chain monovalent hydrocarbon group of a carbon number of 1 to 15, as one embodiment a carbon number of 1 to 10, and as another embodiment a carbon number of 1 to 8. Examples include methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl, isopentyl, neo-pentyl, n-hexyl, isohexyl, n-heptyl, isoheptyl, n-cetyl, isooctyl, n-nonyl, n-decyl, n-undecanyl, dodecanyl, tridecanyl, and the like.

In the present specification, the carbon number in the term “alkyl” may be limited. For example, C3-C6 alkyl means “alkyl” of a carbon number of 3 to 6.

Examples of “alkyl” for R¹³ are methyl, ethyl, and the like.

The alkyl moiety in said “haloalkyl”, “hydroxyalkyl”, “aminoalkyl”, “alkylaminoalkyl”, “alkylamino”, “alkylimino”, “alkylsulfonyl”, “alkylsulfamoyl”, “alkylcarbamoyl”, “arylalkyl”, “alkylsilylalkynyl”, “alkylsulfonyl”, “alkylsulfinyl”, “alkylcarbamoyl”, “alkylcarbamoylalkyl”, “alkylcarbamoylalkyloxy”, “alkylsulfamoyl”, “alkylsulfamoylalkyl”, “haloalkylcarbamoyl”, “hydroxy alkyl carbamoyl”, “alkyloxycarbonylalkyl”, “alkylcarbamoylamino”, “alkyloxycarbonylamino”, “alkylsulfonylcarbamoyl”, and “arylalkylamino” is as defined above for “alkyl”.

The term “alkyloxy” includes an alkyloxy group of which alkyl moiety is as defined above for “alkyl”. For example, methoxy, ethoxy, propoxy, isopropoxy, butoxy, isobutoxy, sec-butoxy, tert-butoxy, pentyloxy, isopentyloxy, neopentyloxy, hexyloxy, etc are exemplified as alkyloxy.

The alkyloxy moiety in said “haloalkyloxy”, “arylalkyloxy”, “alkyloxycarbonyl”, “alkyloxycarbonylalkyl”, “alkyloxyalkyloxy”, “alkylcarbamoylalkyloxy”, “carbamoylalkyloxy”, “carboxyalkyloxy”, and “alkyloxylmino” is as defined above for “alkyloxy”.

For example, methylthio, ethylthio, propylthio, isopropylthio, butylthio, isobutylthio, sec-butylthio, tert-butylthio, pentylthio, isopentylthio, neopentylthio, hexylthio, and the like are exemplified as “alkylthio”.

For example, methyloxycarbonyl, ethyloxycarbonyl, n-propyloxycarbonyl, isopropyloxycarbonyl, n-butyloxycarbonyl, tert-butyloxycarbonyl, n-pentyloxycarbonyl, and the like are exemplified as “alkyloxycarbonyl”.

For example, mono- or di-alkylcarbamoyl, such as methylcarbamoyl, ethylcarbamoyl, n-propylcarbamoyl, isopropylcarbamoyl, cyclopropylcarbamoyl, n-butylcarbamoyl, dimethylcarbamoyl, diethylcarbamoyl, dipropylcarbamoyl, and the like are exemplified as “alkylcarbamoyl”.

The term “alkenyl” includes linear or branched alkenyl of a carbon number of 2 to 15, as one embodiment a carbon number of 2 to 10, and as another embodiment a carbon number of 2 to 6 having one or more double bonds at any available position. Examples include vinyl, propenyl, isopropenyl, butenyl, isobutenyl, prenyl, butadienyl, pentenyl, isopentenyl, pentadienyl, hexenyl, isohexenyl, hexadienyl, heptenyl, octenyl, nonenyl, decenyl, undecenyl, dodecenyl, tridecenyl and the like.

In the present specification, the carbon number in the term “alkenyl” may be limited. For example, C3-C6 alkenyl means “alkenyl” of a carbon number of 3 to 6.

The alkenyl moiety in said “alkenyloxy”, “alkenylthio”, “alkenylcarbamoyl”, “alkenylsulfamoyl” and “alkenyloxycarbonyl” is as defined above for “alkenyl”.

The term “alkynyl” includes a linear or branched alkynyl of a carbon number of 2 to 15, as one embodiment a carbon number of 2 to 10, as another embodiment a carbon number 2 to 6. Examples include ethynyl, propynyl, butynyl, pentynyl, hexynyl, heptynyl, octynyl, nonynyl and decynyl. These have one or more triple bonds at any available position and may further a double bond.

In the present specification, the carbon number in the term “alkynyl” may be limited. For example, C3-C6 alkynyl means “alkynyl” of a carbon number of 3 to 6.

The alkynyl moiety in said “alkynyloxy”, “alkynylthio” and “alkynyloxycarbonyl” is as defined above for “alkynyl”.

The term “acyl” includes a group of the formula R—C(═O)—, wherein R is, for example, “hydrogen”, “alkyl”, “alkenyl” or “alkynyl” as defined above and “cycloalkyl”, “cycloalkenyl”, “non-aromatic heterocyclic group”, “aryl” or “heteroaryl” as defined below.

The acyl moiety in “acylamino” and “acylimine” is as defined above for “acyl”.

The term “cycloalkane” includes a monocyclic or polycyclic saturated cyclic carbocyclic ring containing from 3 to 10 carbons. Monocyclic cycloalkane includes, for example, cyclopropane, cyclobutaue, cyclopentane, cyclohexane, cycloheptane, cyclooctane, cyclononane, cyclodecane, etc. Polycyclic cycloalkane includes norbornanane, tetrahydronaphthalene, etc.

The term “cycloalkyl” includes a monovalent group derived from “cycloalkane” as defined above. Monocyclic cycloalkyl includes, for example, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, cyclononyl, cyclodecyl, etc. As one embodiment, C3 to C8 cycloalkane is exemplified. As another embodiment, C3 to C7 cycloalkane is exemplified. Polycyclic cycloalkyl includes norbornyl, tetrahydronaphthalene-5-yl, tetrahydronaphthalene-6-yl, etc.

Examples of “cycloalkyl” for R² are cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl and the like.

The cycloalkyl moiety in said “cycloalkylcarbonyl”, “cycloalkyloxycarbonyl” and “cycloalkyloxy” is as defined above for “cycloalkyl”.

The term “cycloalkene” includes a non-aromatic monocyclic or polycyclic ring of 3 to 10 carbons containing at least one carbon-carbon double bond. As one embodiment C3 to C8 cycloalkene is exemplified. As another embodiment C3 to C7 cycloalkene is exemplified. Monocyclic cycloalkene includes, for example, cyclopentene, cyclohexene, etc. Polycyclic cycloalkene includes norbornene, indene, etc.

The term “cycloalkenyl” includes a monovalent group derived from “cycloalkene” as defined above. Monocyclic cycloalkenyl includes cyclopentenyl, cyclohexenyl, etc. As one embodiment, C3 to C8 cycloalkyl is exemplified. As another embodiment, C3 to C7 cycloalkyl is exemplified. Polycyclic cycloalkenyl includes norbornenyl, indene-1-yl, indene-2-yl, indene-3-yl, etc.

The cycloalkenyl moiety in said “cycloalkenyloxycarbonyl” and “cyclolalkenyloxy” is as defined above for “cycloalkenyl”.

The term “aromatic carbocyclic ring” includes an aromatic hydrocarbocyclic ring which is monocyclic or fused-cyclic, such as benzene, naphthalene, anthracene, phenanthrene, etc.

The term “aryl” includes a monovalent group derived from “aromatic carbocyclic ring” as defined above. For example, phenyl, 1-naphthyl, 2-naphthyl, anthryl, phenanthryl, etc. are exemplified.

Preferable “aryl” for R² is phenyl.

The aryl moiety in said “aryloxy”, “arylthio” and “aryloxycarbonyl” is as defined above for “aryl”.

The term “heterocyclic ring” includes an aromatic or a non-aromatic monocyclic or fused-cyclic ring, which includes a five- to seven-membered ring having at least one nitrogen atom, oxygen atom, and/or sulfur atom in the ring; a fused ring consisting of two or more said five- to seven-membered rings; or a fused ring consisting of said five- to seven-membered ring having at least one nitrogen atom, oxygen atom, and/or sulfur atom in the ring fused to one or more “aromatic carbocyclic ring”, “cycloalkane” or “cycloalkene” as defined above.

For example, a monocyclic non-aromatic heterocyclic ring such as pyrroline, pyrrolidine, piperidine, piperazine, morpholine, thiomorpholine, tetrahydropyrane, dihydropyridine, dihydropyridazine, dioxane, oxathiolane, thiane, tetrahydrofuran, tetrahydropyran, tetrahydrothiazole, tetrahydroisothiazole, etc.;

-   a monocyclic aromatic heterocyclic ring such as pyrrole, pyrazine,     pyrazole, tetrazole, furan, thiophene, pyridine, imidazole,     triazole, tetrazole, triazine, pyridazine, pyrimidine, isoxazole,     thiazole, isothiazole, thiadiazole, oxazole, oxadiazole, etc; and a     fused heterocyclic ring such as indole, isoindole, indazole,     indolizine, indoline, isoindoline, quinoline, isoquinoline,     cinnoline, phthalazine, quinazoline, naphthyridine, quinoxaline,     purine, pteridine, benzopyrane, benaimidazole, benzisoxazole,     benzoxazole, benzoxadiazole, benzisothiazole, benzothiazole,     benzothiadiazole, benzofuran, isobenzofuran, benzothiophene,     benzotriazole, imidazopyridine, triazolopyridine, imidazothiazole,     pyrazinopyridazine, benzimidazole, benzodioxane,     tetrahydroquinoline, tetrahydrobenzothiophene, etc. are exemplified.

The term “heterocyclic group” includes a monovalent group derived from “heterocyclic ring” as defined above.

For example, monocyclic non-aromatic heterocyclic groups such as pyrrolinyl, pyrrolidine, pyrrolidinyl, imidazolinyl, imidazolidinyl, pyrazolinyl, pyrazolidinyl, piperidino, piperidyl, piperazino, piperazinyl, morpholinyl, morpholino, thiomorpholinyl, thiomorpholine, tetrahydropyranyl, dihydropyridyl, dihydropyridazinyl, dihydropyrazinyl, dioxanyl, oxathiolanyl, thianyl, tetrahydrofuryl, tetrahydropyranyl, tetrahydrothiazolinyl, tetrahydroisothiazolinyl, etc.;

-   monocyclic aromatic heterocyclic groups such as pyrrolyl, pyrazinyl,     pyrazolyl, tetrazolyl, furyl, thienyl, pyridyl, imidazolyl,     triazolyl, tetrazolyl, triazinyl, pyridazinyl, pyrimidinyl,     pyrazinyl, isoxazolyl, thiazolyl, isothiazolyl, thiadiazolyl,     oxazolyl, oxadiazolyl, etc; and -   fused heterocyclic groups such as indolyl, isoindolyl, indazolyl,     indolizinyl, indolinyl, isoindolinyl, quinolyl, isoquinolyl,     cinnolinyl, phthalazinyl, quinazolinyl, naphthyridinyl,     quinoxalinyl, purinyl, pteridinyl, benzopyranyl, benzimidazolyl,     benzisoxazolyl, benzoxazolyl, benzoxadiazolyl, benzisothiazolyl,     benzothiazolyl, benzothiadiazolyl, benzofuryl, isobenzofuryl,     benzothienyl, benzotriazolyl, imidazopyridyl, triazolopyridyl,     imidazothiazolyl, pyrazinopyridazinyl, benzimidazolinyl,     benzodioxanyl, tetrahydroquinoline, tetrahydrobenzothienyl, etc. are     exemplified.

The term “non-aromatic carbocyclic ring” includes “cycloalkane” as defined above, “cycloalkene” as defined above, a fused ring consisting of “aromatic carbocyclic ring” as defined above fused to “cycloalkane” or “cycloalkene” as defined above. As a fused ring, indene and the like are exemplified.

The term “non-aromatic carbocyclic group” includes a monovalent group derived from “non-aromatic carbocyclic ring” as defined above. For example, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, cyclononyl, cyclodecyl, cyclopentenyl, cyclohexenyl, norbornyl, tetrahydronaphthalene-5-yl, tetrahydronaphthalene-6-yl, norbornenyl, inden-1yl, inden2-yl, inden-3-yl and the like are exemplified.

The non-aromatic carbocyclyl moiety in said “non-aromatic carbocyclyloxy” and “non-aromatic carbocyclylalkylosy” is as defined above for “non-aromatic carbocyclic ring”.

The term “aromatic heterocyclic ring” includes aromatic rings of “heterocyclic ring” as defined above.

“Aromatic heterocyclic ring” includes a five- to seven-membered aromatic ring having at least one nitrogen atom, oxygen atom, and/or sulfur atom in the ring;

-   a fused aromatic ring consisting of two or more said rings; and -   a fused ring consisting of a five- to seven-membered aromatic ring     having at least one nitrogen atom, oxygen atom, and/or sulfur atom     in the ring fused to one or more “aromatic carbocyclic ring” as     defined above.

For example, a monocyclic aromatic heterocyclic ring such as pyrazine, pyrazole, tetrazole, furan, thiophene, pyridine, imidazole, triazole, triazine, pyridazine, pyrimidine, pyrazine, isoxazole, thiazoic, isothiazole, thiadiazole, oxazole, oxadiazole, etc; and a fused aromatic heterocyclic ring such as indole, isoindole, imidazole, indolizine, quinoline, isoquinoline, cinnoline, phthalazine, quinazoline, naphthyridine, quinoxaline, purine, pteridine, benzimidazole, benzisoxazole, benzoxazole, benzoxadiazole, benzisothiazole, benzothiazole, benzothiadiazole, benzofuran, isobenzofuran, benzothiophene, benzotriazole, imidazopyridine, triazolopyridine, inmidazothiazole, pyrazinopyridazine, benzimidazoline, etc. are exemplified.

The term “heteroaryl” includes a monovalent group derived from “aromatic heterocyclic ring” as defined above. “Heteroaryl” includes a five- to seven-membered aromatic group having at least one nitrogen atom, oxygen atom, and/or sulfur atom in the ring;

-   a fused aromatic group consisting of two or more said rings; and -   a fused ring consisting of a five- to seven-membered aromatic group     having at least one nitrogen atom, oxygen atom, and/or sulfur atom     in the ring fused to one or more “aromatic carbocyclic ring” as     defined above.

For example, monocyclic heteroaryl such as pyrrolyl, pyrazinyl, pyrazolyl, indolyl, tetrazolyl, furyl, thienyl, pyridyl, imidazolyl, triazolyl, tetrazolyl, triazinyl, pyridazinyl, pyrimidinyl, pyrazinyl, isoxazolyl, thiazolyl, isothiazolyl, thiadiazolyl, oxazolyl, oxadiazolyl, etc; and

-   fused heteroaryl such as isoindolyl, indazolyl, indolizinyl,     isoindolinyl, quinolyl, isoquinolyl, cinnolinyl, phthalazinyl,     quinazolinyl, naphthyridinyl, quinoxalinyl, purinyl, pteridinyl,     benzimidazolyl, bensisoxazolyl, benzoxazolyl, benzoxadiazolyl,     benzisothiazolyl, benzothiazolyl, benzothiadiazolyl, benzofuryl,     isobenzofuryl, benzothienyl, benzotriazolyl, imidazopyridyl,     triazolopyridyl, imidazothiazolyl, pyrazinopyridazinyl,     benzimidazolinyl, etc. are exemplified.

One of examples of “heteroaryl” for R² is pyridyl,

The heteroaryl moiety in said “heteroaryloxy” and “heteroaryloxycarbonyl” is as defined above for “heteroaryl”.

The term “non-aromatic heterocyclic ring” includes non-aromatic rings of “heterocyclic ring” as defined above.

-   “Non-aromatic heterocyclic ring” includes, a four- to seven-membered     non-aromatic ring having at least one nitrogen atom, oxygen atom,     and/or sulfur atom in the ring; -   a fused non-aromatic ring consisting of two or more said rings; -   a fused ring consisting of a five- to seven-membered aromatic ring     having at least one nitrogen atom, oxygen atom, and/or sulfur atom     in the ring fused to one or more “cycloalkane” or “cycloalkene” as     defined above; and -   a fused ring consisting of a five- to seven-membered non-aromatic     heterocyclic ring having at least one nitrogen atom, oxygen atom,     and/or sulfur atom in the ring fused to one or more “aromatic     carbocyclic ring” or “non-aromatic carbocyclic ring” as defined     above.

For example, monocyclic non-aromatic heterocyclic ring such as oxetane, thietane, azetidine, pyrroline, pyrrolidine, imidazoline, imidazolidine, pyrazoline, pyrazolidine, piperidine, piperazine, morpholine, thiomorpholine, thiomorpholine, tetrahydropyran, for example, 2-tetrahydropyran, 3-tetrahydropyran, 4-tetrahydropyran, dihydropyridine, dihydropyridazine, dihydropyrazine, dioxane, oxathiolane, thiane, tetrahydrofuran, tetrahydropyran, tetrahydrothiazoline, tetrahydroisothiazoline etc.;

-   a fused non-aromatic heterocyclic ring such as indoline,     isoindoline, benzopyrane, benzodioxane, tetrahydroquinoline,     benzo[d]oxazole-2(3H)-one, tetrahydrobenzothiophene etc. are     exemplified.

“Non-aromatic heterocyclic group” includes a monovalent group derived from “non-aromatic heterocyclic ring” as defined above.

Examples are monocyclic non-aromatic heterocyclic group such as pyrrolinyl, pyrrolidine, pyrrolidinyl, imidazolinyl, imidazolidinyl, pyrazolinyl, pyrazolidinyl, piperidino, piperidyl, piperazino, piperazinyl, morpholinyl, morpholino, thiomorpholinyl, thiomorpholino, tetrahydropyranyl, dihydropyridyl, dihydropyridazinyl, dihydropyrazinyl, dioxanyl, oxathiolanyl, thianyl, tetrahydrofuryl, tetrahydropyranyl, tetrahydrothiazolinyl, tetrahydroisothiazolinyl etc. and

-   a fused heterocyclic group such as benzodioxane,     tetrahydroquinoline, benzo[d]oxazole-2(3H)-one,     tetrahydrobenzothiophene etc.

The non-aromatic heterocyclyl moiety in said “non-aromatic heterocyclyloxy” and “non-aromatic heterocyclyloxycarbonyl” is as defined above for “non-aromatic heterocyclic ring”.

The term “nitrogen-containing non-aromatic heterocyclic group” includes a group derived from a four- to seven-membered non-aromatic ring which contains at least one nitrogen atom in the ring and may contain one or more atoms arbitrarily selected from an oxygen atom and a sulfur atom in the ring, or a fused ring consisting of two or more said rings. Examples are pyrrolinyl, pyrrolidine, pyrrolidinyl, piperidino, piperidyl, piperazino, piperazinyl, morpholinyl, morpholino, thiomorpholino etc.

The non-aromatic heterocyclyl moiety in said “non-aromatic heterocyclyloxycarbonyl” is as defined above for “non-aromatic heterocyclic ring”.

Substituents for “substituted alkyl”, “substituted alkenyl”, “substituted alkynyl”, “substituted alkyloxy”, “substituted alkenyloxy”, “substituted alkynyloxy”, “substituted alkylthio”, “substituted alkenylthio”, “substituted alkynylthio”, “substituted alkyloxycarbonyl”, “substituted alkenyloxycarbonyl”, “substituted alkynyloxycarbonyl” and “substituted alkylcarbamoyl” include but are not limited to one or more same or different substituents selected from the group consisting of: hydroxy, carboxy, halogen (F, Cl, Br, I), haloalkyloxy (e.g., CF₃O), cycloalkyl (e.g., cyclopropyl), cycloalkenyl (e.g., cyclopropenyl), alkyloxy (e.g., methoxy, ethoxy, propoxy, butoxy, etc.), alkenyloxy (e.g., vinyloxy, allyloxy, etc.), alkyloxycarbonyl (e.g., methoxycarbonyl, ethoxycarbonyl, tert-butoxycarbonyl, etc.), nitro, nitroso, amino, alkylamino (e.g., methylamino, ethylamino, dimethylamino, etc.), acylamino (e.g., acetylamino, benzoylamino, etc.), arylalkylamino (e.g., benzylamino, tritylamino), hydroxyamino, alkylsulfonylamino (e.g., methane sulfonylamino), alkylsulfinylamino (e.g., methanesulfinylamino), non-aromatic heterocyclylamino (e.g. 4-tetrahydropyranylamino etc.) imino, hydroxyimino, alkylimino (e.g., methylimino, ethylimino, dimethylimino, etc.), alkyloxylmino (e.g., methoxyimino, ethoxyimino, etc.), acylimino (e.g., acetylimino, benzoylimino, etc.), azido, aryl (e.g., phenyl, etc.), arylalkyl (e.g., benzyl, phenylethyl etc.), arylalkyloxy (e.g., benzyloxy), a non-aromatic heterocyclic group (e.g., pyrrolinyl, piperidyl, piperazinopyrrolidino, pyrrolidinyl, morpholinyl, morpholino, 2,2-dimethyl-1,3-dioxopyranyl etc.), heteroaryl (e.g., furyl, thienyl, pyridyl, isoxazolyl, thiazolyl, thiadiazolyl, oxazolyl, oxadiazolyl, tetrazolyl, indolyl, benzofuryl etc.), heteroarylalkyl (e.g., pyridylmethyl, pyridylethyl etc.), cyano, isocyano, isocyanato, thiocyanato, isothiocyanato, mercapto, alkylthio (e.g., methylthio, etc.), alkylsulfonyl (e.g., methanesulfonyl, ethanesulfonyl), carbamoyl, alkylcarbamoyl (e.g., methylcarbamoyl, ethylcarbamoyl, dimethylcarbamoyl, etc.), sulfamoyl, alkylsulfamoyl, acyl (e.g., formyl, acetyl, etc.), formyloxy, thioformyl, thiocarboxy, dithiocarboxy, thiocarbamoyl, sulfino, sulfo, hydrazine, azido, ureido, amidino, guanidino, phthalimido, tri-alkylsilyl (e.g., trimethylsilyl, etc.), hydroxyalkylcarbamoyl (hydroxyethylcarbamoyl, etc.), tetrahydropyranyloxy, carbamoylamino, alkylcarbamoylamino (e.g., methylcarbamoylamino, etc.), haloalkylcarbamoyl (e.g., trifluoroethylcarbamoyl, etc.), alkyloxyalkyloxy (e.g., methyloxymethyloxy, etc.), carbamoylcarbamoyl, alkylsulfonylcarbamoyl (e.g., methanesulfonylcarbamoyl) and oxo.

Substituents for “substituted acyl” are selected from the substituents as defined above for “substituted alkyl”, the above “alkyl”, the above “alkenyl” and the above “alkynyl”. If R in acyl (R—C(═O)—) is “cycloalkyl”, “cycloalkenyl”, “non-aromatic heterocyclic group”, “aryl”, or “heteroaryl”, then each ring may be substituted with alkyl (e.g., methyl, ethyl, isopropyl, tert-butyl, etc.), haloalkyl (e.g., CF₃, CH₂CF₃, CH₂CCl₃, etc.), alkenyl, alkynyl (e.g., ethynyl), alkyloxy (e.g., methoxy, ethoxy, isopropyloxy), halogen (e.g., fluoro, chloro etc.) or the like.

Substituents for “substituted carbamoyl” or “substituted sulfamoyl” are one or more same or different groups selected from, but are not limited to, the group consisting of:

-   hydroxy, carboxy, carboxyalkyl (e.g., carboxymethyl, carboxyethyl     etc.), halogen (F, Cl, Br, I), alkyl (e.g., methyl, ethyl), alkenyl     (e.g., vinyl), alkynyl (e.g., ethynyl), cycloalkyl (e.g.,     cyclopropyl), cycloalkenyl (e.g., cyclopropenyl), alkyloxycarbonyl     (e.g., methoxycarbonyl, ethoxycarbonyl, tertbutoxycarbonyl, etc.),     alkyloxycarbonylalkyl (e.g., methoxycarbonylmethyl,     ethoxycarbonylmethyl etc.), amino, alkylamino (e.g., methylamino,     ethylamino, dimethylamino, etc.), acylamino (e.g., acetylamino,     benzoylamino, etc.), arylalkylamino (e.g., benzylamino,     tritylamino), hydroxyamino, aryl (e.g., phenyl, etc.), a     non-aromatic heterocyclic group (e.g., 4-tetrahydropyranyl etc.),     heteroaryl (e.g., pyridyl etc.), cyano, isocyano, isocyanato,     thiocyanato, isothiocyanato and acyl (e.g., formyl, acetyl, etc.).

Substituents for “substituted sulfonyl” or “substituted sulfinyl” are selected from the above “substituted or unsubstituted alkyl”, the above “substituted or unsubstituted alkenyl”, the above “substituted or unsubstituted alkynyl”, the after-mentioned “substituted or unsubstituted cycloalkyl”, the after-mentioned “substituted or unsubstituted cycloalkenyl”, the after-mentioned “a substituted or unsubstituted non-aromatic heterocyclic group”, the after-mentioned “substituted or unsubstituted aryl”, and the after-mentioned “substituted or unsubstituted heteroaryl”. If R in R—S(═O)₂, or R—S(═O)— is “cycloalkyl”, “cycloalkenyl”, “non-aromatic heterocyclic group”, “aryl”, “heteroaryl” or the like, then each ring may be substituted with alkyl (e.g., methyl, ethyl, isopropyl, tert-butyl, etc.), haloalkyl (e.g., CF₃, CH₂CF₃, CH₂CCl₃, etc.), alkenyl, alkynyl (e.g., ethynyl), alkyloxy (e.g., methoxy, ethoxy, isopropyloxy), halogen (e.g., fluoro, chloro etc.) or the like.

Substituents for “substituted amino”, “substituted imino” and “substituted guanidyl” are one or more same or different groups selected from, but are not limited to, the group consisting of:

-   alkyl (e.g., methyl, ethyl, isopropyl, tert-butyl etc.), haloalkyl     (e.g., CF₃, CH₂CF₃, CH₂CCl₃, etc.), hydroxyalkyl (e.g.,     hydroxyethyl, —C(CH₃)₂CH₂OH, etc.), alkenyl (e.g., vinyl), alkynyl     (e.g., ethynyl), cycloalkyl (e.g., cyclopropyl), cycloalkenyl (e.g.,     cyclopropenyl), alkyloxy (e.g., methoxy, ethoxy, propoxy, butoxy,     etc.), haloalkyloxy (e.g., CF₃O), alkenyloxy (e.g., vinyloxy.     allyloxy, etc.), alkyloxycarbonyl (methoxycarbonyl,     tert-butyloxycarbonyl, etc.), alkyloxycarbonylalkyl, amino,     alkylamino (e.g., methylamino, ethylamino, dimethylamino, etc.),     acylamino (e.g., acetyl amino, benzoylamino, etc.), arylalkylamino     (e.g., benzylamino, tritylamino), hydroxy amino, imino,     hydroxyimino, alkylimino (e.g., methylimino, ethylimino,     dimethylimino, etc.), alkyloxyimino (e.g., methoxyimino,     ethoxyimino, etc.), acylimino (e.g., acetylimino, benzoylimino,     etc.), aryl (e.g., phenyl, etc.), arylalkyl (e.g., benzyl, etc.),     aryloxy (e.g., phenoxy etc.), a non-aromatic heterocyclic group     (e.g., pyrrolinyl, pyrrolidine, piperidino, piperidyl, piperazino,     piperazinyl, morpholinyl, morpholino etc.), heteroaryl (e.g.,     pyridyl, thienyl, thiazolyl, furyl etc.), heteroarylalkyl (e.g.,     pyridylmethyl, thienylmethyl, thiazolylmethyl, furylmethyl etc.),     non-aromatic heterocyclyloxy (pipierazinooxy, piperidinooxy etc.),     heteroaryloxy (pyridyloxy etc.), hydroxy, halogen, (F, Cl, Br, I),     cyano, acyl (e.g., formyl, acetyl, etc.), non-aromatic     heterocyclicylcarbonyl (e.g., 4-tetrahydropyranylcarbonyl etc.),     alkylsulfonyl (e.g., methanesulfonyl etc.), non-aromatic     heterocyclicylsulfonyl (e.g., 4-tetrahydropyranylsulfonyl etc.),     alkylsulfinyl (e.g. methansulfinyl), carbamoyl, alkycarbamoyl (e.g.,     methylcarbamoyl etc.), alkylcarbamoylalkyl (e.g.,     methylcarbamoylmethyl etc.), carbamoylalkyl (e.g., carbamoylmethyl     etc.), carboxyalkyl (e.g., carboxymethyl etc.), sulfamoyl,     alkylsulfamoyl (e.g., methylsulfamoyl etc.), alkylsulfamoylalkyl     (e.g., methylsulfamoylmethyl etc.), and sulfamoylalkyl (e.g,     sulfamoylmethyl etc.).

Substituents for “substituted cycloalkyl”, “substituted cycloalkenyl”, “substituted aryl”, “substituted phenyl”, “a substituted heterocyclic group”, “substituted heteroaryl”, “a substituted non-aromatic carbocyclic group”, “a substituted non-aromatic heterocyclic group”, “a substituted nitrogen-containing non-aromatic heterocyclic group”, “substituted cycloalkyloxycarbonyl”, “substituted cycloalkyenyloxycarbonyl”, “substituted non-aromatic heterocyclyloxycarbonyl”, “substituted aryloxycarbonyl”, “substituted heteroaryloxycarbonyl”, “a substituted cyclopropane ring”, “a substituted cyclopropene ring”, “a substituted oxetane ring”, “a substituted thietane ring” and “a substituted azetizine ring” are one or more same or different groups selected from, but are not limited to, the group consisting of alkyl (e.g., methyl, ethyl, isopropyl, tert-butyl etc.), haloalkyl (e.g., CF₃, CH₂CF₃, CH₂CCl₃, etc.), haloalkyloxy (e.g., CF₃O, CHCF₂O etc.), alkenyl (e.g., vinyl), alkynyl (e.g., ethynyl), cycloalkyl (e.g., cyclopropyl), cycloalkenyl (e.g., cyclopropenyl), alkyloxy (e.g., methoxy, ethoxy, propoxy, butoxy, etc.), alkenyloxy (e.g., vinyloxy, allyloxy, etc.), alkyloxycarbonyl (e.g., methoxycarbonyl, ethoxy carbonyl, tert-butoxycarbonyl, etc.), nitro, nitroso, amino, alkylamino (e.g., methylamino, ethylamino, dimethylamino, etc.), acylamino (e.g., acetylamino, benzoylamino, etc.), arylalkylamino (e.g., benzylamino, tritylamino), hydroxy amino, amino substituted with one or two same or different substituent selected from the after-mentioned substituent Group Y, imino, hydroxyimino, alkylimino (e.g., methylimino, ethylimino, dimethylimino etc.), alkyloxylmino (e.g., methoxyimino, ethoxyimino etc.), acylimino (e.g., acetylimino, benzoylimino etc.), azido, aryl (e.g., phenyl etc.), arylalkyl (e.g., benzyl etc.), unsubstituted non-aromatic carbocyclyloxy (e.g., cyclopropyloxy etc.), non-aromatic carbocyclyloxy substituted with one or more same or different substituents selected from the after-mentioned Substituent Group Z, unsubstituted non-aromatic carbocyclylalkyloxy (e.g., cyclopropylmethyloxy etc.), non-aromatic carbocyclylalkyloxy substituted with one or more same or different substituents selected from the after-mentioned Substituent Group Z, unsubstituted aryloxy (e.g., phenoxy etc.), aryloxy substituted with one or more same or different substituents selected from the after-mentioned Substituent Group Z, unsubstituted arylalkyloxy (e.g., benzyloxy etc.), arylalkyloxy substituted with one or more same or different substituents selected from the after-mentioned Substituent Group Z, a non-aromatic heterocyclic group (e.g., pyrrolinyl, pyrrolidine, piperidino, piperidyl, piperazino, piperazinyl, morpholinyl, morpholino etc.), heteroaryl (e.g., pyridyl, thienyl, thiazolyl, furyl etc.), heteroarylalkyl (e.g., pyridylmethyl, thienylmethyl, thiazolylmethyl, furylmethyl etc.), unsubstituted non-aromatic heterocyclyloxy (e.g., piperazinooxy, piperizinooxy etc.), non-aromatic heterocyclyloxy substituted with one or more same or different substituents selected from the after-mentioned Substituent Group Z, unsubstituted heteroaryloxy (e.g., pyridyloxy, pyridazinyloxy, pyrimidinyloxy, pyrazinyloxy, oxazolyloxy, isoxazolyloxy, oxadiazolyloxy, thiazolyloxy, isothiazolyloxy, thiadiazolyloxy, furyloxy, thienyloxy, etc.), heteroaryloxy substituted with one or more same or different substituents selected from the after-mentioned Substituent Group Z, cyano, isocyano, isocyanato, thiocyanato, isothiocyanato, mercapto, alkylthio (e.g., methylthio etc.), alkylsulfonyl (e.g., methanesulfonyl, ethanesulfonyl), substituted or unsubstituted carbamoyl (e.g., carbamoyl, N-methyl-N-methoxycarbamoyl etc.), substituted or unsubstituted alkylcarbamoyl (e.g., methylcarbamoyl, ethylcarbamoyl, dimethylcarbamoyl, hydroxyethylcarbamoyl, trifluoromethylcarbamoyl, trifluoroethylcarbamoyl etc.), sulfamoyl, alkylsulfamoyl, hydroxy, carboxy, halogen (F, Cl, Br, I), acyl (e.g., formyl, acetyl etc.), formyloxy, thioformyl, thiocarboxy, dithiocarboxy, thiocarbamoyl, sulfino, sulfo, hydrazine, azido, ureido, amidino, guanidino, phthalimido and oxo.

A substituent Group Y includes hydroxyalkyl (e.g., hydroxyethyl, —C(CH₃)2CH₂OH etc.), alkyloxycarbonyl (methoxycarbonyl, tert-butyloxycarbonyl etc.), alkyloxycarbonylalkyl, alkylsulfonyl (e.g., methanesulfonyl etc.), alkylsulfinyl (e.g., methanesulfinyl etc.), carbamoyl, alkylcarbamoyl (e.g., methylcarbamoyl etc.), alkylcarbamoyl alkyl (e.g., methylcarbamoylmethyl etc.), carbamoylalkyl (e.g., carbamoylmethyl etc.), carboxyalkyl (e.g., carboxymethyl etc.), sulfamoyl, alkylsulfamoyl (e.g., methylsulfamoyl etc.), alkylsulfamoylalkyl (e.g., methylsulfamoylmethyl etc.) and sulfamoylalkyl (e.g., sulfamoylmethyl etc.).

A substituent Group Z includes halogen (e.g., F, Cl etc.), hydroxy, carboxy, carboxyalkyloxy (e.g., carboxymethyloxy etc.), cyano, nitro, alkyl (e.g., methyl etc.), hydroxyalkyl (e.g., hydroxymethyl etc.), aminoalkyl, alkylaminoalkyl, alkenyl, alkynyl, alkyloxy, alkenyloxy, alkynyloxy, alkylthio, alkenylthio, alkynylthio, acyl, alkyloxycarbonyl (e.g., methyloxycarbonyl, ethyloxycarbonyl etc.), alkenyloxycarbonyl, alkynyloxycarbonyl, carbamoyl, carbamoylalkyloxy (e.g., carbamoylmethyloxy etc.), alkylcarbamoyl (e.g., methylcarbamoyl, ethylcarbamoyl etc.), haloalkylcarbamoyl, cycloalkylcarbamoyl. (e.g., cyclopropylcarbamoyl etc.), alkylcarbamoylalkyloxy (e.g., methylcarbamoylmethyloxy etc), hydroxyalkylcarbamoyl (e.g., hydroxyethylcarbamoyl etc), cyanocarbamoyl, amino, acylamino, amino substituted with one or two same or different substituent selected from the above substituent Group Y, sulfamoyl, methylsulfonyl, methylsulfinyl, cycloalkyl, cycloalkenyl, a non-aromatic heterocyclic group, aryl, heteroaryl (e.g., tetrazolyl etc), cycloalkyloxy, cycloalkenyloxy, non-aromatic heterocyclyloxy, aryloxy heteroaryloxy and oxo.

As substituents for “substituted aryl” and “substituted heteroaryl” for R², halogen, alkyl, alkenyl, alkynyl, alkyloxy, haloalkyl, cycloalkyl, alkylsilylalkynyl and the like are exemplified.

As substituents for “substituted aryl” and “substituted heteroaryl” for R², alkyl, haloalkyl, and the like are exemplified.

As substituents for “substituted aryl” and “substituted heteroaryl” for R², halogen and the like are exemplified.

As substituents for “substituted aryl” and “substituted heteroaryl” for R², fluoro, chloro, bromo, iodo, methyl, ethyl, propyl, isopropyl, propenyl, vinyl, ethynyl, methyloxy, fluoromethyl, difluoromethyl, trifluoromethyl, cyclopropyl, trimethylsilylethynyl and the like are exemplified.

As substituents for “substituted aryl” and “substituted heteroaryl” for R², fluoro, chloro, methyl, fluoromethyl, difluoromethyl and the like are exemplified.

As substituents for “substituted aryl” and “substituted heteroaryl” for R², fluoro, chloro, methyl, difluoromethyl and the like are exemplified.

As substituents for “substituted aryl” and “substituted heteroaryl” for R², chloro, methyl and the like are exemplified.

As substituents for “substituted aryl” and “substituted heteroaryl” for R², methyl and the like are exemplified.

As substituents for “substituted aryl” and “substituted heteroaryl” for R², chloro and the like are exemplified.

Examples of R² are 4-methylphenyl, 4-chlorophenyl, 4-fluoromethyl, 4-difluoromethylphenyl, 2,4-difluorophenyl, 2,4-dichloromethyl, 4-methylcyclohexyl and the like.

Examples of R² are 4- methylphenyl, 4-chlorophenyl, 2,4-difluorophenyl, 4-methylcyclohexyl and the like.

Examples of R² are 4-methylphenyl and the like.

Examples of R² are 4-chlorophenyl and the like.

Examples of R⁹ are halogen, alkyl, haloalkyl, alkenyl, alkynyl and the like.

Examples of R⁹ are fluoro, chloro, bromo, iodo, methyl, ethyl, propyl, isopropyl and the like.

Examples of R⁹ are fluoro, chloro, methyl and the like.

Examples of R^(9′) are halogen, carboxy, cyano, substituted or unsubstituted alkyl, substituted or unsubstituted alkyloxy, substituted or unsubstituted acyl, substituted or unsubstituted alkyloxycarbonyl, substituted sulfonyl, or substituted or unsubstituted aryl, and the like.

Examples of R⁹′ are halogen, carboxy, cyano, substituted or unsubstituted alkyl, substituted or unsubstituted alkyloxy, substituted or unsubstituted alkyloxycarbonyl, substituted or unsubstituted aryl, and the like.

Examples of R^(9′) are fluoro, chloro, bromo, iodo, carboxy, cyano, methyl, ethyl, propyl, isopropyl, hydroxymethyl, hydroxyethyl, methyloxymethyl, ethyloxymethyl, fluoromethyl, difluoromethyl, trifluoromethyl, methyloxy, ethyloxy, propyloxy, isopropyloxy, formyl, acetyl, methyloxycarbonyl, ethyloxycarbonyl, methanesulfonyl, ethanesulfonyl, and the like.

Examples of R^(9′) are fluoro, chloro, bromo, iodo, carboxy, cyano, methyl, ethyl, propyl, isopropyl, hydroxymethyl, fluoromethyl, difluoromethyl, trifluoromethyl, methyloxy, ethyloxy, propyloxy, isopropyloxy, methyloxycarbonyl, ethyloxycarbonyl, and the like.

Examples of R^(9′) are fluoro, chloro, carboxy, cyano, methyl, ethyl, hydroxymethyl, hydroxyethyl, methyloxymethyl, fluoromethyl, difluoromethyl, trifluoromethyl, methyloxy, isopropyloxy, acetyl, methyloxycarbonyl, ethyloxycarbonyl, methanesulfonyl, and the like.

Examples of R^(9′) are fluoro, chloro, carboxy, cyano, methyl, hydroxymethyl, trifluoromethyl, methyloxy, isopropyloxy, difluoromethyl, methyloxycarbonyl, ethyloxycarbonyl, and the like.

Examples of R^(9′) are carboxy, hydroxymethyl, isopropyloxy, difluoromethyl, methyloxycarbonyl, ethyloxycarbonyl, and the like.

In Formula (I), “R^(4a) and R^(4b) attached to the same carbon atom are taken together to form oxo or thioxo” includes the followings:

wherein n, R^(4a), R^(4b) and R² are as defined in the above (1) or the like.

Examples of the group represented by the following formula:

are groups represented by the following formula:

Examples of the group represented by the following formula:

are groups represented by the following formula:

Examples of the group represented by the following formula:

are groups represented by the following formula:

Example of the group represented by the following formula:

is a group represented by the following formula:

Example of the group represented by the following formula:

is a group represented by the following formula:

In Formula (I), “R^(20a) and R^(20b) attached to the same carbon atom are taken together to form substituted or unsubstituted cycloalkane, substituted or unsubstituted cycloalkene, or a substituted or unsubstituted non-aromatic heterocyclic ring” includes the followings:

wherein u, R^(20a) and R^(20b) are as defined in the above (1);

-   Ve is an integer of 0 to 3 (e.g., 0 or 1, and e.g., 0); -   -We- is —O—, —S— or —N(R^(17d))— (e.g., —O—); -   R^(17d) is a hydrogen atom, substituted or unsubstituted alkyl,     substituted or unsubstituted alkenyl, substituted or unsubstituted     alkynyl, substituted or unsubstituted acyl or the like.

In Formula (I), “R^(20a) and R^(20b) attached to the different carbon atoms are taken together to form substituted or unsubstituted cycloalkane, substituted or unsubstituted cycloalkene, or a substituted or unsubstituted non-aromatic heterocyclic ring” includes the followings:

wherein u, R^(20a) and R^(20b) are as defined in the above (1);

-   Vf is an integer of 0 to 3 (e.g., 0 or 1, and e.g., 1); -   Vf is an integer of 1 to 3 (e.g., 1); -   -Wf- is —O—, —S— or —N(R^(1d7))— (e.g., —O—); -   R^(17d) is a hydrogen atom, substituted or unsubstituted alkyl,     substituted or unsubstituted alkenyl, substituted or unsubstituted     alkynyl, substituted or unsubstituted acyl -   or the like.

In Formula (I), the group represented by the following formula:

is the same as a group represented by the following formula:

wherein the bond a is attached to the nitrogen atom of the triazine ring, and the bond b is attached to the “C” atom of the “—CO₂R¹⁸” group.

Examples of the group represented by the following formula:

are groups represented by the following formula:

As described above, the above formulae are the same as groups represented by the following formula:

wherein the bond a is attached to the nitrogen atom of the triazine ring, and the bond b is attached, to the “C” atom of the “—CO₂R¹⁸” group. The binding mode is the same also in the below formula.

Examples of the group represented by the following formula:

are groups represented by the following formula:

Examples of the group represented by the following formula:

are groups represented by the following formula:

Examples of the group represented by the following formula:

are groups represented by the following formula:

Examples of the group represented by the following formula:

are groups represented by the following formula:

Example of the group represented by the following formula:

is a group represented by the following formula:

Example of the group represented by the following formula:

is a group represented by the following formula:

The following is a general method for synthesizing the compounds of this invention. The starting materials and reagents used for synthesizing these compounds are commercially available or can be manufactured in accordance with a widely known method in this field using commercially available compounds.

For example, the compounds of the Formula (I) described in this invention can be manufactured by the following synthesis route, or by reference to what is described in WO2010/092966 and WO2012/020749 if necessary.

[Method A]

wherein, Lg is a leaving group represented by the formula:

R³ is a group represented by the formula:

R^(c) is a group represented by the formula:

R¹⁰ is alkyl, R²⁷ is alkyl, Z² is an oxygen atom or a sulfur atom, X is NH, n′ is an integer of 0 to 3, Lg¹ is a leaving group and other symbols are as defined above. (Step 1)

The compound (i) or its hydrochloride or bromate is reacted with isocyanate (ii) or 1-carbamoyl imidazole (ii)′ in a solvent, such as N,N-dimethylformamide, N,N-dimethylacetamide, N,N′-dimethyl imidazolidinone and dimethylsulfoxide, in the presence of a base, such as DBU, triethylamine and pyridine (preferably DBU) at a temperature between −20 and 50° C., preferably at a temperature between −10° C. and below zero. After that, the compound (iii) can be manufactured by reacting the reactive mixture with a carbonylating or thiocarbonylating agent, such as 1,1′-carbonyldiimidazole, 1,1′-thiocarbonyldiimidazole, phosgene, thiophosgene and triphosgene, etc., and a base, such as DBU, triethylamine or pyridine (preferably DBU) at a temperature between −20 and 50° C., preferably at a temperature between −10° C. and below zero.

(Step 2)

The compound (v) can be manufactured by reacting the compound (iii) with the compound (iv) in a solvent, such as acetonitrile, acetone, DMF and DMSO, in the presence of a base, such as potassium carbonate and sodium carbonate, at a temperature between 50° C. to reflux, preferably at reflux.

The examples of a leaving group include halogen and —OSO₂ (C_(t)F_(2t+1)) wherein t is an integer of 1 to 4. As halogen, chloro, iodo and bromo are preferred. As —OSO₂ (C_(t)F_(2t+1)) group. —OTf group (trifluoromethanesulfonate) is preferred.

(Step 3)

The compound indicated by Formula (II′) can be manufactured by reacting the compound (v) with the compound (vii) in a solvent, such as NMF, DMF and DMSO, or under solvent-free conditions under microwave irradiation at a temperature between 150° C. and 250° C., preferably at a temperature between 200° C. and 230° C., or in a solvent, such as t-butanol, in the presence of an acid, such as acetic acid, at a temperature between 60° C. and 150° C., preferably at a temperature between 80° C. and 120° C.

Using optically active isocyanate (ii) enables to synthesize optically active compound (II′).

[Method B]

wherein Hal² and Hal³ are halogen and other symbols are as defined above. (Step 1)

The compound (ix) can be manufactured by reacting the compound (vii) with alkylating agent (viii), such as methyl iodide and ethyl iodide, in a solvent, such as methanol and ethanol, at a temperature between −40° C. and 30° C., preferably below zero.

(Step 2)

The compound (x) can be manufactured by reacting the compound (ix) with isocyanate, such as N-(chlorocarbonyl) isocyanate, in a solvent, such as dichloromethane, chloroform, 1,2-dichloroethane, in the presence of a base, such as triethylamine and N,N-diisopropylethylamine, at a temperature between −20° C. and 30° C., preferably below zero.

(Step 3)

The compound (xi) can be manufactured by reacting the compound (x) with the compound (vi) in a solvent, such as t-butanol, isopropanol, ethanol and acetonitrile, in the presence of an acid, such as acetic acid, formic acid and methanesulfonic acid, at reflux.

(Step 4)

The compound represented by Formula (II″) can be manufactured by reacting the compound (xi) with the compound (xii) in a solvent, such as DMF or NMP, etc, in the presence of a base, such as potassium t-butoxide, or sodium hydride, at a temperature between 40° C. and 100° C., preferably at a temperature between 50° C. and 70° C.

Using optically-active compound (xii) enables to synthesize optically-active compound (II″).

[Method C]

wherein Pg¹ is an appropriate hydroxy protecting group, s is an integer of 1 to 4 and other symbols are as defined above. (Step 1)

The compound (xiii) can be manufactured by reacting a mixture of the compound (x) obtained by the method B, and the alcohol (xii) whose one hydroxyl group is protected, such as 2-(tetrahydro-2H-pyran-2-yloxy) ethanol in a solvent, such as THF or dioxane, etc, with triphenylphosphine, and diethyl azodicarboxylate, etc.

(Step 2)

The compound (xiv) can be manufactured by reacting the compound (xiii) with the compound (vi) in the presence of an acid, such as formic acid or acetic acid, etc., at reflux.

[Method D]

wherein Pg2 is an appropriate amino protecting group, R¹¹ is substituted or unsubstituted alkyl, substituted or unsubstituted arylalkyl, substituted or unsubstituted heteroarylalkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkenyl, substituted or unsubstituted acyl, a substituted or unsubstituted non-aromatic heterocyclic group, substituted or unsubstituted aryl or substituted or unsubstituted heteroaryl, R¹² is hydroxy or halogen, t is an integer of 1 to 4 and other symbols are as defined above.) (Step 1)

The compound (xvi) can be manufactured by reacting the compound (xv) obtained by the method A or B with acid, such as hydrochloric acid-dioxane solution, hydrochloric acid-methanol, hydrochloric acid-ethyl acetate solution and trifluoroacetic acid, etc.

(Step 2)

The compound (xviii) can be manufactured by reacting the compound (xvi) with the acid halide (xvii) (R¹² is halogen) in a solvent, such as THF or dioxane, etc., in the presence of a base, such as triethylamine or diiscpropylethylamine, etc. If necessary, dimethylaminopyridine, etc., can be added.

Alternatively, the compound (xviii) can be manufactured by reacting the compound (xvi) with the carboxylic acid (xvii, R¹² is hydroxy) in a solvent, such as THF or DMF, in the presence of a condensing agent, such as 1-hydroxybenzotriazole and 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide hydrochloride, and a base, such as triethylamine or diisipropylethylamine, etc.

[Method E]

wherein R¹³ is substituted or unsubstituted alkyl, R^(20a) and R^(20b) are hydrogen, halogen, cyano, hydroxy, carboxy, sulfo, substituted or unsubstituted alkyloxy, substituted or unsubstituted alkenyloxy, substituted or unsubstituted alkynyloxy, substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkenyl, a substituted or unsubstituted non-aromatic heterocyclic group, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted alkyloxycarbonyl, substituted or unsubstituted alkenyloxycarbonyl, substituted or unsubstituted alkynyloxycarbonyl, substituted or unsubstituted carbamoyl, substituted or unsubstituted sulfamoyl, substituted or unsubstituted amino, substituted or unsubstituted imino, substituted or unsubstituted guanidyl or R^(20a) and R^(20b) are taken together to form oxo or thioxo, u is an integer of 1 to 4, and other symbols are as defined above. (Step 3)

The compound (xx) can be manufactured by reacting the compound (x) obtained by the method B with the compound (xix) in a solvent, such as DMF, NMP or THF, etc., in the presence of a base, such as DBU, potassium t-butoxide or sodium hydride, etc., at a temperature between 0° C. and 80° C., preferably at a temperature between 30° C. and 50° C.

(Step 2)

The compound (xxi) can be manufactured by reacting the compound (xx) with the compound (vi) in a solvent, such as t-butanol, isopropanol, ethanol or acetonitrile, etc., in the presence of an acid such as formic acid, acetic acid or methanesulfonic acid, etc., at reflux.

(Step 3)

The compound (xxii) can be manufactured by reacting the compound (xxi) with a solution, such as lithium hydroxide aqueous solution, sodium hydroxide aqueous solution and potassium hydroxide aqueous solution, in a solvent, such as methanol or ethanol, etc., or in a mixture of such solvent and a solvent, such as THF or dioxane, etc.

[Method F]

wherein R¹⁴ is substituted or unsubstituted alkyl, R¹⁵ and R¹⁶ are each independently substituted or unsubstituted alkyl, substituted or unsubstituted arylalkyl, substituted or unsubstituted heteroarylalkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkenyl, substituted or unsubstituted acyl, a substituted, or unsubstituted non-aromatic heterocyclic group, substituted or unsubstituted aryl or substituted or unsubstituted heteroaryl, u is an integer of 1 to 4 and other symbols are as defined above. (Step 1)

The compound (xxiv) can be manufactured by reacting the compound (xxiii) obtained by the method A or B with a solution, such as lithium hydroxide aqueous solution, sodium hydroxide aqueous solution and potassium hydroxide aqueous solution, in a solvent, such as methanol or ethanol, etc., or in a mixture of such solvent and a solvent, such as dioxane THF, etc.

(Step 2)

The compound (xxvi) can be manufactured by reacting the compound (xxiv) with the compound (xxv) in a solvent, such as THF, DMF or NMP, etc., in the presence of a condensing agent, such as 1-hydroxybenzotriazole, HOAt, 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride, HATU or PyBOP, etc., and a base, such as triethylamine or diisipropylethylamine, etc.

[Method L]

wherein the symbols in the formula are as defined above. (Step 1)

The compound (ixl) can be manufactured by reacting a mixture of the compound (x) obtained by the method B and the alcohol (xxxviii) in a solvent, such as THF or dioxane, etc., with triphenylphosphine, etc., and diethyl azodicarboxylate, etc.

(Step 2)

The compound (II) can be manufactured by reacting the compound (ixl) with the compound (vi) in the presence of an acid, such as formic acid or acetic acid, etc., at reflux.

Using the optically-active alcohol (xxxviii) enables to synthesize the optically-active compound (II).

The alcohol used as an intermediate (xxxviii) is commercially available or can be manufactured according to a method specified in the following documents:

-   Tetrahedron (1993), 49(11), 2325-44. -   Chemical Communications (2008), (47), 6408-6410. -   Tetrahedron (1990), 46(24), 8207-28. -   Synlett (1994), (3), 199-200. -   Bulletin of the Chemical Society of Japan (1994), 67(8), 2244-7 -   Canadian Journal of Chemistry (1996), 74, 1731-1737 -   Chemistry—A European Journal (2010), 16(2), 577-587 -   Bioorganic & Medicinal Chemistry Letters (2009), 19(21), 6196-6199. -   Chemische Berichte (1985), 118(10), 3966-79. -   Tetrahedron: Asymmetry (1992), 3(4), 515-16. -   Organic Letters (1999), 1(6), 957-959. -   Chimia (1986), 40 (5), 172-3.     [Method M]

wherein R²¹ is hydrogen, substituted or unsubstituted alkyl or substituted or unsubstituted alkoxy, etc., R²² is bromo or iodo, R²³ and R²⁴ are each independently substituted or unsubstituted alkyl, substituted or unsubstituted arylalkyl, substituted or unsubstituted heteroarylalkyl, substituted or unsubstituted cycloalkyl, a substituted or unsubstituted non-aromatic heterocyclic group, substituted or unsubstituted aryl or substituted or unsubstituted heteroaryl, and other symbols are as defined above. (Step 1)

The compound (xxxix) can be manufactured by reacting the compound (xxxvii) obtained by the method from A to F or L with the compound (xxxviii) in a solvent, such as THF or dioxane, etc., in the presence of a palladium catalyst and a solution, such as potassium carbonate, cesium carbonate or sodium carbonate aqueous solution, etc., at a temperature between 50° C. and reflux, preferably at reflux, or under microwave irradiation at a temperature between 120° C. and 200° C., preferably at a temperature between 130° C. and 150° C.

(Step 2)

The compound (xl) can be obtained by dissolving the compound (xxxix) in an alcohols solvent, such as methanol or ethanol, etc., and performing catalytic reduction using a hydrogenation reactor (such as H-Cube (10% Pt—C, H2=1 atm)) or a metallic catalyst, such as palladium-carbon, platinum oxide, chlorotris (triphenylphosphine) rhodium (I), etc.

[Method N]

wherein the symbols in the formula are as defined above. (Step 1)

The compound (xlii) can be manufactured by reacting the compound (xli) obtained by the method from A to P or L with the compound (xxxviii) in a solvent, such as THF or dioxane, etc., in the presence of a palladium catalyst and a solution, such as potassium carbonate, cesium carbonate or sodium carbonate aqueous solution, etc., at a temperature between 50° C. and reflux, preferably at reflux, or under microwave irradiation at a temperature between 120° C. and 200° C., preferably at a temperature between 130° C. and 150° C.

(Step 2)

The compound (xliii) can be obtained by dissolving the compound (xlii) in an alcohols solvent, such as methanol or ethanol, etc., and performing catalytic reduction using a hydrogenation reactor (such as H-Cube (10% Pt—C, H2=1 atm)) or a metallic catalyst, such as palladium-carbon, platinum oxide or chlorotris (triphenylphosphine) rhodium (I), etc.

[Method O]

wherein R²⁵ is substituted or unsubstituted alkyl or substituted or unsubstituted alkoxy, R²⁶ is bromo or iodo, and other symbols are as defined above. (Step 1)

The compound (xlvi) can he obtained from the compound (xliv) in the presence of Lewis acid or trifluoroacetic acid, etc., under solvent-free conditions or in an appropriate solvent at a temperature between 0° C. and reflux.

(Step 2)

The compound (xlviii) can be manufactured by reacting the compound (xlvi) with the compound (xivii) in a solvent, such as THF or dioxane, etc., in the presence of a palladium catalyst and a solution, such as potassium carbonate, cesium carbonate or sodium carbonate aqueous solution, etc., at a temperature between 50° C. and reflux, preferably at reflux, or under microwave irradiation at a temperature of 120° C. and 200° C., preferably at a temperature between 130° C. and 150° C.

[Method P]

wherein the symbols in the formula are as defined above.

The compound (xlii) can be manufactured by reacting the compound (xli) or its hydrochloride or bromate with a reducing agent, such as lithium aluminum hydride, diisobutylaluminum hydride, diborane, lithium borohydride, sodium borohydride etc., in a solvent, such as THF, dioxane, methanol etc., in the presence or absence of Lewis acid or acid, such as titanium tetrachloride, cobalt chloride (II), methane sulfonic acid etc., at a temperature between −20° C. and reflux, preferably at room temperature.

The preferred embodiment of the present invention is a compound or its pharmaceutically acceptable salt as mentioned below.

A compound of Formula (I):

or its pharmaceutically acceptable salt.

-   1) The compound of Formula (I), wherein     the group represented by the following formula:

is a group represented by the following formula:

and the group represented by the following formula:

is a group represented by the following formula:

or its pharmaceutically acceptable salt.

-   2) The compound of Formula (I), wherein     the group represented by the following formula:

is a group represented by the following formula:

and the group represented by the following formula:

is a group represented by the following formula:

or its pharmaceutically acceptable salt.

-   3) The compound of Formula (I), wherein     the group represented by the following formula:

is a group represented by the following formula:

and the group represented by the following formula:

is a group represented by the following formula:

or its pharmaceutically acceptable salt.

-   4) The compound of Formula (I), wherein     the group represented by the following formula:

is a group represented by the following formula:

and the group represented by the following formula:

is a group represented by the following formula:

or its pharmaceutically acceptable salt.

-   5) The compound Formula (I), wherein     the group represented by the following formula:

is a group represented by the following formula:

and the group represented by the following formula:

is a group represented by the following formula:

or its pharmaceutically acceptable salt.

-   6) The compound of Formula (I), wherein     the group represented by the following formula:

is a group represented by the following formula:

and the group represented by the following formula:

is a group represented by the following formula:

or its pharmaceutically acceptable salt.

-   7) The compound of Formula (I), wherein -   R^(a) and R^(b) are taken together to form oxo: -   R^(d) and R^(e) are taken together to form oxo; -   R^(4a) and R^(4b) are both hydrogen atoms; -   n is 1; -   R² is phenyl substituted with methyl; -   s is 0; and -   s′ is 1. -   or its pharmaceutically acceptable salt. -   8) The compound of Formula (I), wherein -   R^(a) and R^(b) are taken together to form oxo: -   R^(d) and R^(e) are taken together to form oxo; -   R^(4a) and R^(4b) are both hydrogen atoms; -   n is 1; -   R² is phenyl substituted with halogen; and -   s and s′ are both 0, -   or its pharmaceutically acceptable salt. -   (Substituent groups not specially defined, in the above 1)-8) are as     defined in the above (1))

When the group represented by the following formula in the compound of Formula (I):

is the group represented by the following formula:

the absolute configuration of the formula is exemplified by the following configuration:

When the group represented by the following formula in the compound of Formula (I):

is the group represented by the following formula:

the absolute configuration of the formula is exemplified by the following configuration:

Particularly, when the group represented by the following formula:

is the group represented by the following formula:

the absolute configuration of the formula is preferably the following configuration:

wherein R^(20a) is preferably methyl.

The compounds of Formula (I) are not limited to specific isomers but include all possible isomers (e.g., keto-enol isomers, imine-enamine isomers, diastereoisomers, enantiomers, rotamers or the like), racemates or mixtures thereof. For example, a compound of Formula (I) includes the following tautomer.

In addition, one or more hydrogen atoms, carbon atoms or other atoms of the compound of Formula (I) can be replaced by an isotope of the hydrogen atom, carbon atom or other atoms. Compounds of Formula (I) include all radiolabeled forms of compounds of Formula (I). The “radiolabeled,” “radiolabeled form” and the like of the compound of Formula (I) are encompassed by the present invention and useful as a research and/or diagnostic tool in metabolism pharmacokinetic studies and in binding assays. It is also useful for a medicament.

One or more hydrogen, carbon and/or other atoms in the compounds of Formula (I) may be replaced with isotopes of hydrogen, carbon and/or other atoms respectively. Examples of isotopes include hydrogen, carbon, nitrogen, oxygen, phosphorus, sulfur, fluorine, iodine and chlorine, such as ²H, ³H, ¹¹C, ¹³C, ¹⁴C, ¹⁵N, ¹⁸O, ¹⁷O, ³¹P, ³²P, ³⁵S, ¹⁸F, ¹²³I and 36Cl respectively. The compounds of Formula (I) include the compounds replaced with these isotopes. The compounds replaced with the above isotopes are useful as medicines and include all of radiolabeled compounds of the compound of Formula (I). A “method of radiolabeling” in the manufacture of the “radiolabeled compounds” is encompassed by the present invention, and the “radiolabeled compounds” are useful for studies on metabolized drug pharmacokinetics, studies on binding assay and/or diagnostic tools.

A radiolabeled compound of the compounds of Formula (I) can be prepared using well-known methods in this field of the invention. For example, a tritium-labeled compound of Formula (I) can be prepared by introducing a tritium to a certain compound of Formula (I), through a catalytic dehalogenation reaction using a tritium. This method comprises reacting with an appropriately-halogenated precursor of the compound of Formula (I) with tritium gas in the presence of an appropriate catalyst, such as Pd/C, and in the presence or absent of a base. The other appropriate method of preparing a tritium-labeled compound can be referred to “Isotopes in the Physical and Biomedical Sciences, Vol. 1, Labeled Compounds (Part A), Chapter 6 (1987)”. A ¹⁴C-labeled compound can be prepared by using a raw material having ¹⁴C.

The pharmaceutically acceptable salts of the compounds of Formula (I) include, for example, salts with alkaline metal (e.g., lithium, sodium, potassium or the like), alkaline earth metal (e.g., calcium, barium or the like), magnesium, transition metal (e.g., zinc, iron or the like), ammonia, organic bases (e.g., trimethylamine, triethylamine, dicyclohexylamine, ethanolamine, diethanolamine, triethanolamine, meglumine, ethylenediamine, pyridine, picoline, quinoline or the like) or amino acids, or salts with inorganic acids (e.g., hydrochloric acid, sulfuric acid, nitric acid, carbonic acid, hydrobromic acid, phosphoric acid, hydroiodic acid or the like) or organic acids (e.g., formic acid, acetic acid, propionic acid, trifluoroacetic acid, citric acid, lactic acid, tartaric acid, oxalic acid, maleic acid, fumaric acid, mandelic acid, glutaric acid, malic acid, benzoic acid, phthalic acid, ascorbic acid, benzenesulfonic acid, p-toluenesulfonic acid, methanesulfonic acid, ethanesulfonic acid or the like). Especially, salts with hydrochloric acid, sulfuric acid, phosphoric acid, tartaric acid, methanesulfonic acid and the like are included. These salts can be formed by the usual methods.

The compounds of Formula (I) of the present invention or pharmaceutically acceptable salts thereof may form solvates (e.g., hydrates or the like) and/or crystal polymorphs. The present invention encompasses those various solvates and crystal polymorphs. “Solvates” may be those wherein any numbers of solvent molecules (e.g., water molecules or the like) are coordinated with the compounds of Formula (I). When the compounds of Formula (I) or pharmaceutically acceptable salts thereof are allowed to stand in the atmosphere, the compounds may absorb water, resulting in attachment of adsorbed water or formation of hydrates. Recrystallization of the compounds of Formula (I) or pharmaceutically acceptable salts thereof may produce crystal polymorphs.

The compounds of Formula (I) of the present invention or pharmaceutically acceptable salts thereof may form prodrugs. The present invention also encompasses such various prodrugs. Prodrugs are derivatives of the compounds of the present invention that have chemically or metabolically degradable groups, and compounds that are converted to the pharmaceutically active compounds of the present invention through solvolysis or under physiological conditions in vivo. Prodrugs include compounds that are converted to the compounds of Formula (I) through enzymatic oxidation, reduction, hydrolysis or the like under physiological conditions in vivo, compounds that are converted to the compounds of Formula (I) through hydrolysis by gastric acid etc., and the like. Methods for selecting and preparing suitable prodrug derivatives are described in, for example, “Design of Prodrugs, Elsevier, Amsterdam, 1985”. Prodrugs themselves may have some activity.

When the compounds of Formula (I) or pharmaceutically acceptable salts thereof have hydroxyl group(s), prodrugs include acyloxy derivatives and sulfonyloxy derivatives that are prepared by, for example, reacting compounds having hydroxyl group(s) with suitable acyl halide, suitable acid anhydride, suitable sulfonyl chloride, suitable sulfonyl anhydride and mixed anhydride, or with a condensing agent. For example, they include CH₃COO—, C₂H₃COO—, tert-BuCOO—, C₁₅H₃₁COO—, PhCOO—, (m-NaOOCPh)COO—, NaOOCCH₂CH₂COO—, CH₃CH(NH₂)COO—, CH₂N(CH₃)₂COO—, CH₃SO₃—, CH₃CH₂SO₃—, CF₃SO₃—, CH₂FSO₃—, CF₃CH₂SO₃—, p-CH₃O—PhSO₃—, PhSO₃— and p-CH₃PhSO₃.

The compound of the Formula (I) has an antagonistic activity on P2X₃ and/or P2X_(2/3) receptor, and therefore, is useful as a therapeutic agent for diseases associated with a P2X₃ and/or P2X_(2/3) receptor. Since P2X₃ and/or P2X_(2/3) receptor is believed to associate with pain, diseases in urinary system and respiratory disease (Nature 407, 26, 1011-1015 (2000), Nature, Vol.407, No.26, 1015-1017 (2000), Non-Patent Document 1, Non-Patent Document 2, Non-Patent Documents 9-11 etc.), the compound of the invention is useful in the treatment, alleviation of symptoms or prevention of diseases, such as for example, pain associated with rheumatoid arthritis, pain associated with osteoarthritis, headache, migraine, orofacial pain, toothache, glossagra, pain associated with temporomandibular arthrosis, trigeminal neuralgia, shoulder pain, pain associated with hernia of intervertebral disk, pain associated with cervical spondylosis deformans, pain associated with spinal canal stenosis, pain associated with thoracic outlet syndrome, pain associated with traumatic brachial plexus injury syndrome, pain associated with shoulder-hand syndrome, pain associated with whiplash injury, chest pain, abdominal pain, colic pain, pain associated with cholelithiasis, pain associated with pancreatitis, pain associated with urinary calculosis, pain associated with irritable bowel syndrome, lumbar backache, sciatica, pain associated with bone fracture, pain associated with osteoporosis, joint pain, pain associated with gout, pain associated with cauda equina syndrome, pain associated with ankylosing spondylitis, sore muscle, pain associated with painful spasm, pain associated with myofascial pain syndrome, pain associated with fibromyalgia syndrome, complex regional pain syndrome, pain associated with arteriosclerosis obliterans, pain associated with Buerger's disease, pain associated with Raynaud's phenomenon, pain associated with zoster, causalgic pain, pain associated with entrapment neuropathy, pain associated with carpal canal syndrome, pain associated with diabetes, pain associated with Guillain-Barre syndrome, pain associated with Hansen's disease, pain associated with drug therapy, pain associated with radiation therapy, pain associated with cord injury, pain associated with syringomyelia, pain associated with stroke, thalamic pain, pain associated with deafferentation, sympathetically-maintained pain, ABC syndrome, multiple sclerosis, pain associated with skin disease, cancer pain, postoperative pain, pain associated with injury, pain associated with gangrene, pain associated with somatoform disorder, pain associated with somatization disorder, pain associated with depression, pain associated with Parkinson's disease, knee joint pain, pain associated with arthritis, neuropathic pain such as menstrual pain, intermenstrual pain, labor pain, etc., inflammatory pain, nociceptive pain, psychogenic pain, pains associated with endometriosis, and the like; Overactive bladder, urge incontinence, stress urinary incontinence, reflex incontinence, urinary urgency, neurogenic bladder, unstable bladder, urethritis, urinary tract infections, interstitial cystitis, cystitis, bladder cancer, chemotherapy-induced urinary tract disorder, urinary tract disorders associated with brain disorders such as stroke etc., voiding dysfunction, pain, etc. associated with prostatic hyperplasia, prostatitis, etc., and the like.

And chronic obstructive pulmonary disease (COPD), asthma, bronchospasm, chronic cough, and the like.

“A pharmaceutical composition having an improving effect of urination disorder” includes a pharmaceutical composition for use to improve the treatment and/or prevention of urination disorder.

The compound of the present invention or the pharmaceutical composition of the present invention can be a drug with reduced side-effect such as effect on motor function because it has a high affinity for ATP receptor, especially P2X₃ receptor, and also has high subtype selectivity and high selectivity for other receptors. Also, the compound encompassed by the present invention or the pharmaceutical composition encompassed by the present invention is advantageous because of its high P2X₃ receptor inhibitor activity in the presence of RSA, high metabolic stability, high oral absorption, high solubility, good bioavailability, low total body clearance, long half-life, prolonged duration of action, low activity of hepatic enzyme inhibition, high unbound fraction in serum and/or high safety etc.

The compound of the present invention or the pharmaceutical composition of the present invention can be a drug with high persistence after administration because of its low total body clearance.

When administering the pharmaceutical composition of the present invention, it can be administered in any method of orally and parenterally methods. Methods for parenteral administration include dermal, subcutaneous, intravenous, intraarterial, intramuscular, intraperitoneal, transmucosal, inhalation, transnasal, ophthalmic, inner ear or vaginal administration and the like.

In case of oral administration, any forms, which are usually used, such as oral solid formulations (e.g., tablets, powders, granules, capsules, pills, films or the like), oral liquid formulations (e.g., suspension, emulsion, elixir, syrup, lemonade, spirit, aromatic water, extract, decoction, tincture or the like) and the like may prepared according to the usual method and administered. The tablets can be sugar-coated tablets, film-coated tablets, enteric-coating tablets, sustained-release tablets, troche tablets, sublingual tablets, buccal tablets, chewable tablets or orally dispersing tablets. Powders and granules can be dry syrups. Capsules can be soft capsules, micro capsules or sustained-release capsules.

In case of parenteral administration, any forms, which are usually used, such as injections, drips, external preparations (e.g., ophthalmic drops, nasal drops, ear-drops, aerosols, inhalations, lotion, infusion, liniment, mouthwash, enema, ointment, plaster, jelly, cream, patch, cataplasm, external powder, suppository or the like) and the like can be preferably administered. Injections can be emulsions whose type is O/W, W/O, O/W/O, W/O/W or the like.

Various pharmaceutical additives such as excipients, binders, disintegrating agents and lubricants suitable for the dosage form can be mixed as necessary in an effective amount of the compound of the present invention, to make the compound into a pharmaceutical composition. Furthermore, the pharmaceutical composition can be for pediatric patients, geriatric patients, serious cases or operations by appropriately changing the effective amount of the compound of the present invention, formulation and/or various pharmaceutical additives. The pediatric pharmaceutical compositions are preferably administered to patients under 12 or 15 years old. In addition, the pediatric pharmaceutical compositions can be administered to patients who are under 27 days old after the birth, 28 days to 23 months old after the birth, 2 to 11 years old, 12 to 16 years old, or 18 years old. The geriatric pharmaceutical compositions are preferably administered to patients who are 65 years old or over.

Although the dosage of a pharmaceutical composition of the present invention should be determined in consideration of the patient's age and body weight, the type and degree of diseases, the administration route and the like, a usual oral dosage is 0.05 to 100 and preferably 0.1 to 10 mg/kg/day. For parenteral administration, although the dosage highly varies with administration routes, a usual dosage is 0.005 to 10 and preferably 0.01 to 1 mg/kg/day. The dosage may be administered in one to several divisions per day.

The dosage amount of the concomitant drug can be appropriately selected based on the clinically used dose. In addition, the blending ratio of the compound of the present invention to the concomitant drug cart be appropriately selected depending on the administration subject, administration route, target disease, symptoms, combination and the like. For example, when the administration subject is a human, 0.01 to 100 parts by weight of the concomitant drug may be used, based on 1 part by weight of the compound of the present invention.

Following examples illustrate the present invention in more detail, but the present invention is not limited by these examples. The meaning of each abbreviation is as follows:

-   Me: methyl -   TMS: tetramethylsilane -   DMSO: dimethyl sulfoxide -   DMA: dimethyl acetamide -   DMF: dimethylformamide -   THF: tetrahydrofuran -   DBU: 1,8-diazabicyclo[5.4.0]undeca-7-ene -   NMP: N-methyl-2-pyrrolidone -   HOAt: 1-hydroxy-7-azabenzotriazole -   HATU: 2-(7-azabenzotriazole-1-yl)-1,3,3-tetramethyluronium     hexafluorophosphate -   PyBOP: benzotriazole-1-yl-oxytrispyrrolidinophosphonium     hexafluorophosphate -   rt: room temperature -   M: mol/L

EXAMPLE 1 (1) Preparation of trans-3-(4-ethoxycarbonylcyclobutyl)-6-(1-pyrazolyl)-1,3,5-triazine-2,4(1H,3H)-dione

To a solution of ethyl trans-3-aminocyclobutanecarboxylate hydrochloride (340 mg, 2.3 mmol) in DMA (3.4 mL) were added 1,1-Carbonyldiimidazole (496 g, 3.1 mmol) and DBU (0.46 ml, 3.1 mmol) under ice-cooling. The reaction mixture was stirred at room temperature for 4.5 hours, then 1-amidinopyrazole hydrochloride (340 mg, 2.3 mmol) and DBU (0.37 mL, 2.4 mmol) were added. The reaction mixture was stirred at room temperature for 7.5 hours. 1,1′-Carbonyldiimidazole (564 mg, 3.5 mmol) was added to the reaction mixture under ice-cooling, then DBU (0.52 mL, 3.5 mmol) was added. The reaction mixture was stirred at 50° C. for 15 hours. 4 mol/L Hydrochloric acid (7.5 mL) was added to the reaction mixture under ice-cooling. The resulting powder was collected by filtration to give trans-3-(4-ethoxycarbonylcyclobutyl)-6-(1-pyrazolyl)-1,3,5-triazine-2,4(1H,3H)-dione (376 mg, yield: 53%) as white powder.

1H-NMR (δ ppm TMS/DMSO-d6): 1.21 (3H, t, J=6.9 Hz), 2.40 (2H, t, J=9.4 Hz), 3.03 (2H, dd, J=19.4, 9.9 Hz), 3.09-3.17 (1H, m), 4.12 (2H, q, J=6.8 Hz), 5.13-5.31 (1H, m), 6.72 (1H, s), 8.05 (1H, s), 8.56 (1H, s), 13.05 (1H, br s).

(2) Preparation of trans-3-(4-ethoxycarbonylcyclobutyl)-1-(4-methylbenzyl)-6-(1-pyrazolyl)-1,3,5-triazine-2,4(1H,3H)-dione

Diisopropylethylamine (0.19 mL, 1.1 mmol) was added to mixture of trans-3-(4-ethoxycarbonylcyclobutyl)-6-(1-pyrazolyl)-1,3,5-triazine-2,4(1H,3H)-dione (279 mg, 0.9 mmol), 4-methylbenzyl bromide (203 mg, 1.1 mmol), and DMA (2.8 mL), and the reaction mixture was stirred at 60° C. for 7 hours. The reaction mixture was acidified by 5% aqueous solution of citric acid, and extracted with ethyl acetate. The organic layer was washed by brine, dried over anhydrous sodium sulfate, and concentrated in vacuo to give crude trans-3-(4-ethoxycarbonylcyclobutyl)-1-(4methylbenzyl)-6-(1-pyrazolyl)-1,3,5-triazine-2,4(1H,3H)-dione (371 mg, yield:99%) as yellow solid.

(3) Preparation of 6-[4-(5-chloro-2-pyridyloxy)phenylimino]-3-(4-ethoxycarbonylcyclobutyl)-1-(4-methylbenzyl)-1,3,5-triazinane-2,4-dione (I-172)

Mixture of trans-3-(4-ethoxycarbonylcyclobutyl)-1-(4-methylbenzyl)-6-(1-pyrazolyl)-1,3,5-triazine-2,4(1H,3H)-dione (123 mg, 0.3 mmol), 4-(5-chloro-2-pyridyloxy)aniline (73 mg, 0.33 mmol), and t-butanol (1.2 mL) was heated under reflux with stirring for 2 hours. The reaction mixture was concentrated in vacuo, and the residue was purified by silica-gel chromatography (ethyl acetate/hexane) to give 6-[4-(5-chloro-2-pyridyloxy)phenylimino]-3-(4-ethoxycarbonylcyclobutyl)-1-(4-methylbenzyl)-1,3,5-triazinane-2,4-dione (I-172, 140 mg, yield: 83%) as pale yellow amorphous.

1H-NMR (CDCl3)δ: 1.28 (3H, t, J=6.8 Hz), 2.35 (3H, s), 2.50-2.70 (2H, m), 3.03-3.15 (2H, m), 3.16-3.30 (1H, m), 4.17 (2H, q, J=7.0 Hz), 5.20 (2H, s), 5.34-5.58 (1H, m). 6.59-7.08 (4H, m), 7.14 (3H, dd, J=14.4, 7.8 Hz), 7.49 (2H, d, J=7.4 Hz), 7.56-7.71 (2H, m), 8.10 (1H, s).

EXAMPLE 2 Preparation of 6-[4-(5-chloro-2-pyridyloxy)phenylimino]-3-(4-hydroxycarbonylcyclobutyl)-1-(4-methylbenzyl)-1,3,5-triazinane-2,4-dione (I178)

4mol/L Lithium hydroxide (0.24 mL, 0.96 mmol) was added to mixture of6-[4-(5-chloro-2-pyridyloxy)phenylimino]-3-(4-ethoxycarbonylcyclobutyl)-1-(4-methylbenzyl)-1,3,5-triazinane-2,4-dione (135 mg, 0.24 mmol), methanol (0.7 mL), and THF (0.7 mL), and stirred at 50° C. for 3 hours. 2mol/L Hydrochloric acid (0.43 mL) was added to the reaction mixture, and the resulting mixture was concentrated in vacuo. The residue was purified by silica-gel chromatography (chloroform/methanol) and powderized by ethyl acetate and hexane to give 6-[4-(5-chloro-2-pyridyloxy)phenylimino]-3-(4-hydroxycarbonylcyclobutyl)-1-(4-methylbenzyl)-1,3,5-triazinane-2,4-dione (I-178, 103 mg, yield: 80%) as white powder.

1H-NMR (CDCl₃) δ: 2.35 (3H, s), 2.52-2.72 (2H, m), 3.08-3.42 (3H, m), 5.20 (2H, s), 5.37-5.61 (1H, m), 6.82-8.95 (3H, m), 7.01-7.20 (4H, m), 7.48 (2H, d, J=7.3 Hz), 7.61-7.81 (2H, m), 8.11 (1H, s).

REFERENCE EXAMPLE 1 (1) Preparation of 1-(4-chlorobenzyl)-6-(ethylthio)-1,3,5-triazine-2,4(1H,3H)-dione

t-Butyl isocyanate (1.2 mL, 10.5 mmol) and DBU (1.9 mL, 12.8 mmol) were added to mixture of S-ethylthiourea hydrobromate (1.85 g, 10 mmol) and DMF (9.3 mL) under ice-cooling, and the resulting mixture was stirred for 6 hours. 1,1′-Carbonyldiimidazole (1.95 g, 12 mmol) and DBU (1.9 mL, 12.8 mmol) were added to the reaction mixture under ice-cooling and the mixture was stirred for 2 hours. 2 mol/L Hydrochloric acid (80 mL) was added to the reaction mixture under ice-cooling over 50 minutes, and the generated powder was collected by filtration. The powder was dissolved in ethyl acetate, dried over anhydrous magnesium sulfate, and concentrated in vacuo to give 6-(ethylthio)-3-t-butyl-1,3,5-triazine-2,4(1H,3H)-dione (1.15 g, yield: 50%) as pale brown powder.

1H-NMR (δ ppm TMS/DMSO-d6): 1.27 (3H, t, J=7.3 Hz), 1.55 (9H, s), 3.03 (2H, q, J=7.3), 12.30 (1H, brs)

Potassium carbonate (17.97 g, 130 mmol) was added to mixture of 6-(ethylthio)-3-t-butyl-1,3,5-triazine-2,4(1H,3H)-dione (22.93 g, 100 mmol), 4-chlorobenzyl bromide (22.60 g, 110 mmol), and acetonitrile (200 mL), and the resulting mixture was heated at reflux and stirred for 3 hours. The reaction mixture was filtered, and the filtrate was concentrated in vacuo to give the crude product (39.9 g) of 3-t-butyl-1-(4-chlorobenzyl)-6-(ethylthio)-1,3,5-triazine-2,4(1H,3H)-dione as pale brown oil.

Trifluoroacetic acid (100 mL) was added to the resulting crude product, the resulting mixture was stirred at room temperature for 17 hours. The reaction mixture was concentrated in vacuo to give 1-(4-chlorobenzyl)-6-(ethylthio)-1,3,5-triazine-2.4(1H,3H)-dione (29.03 g, yield: 97%) as pale brown powder.

1H-NMR (δ ppm TMS/d6-DMSO): 1.25 (3H, t, J=7.3 Hz), 3.08 (2H, q, J=7.3Hz), 5.02 (2H, s), 7.30-7.33 (2H, m), 7.39-7.42 (2H, m), 11.61 (1H, s).

(2) Preparation of 1-(4-chlorobenzyl)-3-(methoxycarbonylmethyl)-6-[4-(2-pyridyloxy)phenylimino]-1,3,5-triazinane-2,4-dione (R-238)

Potassium carbonated (80 g, 13 mmol) was added to mixture of 1-(4-chlorobenzyl)-6-(ethylthio)1,3,5-triazine-2,4(1H,3H)-dione (2.98 g, 10 mmol), methyl bromoacetate (1.04 mL, 11 mmol), and DMF (30 mL), and the resulting mixture was stirred at room temperature for 4 hours. Water (250 mL) was added to the reaction mixture, and the resulting mixture was extracted with ethyl acetate (200 mL). The organic layer was washed by brine (250 mL), and dried over anhydrous magnesium sulfate. After concentrated in vacuo, to the residue were added ethyl acetate and hexane. The generated powder was collected by filtration to give 1-(4-chlorobenzyl)-3-(methoxycarbonymethyl)-6-(ethylthio)1,3,5-triazine-2,4(1H,3H)-dione (3.26 g, yield: 88%) as colorless powder.

1H-NMR (δ ppm TMS/CDCl₃): 1.37 (3H, t, J=7.2 Hz), 3.23 (2H, q, J=7.2 Hz), 3.78 (3H, s), 4.68 (2H, s), 5.11 (2H, 3), 7.27-7.35 (4H, m).

Mixture of 1-(4-chlorobenzyl)-3-(methoxycarbonymethyl)-6-(ethylthio)1,3,5-triazine-2,4(1H,3H)-dione (1.0 g, 2.70 mmol), 4-(2-pyridyloxy)aniline (1.0 g, 5.4 mmol), t-butanol (10.0 mL), and acetic acid (2.3 mL) was heated under reflux with stirring for 8 hours. Saturated aqueous solution of sodium hydrogen carbonate (30 mL) was added to the reaction mixture, and the resulting mixture was extracted with ethyl acetate (20 mL×3). The organic layer was washed by water (20 mL) and brine (20 mL) and dried over anhydrous magnesium sulfate. After concentrated in vacuo, the residue was purified by silica-gel chromatography (ethyl acetate/hexane) to give 1-(4-chlorobenzyl)-3-(methoxycarbonymethyl)-6-[4-(2-pyridyloxy)phenylimino]-1,3,5-triazinane-2,4-dione (R-238, 1.24 g, yield: 93%) as pale yellow amorphous.

1H-NMR (CDCl3)δ: 3.78 (3H, s), 4.59 (2H, s), 5.23 (2H, s), 6.86 (2H, d, J=7.8 Hz), 6.96 (1H, d, J=8.1 Hz), 7.00 (1H, t, J-6.0 Hz), 7.15 (2H, d, J=8.1 Hz), 7.31 (2H, d, J=7.8 Hz), 7.49 (2H, d, J=7.8 Hz), 7.71 (1H, t, J=7.8 Hz), 7.86 (1H, s), 8.15 (1H, s).

(3) Preparation of 1-(4-chlorobenzyl)-3-(hydroxylcarbonymethyl)-6-[4-(2-pyridyloxy)phenylimino]1,3,5-triazinane-2,4-dione (R-239)

4mol/L Lithium hydroxide (2.43 mL, 9.7 mmol) was added to mixture of 1-(4-chlorobenzyl)-3-(methoxycarbonylmethyl)-6-[4-(2-pyridyloxy)phenylimino]-1,3,5-triazinane-2,4-dione (1.2 g, 2.43 mmol), methanol (12 mL), THF (12 mL), and water (12 mL), and the resulting mixture was stirred under ice-cooling for 1 hour. The reaction mixture was poured into ice water, acidified by 1 mol/L hydrochloric acid, and extracted with ethyl acetate (100 mL). The organic layer was washed by water (50 mL) and brine (50 mL) and dried over anhydrous magnesium sulfate. After concentrated in vacuo, to the residue were added ethyl acetate and diethylether, and the generated powder was collected by filtration to give 1-(4-chlorobenzyl)-3-(hydroxylcarbonylmethyl)-6-[4-(2-pyridyloxy)phenylimino]-1,3,5-triazinane-2,4-dione (R-239, 2.23 mg, yield: 92%) as pale brown powder.

1H-NMR (δ ppm TMS/d6-DMSO): 4.40 (2H, s), 5.30 (2H, s), 7.03 (2H, d, J=7.8 Hz), 7.12 (2H, s), 7.13 (1H, s), 7.37 (4H, d, J=7.5 Hz), 7.45 (4H, d, J=7.5 Hz), 7.84 (1H, t, J=7.8 Hz), 8.16 (1H, s), 9.48 (1H, brs).

(4) Preparation of 1-(4-chlorobenzyl)-3-(carbamoylmethyl)-6-[4-(2-pyridyloxy)phenylimino]-1,3,5-triazinane-2,4-dione (R-240)

1-(4-chlorobenzyl)-3-(methoxycarbonymethyl)-6-[4-(2-pyridyloxy)phenylimino]-1,3,5-triazinane-2,4-dione (150 mg, 0.31 mmol) was dissolved in DMF (2 mL). Ammonium chloride (16.7 mg, 0.31 mmol), 1-hydroxybenzotriazole hydrate (57.4 mg, 0.38 mmol), 4-dimethylaminopyridine (3.8 mg, 0.03 mmol), 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (71.9 mg, 0.38 mmol), and triethylamine (0.05 mL, 0.38 mmol) were added to the reaction mixture, and the resulting mixture was stirred at room temperature for 16 hours. To the reaction mixture was added saturated aqueous solution of sodium hydrogen carbonate (20 mL) and extracted with ethyl acetate (30 mL). The organic phase was washed by water (10 mL) and brine (10 mL) and dried over anhydrous magnesium sulfate. After concentrated in vacuo, to the residue was added ethyl acetate, and the generated powder was collected by filtration to give 1-(4-chlorobenzyl)-3-(carbamoylmethyl)-6-[4-(2-pyridyloxy)phenylimino]-1,3,5-triazinane-2,4-dione (R-240, 79 mg, yield: 53%) as pale yellow powder.

1H-NMR (δ ppm TMS/DMSO-d6): 4.28 (2H, s), 5.29 (2H, s), 7.03 (2H, d, J=7.2 Hz), 7.12 (4H, s), 7.35 (1H, s), 7.38 (1H, d, J=7.2 Hz), 7.42 (4H, d, J=9.3 Hz), 7.54 (1H, s), 7.85 (1H, t, J=7.2 Hz), 8.16 (1H, s), 9.37 (1H, s).

REFERENCE EXAMPLE 2 (1) Preparation of 3-ethyl-6-(1-pyrazolyl)-(1,3,5-triazine-2,4(1H,3H)-dione

DBU (63.3 mL, 420 mmol) was added dropwise to mixture of 1-amidinopyrazole hydrochloride (58.6 g, 400 mmol), ethyl isocyanate (33.2 mL, 420 mmol), and DMA (240 mL) at −10° C. over 15 minutes, and the resulting mixture was stirred under ice-cooling for 30 minutes. 1,1′-Carbonyldiimidazole (97.2 g, 600 mmol) was added to the reaction mixture under ice-cooling, and then DBU (93 mL, 620 mmol) was added at −5° C. over 30 minutes. The reaction mixture was stirred under ice-cooling for 1 hour and then stirred at room temperature for 1 hour. 2 mol/L Hydrochloric acid (1.16 L) was added to the reaction mixture at 20° C. over 1 hour. The resulting powder was collected by filtration to give 3-ethyl-6-(1-pyrazolyl)-1,3,5-triazine-2,4(1H,3H)-dione (73.0 g, yield: 88%) as pale brown powder.

1H-NMR (δ ppm TMS/CDCl3): 1.30 (6H, t, J=7.0 Hz), 4.02 (2H, q, J=7.0 Hz), 6.59 (1H, m), 7.34 (1H, m), 8.48 (1H, m), 9.79 (1H, brs).

(2) Preparation of 1-(4-chlorobenzyl)-3-ethyl-6-(1-pyrazolyl)-1,3,5-triazine-2,4(1H,3H)-dione

Diisopropylethylamine (92 mL, 528 mmol) was added dropwise to mixture of 3-ethyl-6-(1-pyrazolyl)-1,3,5-triazine-2,4(1H,3H)-dione (89 g, 480 mmol), 4-chlorobenzyl bromide (108 g, 528 mmol), and DMA (400 mL) at room temperature over 10 minutes, and the resulting mixture was stirred at 60° C. for 2 hours. Water (800 mL) was added dropwise to the reaction mixture under ice-cooling over 40 minutes, and then hexane (200 mL) was added. The resulting powder was collected by filtration to give 1-(4-chlorobenzyl)-3-ethyl-6-(1-pyrazolyl)-1,3,5-triazine-2,41H,3H)-dione (156 g, yield: 97.6%.) as pale brown powder.

1H-NMR (δ ppm TMS/CDCl₃): 1.30 (3H, t, J=7.1 Hz), 4.04 (2H, q, J=7.1 Hz), 5.86 (2H, s), 6.48 (1H, m), 7.02 (2H, d, J=8.6 Hz), 7.20-7.25 (2H, m), 7.84 (1H, m), 8.33 (1H, m).

(3) Preparation of 1-(4-chlorobenzyl)-6-[4-(3-chloro-5-ethoxycarbonyl-2-pyridyloxy)phenylimino]-3-ethyl-1,3,5-triazinane-2,4-dione (R-015)

Mixture of 1-(4-chlorobenzyl)-2-ethyl-6-(1-pyrazolyl)-1,3,5-triazine-2,4(1H,3H)-dione (200 mg, 0.6 mmol), 4-(3-chloro-5-ethoxycarbonyl-2-pyridyloxy)aniline (176 mg, 0.6 mmol), and t-butanol (4 mL) was stirred at 80° C. for 1 hour. The reaction mixture was concentrated in vacuo, and the residue was purified by silica-gel chromatography (ethyl acetate/hexane) to give 1-(4-chlorobenzyl)-6-[4-(3-chloro-5-ethoxycarbonyl-2-pyridyloxy)phenylimino]-3-ethyl-1,3,5-triazinane-2,4-dione (R-015, 321 mg, yield: 96%) as white powder.

1H-NMR (CDCl3) δ: 1.24 (3H, t, J=7.2 Hz), 1.39 (3H, t, J=7.2 Hz), 3.90 (2H, q, J=7.1 Hz), 4.39 (2H, q, J=7.1 Hz), 5.21 (2H, s), 6.88 (2H, dd, J=6.5, 2.0 Hz), 7.16 (2H, dd, J=6.7, 2.1 Hz), 7.30-7.33 (2H, m), 7.52 (2H, t, J=4.1 Hz), 7.89 (1H, s), 8.35 (1H, d, J=2.0 Hz), 8.63 (1H, d, J=2.0 Hz).

(4) Preparation of 1-(4-chlorobenzyl)-6-[4-(3-chloro-5-hydroxycarbonyl-2-pyridyloxy)phenylimino]-3-ethyl-1,3,5-triazinane-2 (4-dione (R-016)

1 mol/L Sodium hydroxide (0.75 mL) was added to mixture of 1-(4-chlorobenzyl)-6-[4-(3-chloro-5-ethoxycarbonyl-2-pyridyloxy)phenylimino]-3-ethyl-1,3,5-triazinane-2,4-dione (209 mg, 0.38 mmol), THF (0.75 mL), and methanol (0.75 mL). and the resulting mixture was stirred at room temperature for overnight. The reaction mixture was poured into water, acidified by 5% aqueous solution of citric acid, and then extracted with ethyl acetate. The organic phase was dried over anhydrous sodium sulfate. After concentrated in vacuo, to the residue was added diethylether, and the generated powder was collected by filtration to give 1-(4-chlorobenzyl)-6-[4-(3-chloro-5-hydroxycarbonyl-2-pyridyloxy)phenylimino]-3-ethyl-1,3,5-triazinane-2,4-dione (R-016, 125 mg, yield: 63%) as white powder.

1H-NMR (CDCl₃)δ: 1.24 (3H, q, J=8.3 Hz), 3.93 (2H, q, J=7.0 Hz), 5.23 (2H, s), 6.91 (2H, d, J=8.5 Hz), 7.14 (2H, dd, J=6.8, 2.0 Hz), 7.32 (2H, d, J=8.3 Hz), 7.53 (2H, d, J=8.3 Hz), 8.36 (1H, d, J=2.0 Hz), 8.74 (1H, d, J=1.8 Hz), 9.78 (1H, s).

REFERENCE EXAMPLE 3 (1) Preparation of (S)-1-(4-chlorobenzyl)-6-(4-hydroxyphenylimino)-3-(2-hydroxycarbonylpropyl)-1,3,5-triazinane-2,4-dione

Di-2-methoxyethylazo dicarboxylate (56.2 g, 240 mmol) was gradually added to mixture of 1-(4-chlorobenzyl)-6-(ethylthio)-1,35-triazine-2,4(1H,3H)-dione (59.6 g, 200 mmol), methyl (S)-(+)-3-hydroxyisolactate (28.4 g, 240 mmol), triphenylphosphine (62.9 g, 240 mmol) and dioxane (400 mL), and the resulting mixture was stirred at room temperature for 3 hours. The reaction mixture was added to ice water (1000 mL) and extracted with toluene (500 mL). The organic phase was washed by brine (700 mL) and dried over anhydrous magnesium sulfate. After concentrated in vacuo, the residue was purified by silica-gel column chromatography (ethyl acetate/hexane) to give (S)-1-(4-chloro benzyl)-6-(ethylthio)-3-(2-methoxycarbonylpropyl)-1,3,5-triazine-2,4(1H,3H)-dione (64.44 g, yield: 81%) as white solid.

1H-NMR (δ ppm TMS/CDCl₃): 1.19 (3H, d, J=5.7 Hz), 1.37 (3H, t, J=7.1 Hz), 2.96 (1H, m), 3.12 (2H, q, J=7.1 Hz), 3.60 (3H, s), 3.98 (1H, m), 4.21 (1H, m), 5.08 (2H, s), 7.29-7.34 (4H, m).

Mixture of (S)-1-(4-chlorobenzyl)-8-(ethylthio)-3-(2-methoxycarbonylpropyl)-1,3,5-triazine-2,4(1H,3H)-dione (5.0 g, 12.6 mmol), 4-aminophenol (2.06 g, 18.9 mmol), acetic acid (11.32 g, 189 mmol), and t-butanol (100 mL) was stirred under heating at reflux for 3 hours. After the reaction, the reaction mixture was added to saturated aqueous solution of sodium hydrogen carbonate (500 mL) and extracted with ethyl acetate (500 mL). The organic layer was washed by 1 mol/L hydrochloric acid (500 mL), dried over anhydrous sodium sulfate. After concentrated in vacuo, to the residue were added toluene and ethyl acetate, and heated, and the generated powder was collected by filtration to give (S)-1-(4-chlorobenzyl)-6-(4-hydroxyphenylimino)-3-(2-methoxycarbonylpropyl)-1,3,5-triazinane-2,4-dione (5.17 g, yield: 92%) as white powder.

2 mol/L Sodium hydroxide (25 mL) was added to mixture of (S)-1-(4-chlorobenzyl)-6-(4-hydroxyphenylimino)-3-(2-methoxycarbonyl propyl)-1,3,5-triazinane-2,4-dione (5.13 g, 11.5 mmol) and DMSO (50 mL), the resulting mixture was stirred at room temperature for 1 hour, To the reaction mixture was added 2 mol/L hydrochloric acid (25 mL), then the mixture was poured into water and extracted with ethyl acetate. The organic phase was washed by brine (700 mL/ and dried over anhydrous sodium sulfate. After concentrated in vacuo, to the residue was added ethyl acetate, and the generated powder was collected by filtration to give (S)-1-(4-chlorobenzyl)-6-(4-hydroxyphenylimino)-3-(2-hydroxycarbonylpropyl)-1,3,5-triazinane-2,4-dione (3.92 g, yield: 79%) as white powder.

1H-NMR (δ ppm TMS/d6 DMSO): 0.99 (3H, d, J=7.0 Hz), 2.50 (1H, t, J=1.8 Hz), 2.74 (1H, td, J=14.5, 7.2 Hz), 3.89-3.95 (1H, m), 5.21 (2H, s), 6.70-6.75 (2H, m), 7.01 (2H, d, J=7.8 Hz), 7.29 (2H, d, J=8.5 Hz), 7.41 (2H, d, J=8.5 Hz), 9.16 (1H, br s), 9.66 (1H, br s).

(2) Preparation of (S)-1-(4-chlorobenzyl)-6-[4-(2-benzoxazolyloxy)phenylimino]-3-(2-methoxycarbonylpropyl)1,3,5-triazinane-2,4-dione (R-144)

Cesium carbonate (454 mg, 1.39 mmol) was added to mixture of (S)-1-(4-chlorobenzyl)-6-(4-hydroxyphenylimino)-3-(2-hyclroxycarbonylpropyl)-1,3,5-triazinane-2,4-dione (200 mg, 0.46 mmol), 2-chlorobenzoxazol (78 mg, 0.51 mmol), and DMSO (1 mL), and the resulting mixture was stirred overnight at room temperature. The reaction mixture was poured into water, acidified by 5% aqueous solution of citric acid, and then extracted with ethyl acetate. The organic phase was washed by brine and dried over anhydrous sodium sulfate. After concentrated in vacuo, the residue was purified by high-performance liquid chromatography (acetnitrile/water containing 0.3% formic acid) to give (S)-1-(4-chlorobenzyl)-6-[4-(2-benzoxazolyloxy)phenylimino]-3-(2-methoxycarbonylpropyl)-1,3,5-triazinane-2,4-dione (R-144, 55.3 mg, yield: 22%) as white powder.

¹H-NMR (CDCl₃) δ: 1.13 (3H, d, J=6.8 Hz), 2.74-2.79 (1H, m), 3.82 (1H, dd, J=13.3, 5.4 Hz), 4.04 (1H, dd, J=12.8, 9.2 Hz), 5.13 (1H, d, J=14.4 Hz), 5.22 1H, d, J=14.3Hz), 6.88 (2H, d, J=7.5 Hz), 7.23-7.49 (10H, m), 8.96 (1H, s).

REFERENCE EXAMPLE 4 (1) Preparation of 1-(4-chlorobenzyl)-3-(2-hydroxymethyl-2-propenyl)-6-[4-(2-pyridyloxy)phenylimino]-1,3,5-triazinane-2,4-dione (R-254)

1-(4-Chlorobenzyl)-6-(ethylthio)-1,3,5-triazine-2,4(1H,3H)-dione (1090 mg, 3.65 mmol), 2-(tetrahydropyran-2-yloxy)methyl-2-propenol (628 mg, 3.65 mmol), and triphenylphosphine (956 mg, 3.65 mmol) were dissolved in 1,4-dioxane (5.0 mL). Dimethoxyethylazadicarboxylate (854 mg, 3.65 mmol) was added to the reaction mixture, the resulting mixture was stirred at room temperature for 3 hours. Then, triphenylphosphine (478 mg, 1.82 mmol) and dimethoxyethylazadicarboxylate (478 mg, 1.82 mmol) were added to the reaction mixture, and the resulting mixture was stirred at room temperature for 4 hours. The reaction mixture was concentrated in vacuo, and to the resulting residue was added diethylether. The generated powder was removed by filtration. The filtrate was washed by water and brine, dried over anhydrous sodium sulfate, and concentrated in vacuo. The resulting residue was purified by silica-gel chromatography (ethyl acetate/hexane) to give 1-(4-chlorobenzyl)-6-(ethylthio)-3-(2-tetrahydropyran-2-yloxymethyl-2-propenyl)-1,3,5-triazine-2,4(1H,3H)-dione (1589 mg, yield: 96%) as colorless oil.

t-Butanol (2.4 mL), 4-(2-pyridyloxy)aniline (148 mg, 0.8 mmol) and acetic acid (0.58 mL, 10 mmol) were added to 1-(4-chlorobenzyl)-6-(ethylthio)-3-(2-tetrahydropyran-2-yloxymethyl-2-propenyl)-1,3,5-triazine-2,4(1H,3H)-dione (300 mg, 0.66 mmol), and the reaction mixture was heated at reflux for 15 hours. To the reaction mixture was added 2 mol/L hydrochloric acid (0.33 mL) and stirred at room temperature for 8 hours. To the reaction mixture was added saturated aqueous solution of sodium hydrogen carbonate and extracted with ethyl acetate. The organic phase was washed by brine (30 mL) and dried over anhydrous sodium sulfate. After concentrated in vacuo, the residue was purified by silica-gel chromatography (ethyl acetate/hexane) to give 1-(4-chlorobenzyl)-3-(2-hydroxymethyl-2-propenyl)-6-[4-(2-pyridyloxy)phenylimino]1,3,5-triazinane-2,4-dione (R-254, 206 mg, yield: 63%) as white amorphous.

1H-NMR (CDCl3) δ: 52-2.66 (1H, m), 4.08 (2H, d, J=5.0 Hz), 4.50 (2H, s), 5.16 (2H, d, J=21.1 Hz), 5.21 (2H, s), 6.86 (2H, d, J=8.5 Hz), 6.96-7.01 (2H, m), 7.13 (2H, d, J=8.8 Hz), 7.31 (2H, d, J=8.3 Hz), 7.51 (2H, d, J=8.5 Hz), 7.69-7.73 (1H, m), 8.10 (1H, d, J=3.5 Hz), 8.14-8.40 (1H, m).

(2) Preparation of 1-(4-chlorobenzyl)-3-(2-hydroxymethyl-2,3-dihydroxypropyl)-6-[4-(2-pyridyloxy)phenylimino]-1,3,5-triazinane-2,4-dione (R-255)

1-(4-chlorobenzyl)-3-(2-hydroxymethyl-2-propenyl)-6-[4-(2-pyridyloxy)phenylimino]-1,3,5-triazinane-2,4-dione (192 mg, 0.39 mmol) was dissolved in 95% aqueous solution of THF (2.2 mL). Potassium osmate (VI) dehydrate (14.4 mg, 0.04 mmol) and N-methylmorpholine (92 mg, 0.78 mmol) were added to the reaction mixture, the resulting mixture was stirred at room temperature for 2 hours. To the reaction mixture was added 5% aqueous solution of sodium sulfite (1.0 mL) and water (50 mL) and extracted with ethyl acetate (50 mL). The organic phase was washed by brine (50 mL) and dried, over anhydrous sodium sulfate. After concentrated in vacuo, the residue was purified by silica-gel chromatography (chloroform/methanol) and powdered with ethyl acetate and hexane to give 1-(4-chlorobenzyl)-3-(2-hydroxymethyl-2,3-dihydroxypropyl)-6-[4-(2-pyridyloxy)phenylimino]-1,3,5-triazinane-2,4-dione (R-255, 155 mg, yield: 75%) as white powder.

¹H-NMR (DMSO-d₆) δ: 3.26-3.31 (4H, m), 3.94 (2H, s), 4.31 (1H, s), 4.42 (2H, t, J=6.0 Hz), 5.29 (2H, s), 6.97-7.18 (4H, m), 7.30-7.52 (6H, m), 7,85 1H, t, J=7.3 Hz), 8.16 (1H, d, J=3.3 Hz), 9.39 (1H, s).

REFERENCE EXAMPLE 5 Preparation of 1-(4-chlorobenzyl)-3-(2-hydroxyethyl)-6-[4-(2-pyridyloxy)phenylimino]-1,3,5-triazinane-2,4-dione (R-257)

Lithium aluminum hydride (38 mg, 1 mmol) was added to 1-(4-chlorobenzyl)-3-(methoxycarbonylmethyl)-6-[4-(2-pyridyloxy)phenylimino]-1,3,5-triazinane-2,4-dione (248 mg, 0.5 mmol) in THF (6 mL) under ice-cooling, and the resulting mixture was stirred at room temperature for 1.5 hours. To the reaction mixture were added water (0.04 ml) and 10% aqueous solution of sodium hydroxide (0.04 ml) and stirred at room temperature for 1 hour. The reaction mixture was filtrated through Celite, washed by ethyl acetate, and dried over anhydrous magnesium sulfate. After concentrated in vacuo, the residue was purified by silica-gel chromatography (ethyl acetate/hexane) to give 1-(4-chlorobenzyl)-3-(2-hydroxyethyl)-6-[4-(2-pyridyloxy)phenylimino]-1,3,5-triazinane-2,4-dione (R-257, 65.4 mg, yield: 28%) as white solid.

1H-NMR (CDCl3) δ: 2.25 (1H, t, J=5.7 Hz), 3.80 (2H, q, J=5.4 Hz), 4.05 (2H, t, J=5.1 Hz), 5.20 (2H, s), 6.85 (2H, d, J=8.5 Hz), 6.97 (1H, d, J=8.3 Hz), 7.00 (1H, dd, J=6.8, 5.3 Hz), 7.13 (2H, d, J=8.5 Hz), 7.30 (2H, d, J=8.3 Hz), 7.51 (2H, d, J=8.3 Hz), 7.71 (1H, t, J=8.0 Hz), 8.07 (1H, brs), 8.16 (1H, dd, J=4.8, 1.2 Hz).

REFERENCE EXAMPLE 6 (1) Preparation of 1-(4-chlorobenzyl)-3-(3-tetrahydropyran-2-yloxypropyl)-6-[4-(2-pyridyloxy)phenylimino]-1,3,5-triazinane-2,4-dione

Mixture of 1-(4-chlorobenzyl)-6-(ethylthio)--3-(3-tetrahydropyran-2-yloxypropyl)-1,3,5-triazine-2,4(1H,3H)-dione (230 mg, 0.52 mol), 4-(2-pyridyloxy)aniline (146 mg, 0.78 mmol), acetic acid (0.45 mL), and t-butanol (4 ml) was stirred overnight under heating at reflux. To the reaction mixture was added saturated aqueous solution of sodium hydrogen carbonate (50 mL) and extracted with ethyl acetate (50 mL). The organic phase was washed by brine and dried over anhydrous sodium sulfate, After concentrated in vacuo, the residue was purified by silica-gel column chromatography (hexane/ethyl acetate) to give 1-(4-chlorobenzyl)-3-(3-tetrahydropyran-2-yloxypropyl)-6-[4-(2-pyridyloxy)phenylimino]-1,3,5-triazinane-2,4-dione (188 mg, yield: 64%) as colorless amorphous.

1H-NMR (CDCl₃) δ: 1.47-1.66 (6H, m), 1.95 (2H, td, J=12.3, 6.6 Hz), 3.42-3.49 (2H, m), 3.80-3.84 (2H, m), 3.96-4.00 (2H, m), 4.52 (1H, br s), 5.20 (2H, s), 6.84 (2H, d, J=8.6 Hz), 6.95-7.01 (2H, m), 7.13 (2H, d, J=8.6 Hz), 7.30 (2H, d, J=8.3 Hz), 7.52 (2H, d, J=8.3 Hz), 7.68-7.73 (1H, m), 7.95 (1H, s), 8.13 (1H, t, J=2.5 Hz).

(2) Preparation of 1-(4-chlorobenzyl)-3-(3-hydroxypropyl)-6-[4-(2-pyridyloxy)phenylimino]-1,3,5-triazinane-2,4-dione (R-251)

p-Toluenesulfonic acid hydrate (12 mg, 0.064 mmol) was added to 1-(4-chlorobenzyl)-3-(3-tetrahydropyran-2-yloxypropyl)-6-[4-(2-pyridyloxy)phenylimino]-1,3,5-triazinane-2,4-dione (180 mg, 0.32 mol) in methanol (2 ml), and the resulting mixture was stirred at 50° C. for 2 hours. To the reaction mixture was added triethylamine and concentrated in vacuo. The residue was purified by silica-gel column chromatography (hexane/ethyl acetate) to give 1-(4-chlorobenzyl)-3-(3-hydroxypropyl)-6-[4-(2-pyridyloxy)phenylimino]-1,3,5-triazinane-2,4-dione (R-251, 150 mg, yield: 99%) as colorless amorphous.

1H-NMR (CDCl₃) δ: 1.83-1.89 (2H, m), 2.63 (1H, t, J=6.5 Hz), 3.59 (2H, q, J=5.9 Hz), 4.00 (2H, t, J=6.1 Hz), 5.22 (2H, s), 6.86 (2H, d, J=8.8 Hz), 6.97-7.01 (2H, m), 7.13 (2H, d, J=8.5 Hz), 7.31 (2H, d, J=8.5 Hz), 7.52 (2H, d, J=8.3 Hz), 7.69-7.74 (1H, m), 8.10 (1H, dd, J=4.9, 1.4 Hz).

The following compounds of the invention were synthesized in a similar manner to those described in the above general procedures for the synthesis of the compound of the invention and Examples, with reference to the contents described in WO2010/092966 and WO2012/020749 as needed. The chemical structure of the compounds and the physical properties of them are described below.

(Method of Identification for the Compound)

LC/MS data of compound of the present invention were measured under any one of the following 2 conditions (Methods 1 and 2), and a retention time (RT) (unit: min) and [M+H]⁺ are shown.

(Method 1)

-   Column: Shim-pack XR-ODS (2.2 μm, i.d. 50×3.0 mm) (Shimadzu) -   Flow rate: 1.6 g mL/min -   UV detection wavelength: 254 nm -   Mobile phase: [A] is 0.1% formic acid-containing aqueous solution,     and [B] is 0.1% formic acid-containing acetonitrile solution. -   Gradient: Linear gradient of 10% to 100% solvent [B] for 3 minutes     was performed, and 100% solvent [B] was maintained for 1 minute.     (Method 2) -   Column: ACQUITY UPLC (registered trademark) BEH C18 (1.7 μm, i.d.2.     1×50 mm) -   (Waters) -   Flow rate: 0.8 mL/min -   UV detection wavelength: 254 nm -   Mobile phase: [A] is 10 mM ammonium carbonate-containing aqueous     solution, and [B] is acetonitrile -   Gradient: Linear gradient of 5% to 100% solvent [B] for 3.5 minutes     was performed, and 100% solvent [B] was maintained for 0.5 minute.

TABLE 1 Compound No Structure [M + H]+ RT Method I-001

572 2.61 1 I-002

558 2.33 1 I-003

554 2.43 1 I-004

570 2.57 1 I-005

540 2.15 1

TABLE 2 Compound No Structure [M + H]+ RT Method I-006

556 2.28 1 I-007

554 2.43 1 I-008

554 2.45 1 I-009

540 2.2 1 I-010

540 2.21 1

TABLE 3 Compound No Structure [M + H]+ RT Method I-011

556 2.43 1 I-012

570 2.58 1 I-013

570 2.56 1 I-014

542 2.18 1 I-015

556 2.25 1

TABLE 4 Compound No Structure [M + H]+ RT Method I-016

556 2.28 1 I-017

538 2.13 1 I-018

538 2.11 1 I-019

538 2.13 1 I-020

538 2.08 1

TABLE 5 Compound No Structure [M + H]+ RT Method I-021

602 2.48 1 I-022

574 2.15 1 I-023

588 2.22 1 I-024

542 2.23 1 I-025

542 2.22 1

TABLE 6 Compound No Structure [M + H]+ RT Method I-026

542 2.24 1 I-027

528 1.99 1 I-028

528 1.98 1 I-029

528 2 1 I-030

590 2.52 1

TABLE 7 Compound No Structure [M + H]+ RT Method I-031

604 2.61 1 I-032

576 2.28 1 I-033

590 2.35 1 I-034

570 2.46 1 I-035

570 2.4 1

TABLE 8 Compound No Structure [M + H]+ RT Method I-036

520 2.24 1 I-037

534 2.34 1 I-038

556 2.21 1 I-039

556 2.17 1 I-040

506 1.98 1

TABLE 9 Compound No Structure [M + H]+ RT Method I-041

520 2.06 1 I-042

540 2 1 I-043

588 2.36 1 I-044

574 2.13 1 I-045

547 2.24 1

TABLE 10 Compound No Structure [M + H]+ RT Method I-046

561 2.34 1 I-047

533 1.99 1 I-048

547 2.07 1 I-049

554 1.97 1 I-050

554 1.95 1

TABLE 11 Compound No Structure [M + H]+ RT Method I-051

536 2.37 1 I-052

520 2.25 1 I-053

520 2.27 1 I-054

522 2.12 1 I-055

550 2.48 1

TABLE 12 Compound No Structure [M + H]+ RT Method I-056

506 2 1 I-057

506 2.02 1 I-058

536 2.2 1 I-059

554 1.94 1 I-060

556 2.5 1

TABLE 13 Compound No Structure [M + H]+ RT Method I-061

566 2.52 1 I-062

566 2.47 1 I-063

538 2.14 1 I-064

538 2.09 1 I-065

542 2.25 1

TABLE 14 Compound No Structure [M + H]+ RT Method I-066

566 2.49 1 I-067

538 2.12 1 I-068

540 2.35 1 I-069

538 2.02 1 I-070

526 2.11 1

TABLE 15 Compound No Structure [M + H]+ RT Method I-071

602 2.51 1 I-072

588 2.25 1 I-073

550 2.52 1 I-074

536 2.23 1 I-075

561 2.43 1

TABLE 16 Compound No Structure [M + H]+ RT Method I-076

536 2.38 1 I-077

522 2.2  1 I-078

536 2.28 1 I-079

538 2.04 1 I-080

522 2.12 1

TABLE 17 Compound No Structure [M + H]+ RT Method I-081

570 2.6  1 I-082

590 2.56 1 I-083

552 2   1 I-084

538 1.77 1 I-085

604 2.66 1

TABLE 18 Compound No Structure [M + H]+ RT Method I-086

556 2.33 1 I-087

570 2.64 1 I-088

576 2.33 1 I-089

570 2.17 1 I-090

542 1.88 1

TABLE 19 Compound No Structure [M + H]+ RT Method I-091

556 2.37 1 I-092

590 2.4  1 I-093

552 2.23 1 I-094

552 2.26 1 I-095

534 2.39 1

TABLE 20 Compound No Structure [M + H]+ RT Method I-096

520 2.11 1 I-097

536 2.38 1 I-098

550 2.49 1 I-099

556 2.23 1 I-100

522 2.15 1

TABLE 21 Compound No Structure [M + H]+ RT Method I-101

536 2.22 1 I-102

542 2.01 1 I-103

534 2.38 1 I-104

534 2.41 1 I-105

520 2.1 1

TABLE 22 Compound No Structure [M + H]+ RT Method I-106

520 2.13 1 I-107

550 2.52 1 I-108

516 2.29 1 I-109

530 2.43 1 I-110

530 2.4  1

TABLE 23 Compound No Structure [M + H]+ RT Method I-111

536 2.23 1 I-112

502 2.04 1 I-113

516 2.14 1 I-114

516 2.12 1 I-115

536 2.36 1

TABLE 24 Compound No Structure [M + H]+ RT Method I-116

550 2.46 1 I-117

522 2.13 1 I-118

536 2.21 1 I-119

522 2.11 1 I-120

550 2.52 1

TABLE 25 Compound No Structure [M + H]+ RT Method I-121

556 2.22 1 I-122

556 2.24 1 I-123

536 2.24 1 I-124

542 1.99 1 I-125

542 2.01 1

TABLE 26 Compound No Structure [M + H]+ RT Method I-126

522 2.28 1 I-127

508 2.02 1 I-128

536 2.2  1 I-129

523 2.24 1 I-130

509 1.99 1

TABLE 27 Compound No Structure [M + H]+ RT Method I-131

522 2.27 1 I-132

568 2.32 1 I-133

582 2.42 1 I-134

547 2.16 1 I-135

554 2.08 1

TABLE 28 Compound No Structure [M + H]+ RT Method I-136

568 2.15 1 I-137

582 2.43 1 I-138

568 2.16 1 I-139

552 2.29 1 I-140

502 2.19 1

TABLE 29 Compound No Structure [M + H]+ RT Method I-141

508 2.02 1 I-142

508 2.42 1 I-143

538 2.16 1 I-144

536 2.43 1 I-145

494 2.14 1

TABLE 30 Compound No Structure [M + H]+ RT Method I-146

524 1.94 1 I-147

522 2.12 1 I-148

488 1.94 1 I-149

536 2.39 1 I-150

516 2.3 1

TABLE 31 Compound No Structure [M + H]+ RT Method I-151

536 2.42 1 I-152

522 2.14 1 I-153

552 2.22 1 I-154

522 2.11 1 I-155

502 2.02 1

TABLE 32 Compound No Structure [M + H]+ RT Method I-156

538 1.98 1 I-157

522 2.32 1 I-158

540 2.4 1 I-159

566 2.35 1 I-160

540 2.38 1

TABLE 33 Compound No Structure [M + H]+ RT Method I-161

540 2.39 1 I-162

506 2.06 1 I-163

526 2.14 1 I-164

552 2.07 1 I-165

526 2.12 1

TABLE 34 Compound No Structure [M + H]+ RT Method I-166

526 2.13 1 I-167

542 1.97 1 I-168

542 1.99 1 I-169

542 1.98 1 I-170

548 2.49 1

TABLE 35 Compound No Structure [M + H]+ RT Method I-171

548 2.43 1 I-172

562 2.6 1 I-173

562 2.54 1 I-174

520 2.1 1 I-175

520 2.04 1

TABLE 36 Compound No Structure [M + H]+ RT Method I-176

546 2.47 1 I-177

546 2.41 1 I-178

534 2.22 1 I-179

534 2.17 1 I-180

528 2.42 1

TABLE 37 Compound No Structure [M + H]+ RT Method I-181

528 2.35 1 I-182

518 2.07 1 I-183

518 2.02 1 I-184

500 2.01 1 I-185

500 1.96 1

TABLE 38 Compound No Structure [M + H]+ RT Method I-186

502 2.23 1 I-187

488 1.97 1 I-188

520 2.3 1 I-189

506 2.05 1 I-190

520 2.29 1

TABLE 39 Compound No Structure [M + H]+ RT Method I-191

506 2.05 1 I-192

548 2.46 1 I-193

520 2.08 1 I-194

538 2.14 1 I-195

502 2.06 1

TABLE 40 Compound No Structure [M + H]+ RT Method I-196

520 2.33 1 I-197

506 2.07 1 I-198

505 2.18 1 I-199

491 1.93 1

TABLE 41 Compound No Structure [M + H]+ RT Method I-200

524 1.94 1 I-201

524 1.9 1 I-202

506 2.15 1 I-203

538 2.16 1 I-204

520 2.36 1

TABLE 42 Compound No Structure [M + H]+ RT Method I-205

540 2.47 1 I-206

520 2.05 1 I-207

538 2.14 1 I-208

538 2.11 1 I-209

538 2.16 1

Table 43 Compound No Structure [M + H]+ RT Method I-210

506 2.11 1 I-211

526 2.19 1 I-212

522 2.14 1 I-213

502 2.06 1 I-214

506 1.82 1

TABLE 44 Compound No Structure [M + H]+ RT Method I-215

524 1.89 1 I-216

524 1.88 1 I-217

524 1.91 1 I-218

518 2.08 1 I-219

536 2.22 1

TABLE 45 Compound No Structure [M + H]+ RT Method I-220

536 2.26 1 I-221

532 2.34 1 I-222

532 2.2 1 I-223

536 2.4 1 I-224

TABLE 46 Compound No Structure [M + H]+ RT Method I-225

550 2.51 1 I-226

550 2.55 1 I-227

554 2.54 1 I-228

554 2.57 1 I-229

518 1.96 1

TABLE 47 Compound No Structure [M + H]+ RT Method I-230

540 2.26 1 I-231

540 2.29 1 I-232

540 2.05 1 I-233

540 1.95 1 I-234

524 2.22 1

TABLE 48 Compound No Structure [M + H]+ RT Method I-235

524 2.19 1 I-236

538 2.49 1 I-237

538 2.46 1 I-238

554 2.33 1 I-239

554 2.23 1

TABLE 49 Compound No Structure [M + H]+ RT Method I-240

537.952 1.5 1 I-241

552 2.04 1 I-242

520 1.98 1 I-243

542 2.29 1 I-244

512 2.33 1

TABLE 50 Compound No Structure [M + H]+ RT Method I-245

552 2.06 1 I-246

532 1.97 1 I-247

566 2.28 1 I-248

548 2.19 1 I-249

566 2.32 1

TABLE 51 Compound No Structure [M + H]+ RT Method I-250

546 2.23 1 I-251

550 2.5 1 I-252

556 2.54 1 I-253

526 2.6 1 I-254

532 1.95 1

TABLE 52 Compound No Structure [M + H]+ RT Method I-255

552 2.07 1 I-256

532 1.99 1 I-257

538 1.83 1 I-258

536 2.24 1 I-259

550 2.01 1

TABLE 53 Compound No Structure [M + H]+ RT Method I-260

530 1.93 1 I-261

520 2.01 1 I-262

532 1.77 1 I-263

492 2.11 1 I-264

510 2.18 1

TABLE 54 Compound No Structure [M + H]+ RT Method I-265

642 2.42 1 I-266

534 2.26 1 I-267

554 2.17 1 I-268

506 2.37 1 I-269

524 2.43 1

TABLE 55 Compound No Structure [M + H]+ RT Method I-270

530 2.43 1 I-271

527.98 2.43 1 I-272

545.97 2.47 1 I-273

513.953 2.14 1 I-274

532 2.19 1

TABLE 56 Compound No Structure [M + H]+ RT Method I-275

516 2.18 1 I-276

546 2.32 1 I-277

601 2.15 1 I-278

587 1.89 1

The following compounds of the Reference Examples were synthesized in a similar manner to those described in the above general procedures for the synthesis of the compound of the invention and Reference Examples, with reference to the contents described in WO2010/092966 and WO2012/020749 as needed.

REFERENCE EXAMPLES

TABLE 57 Compound No Structure [M + H]+ RT Method R-001

598 2.55 1 R-002

556 2.38 1 R-003

542 2.07 1 R-004

599 2.59 1

TABLE 58 Compound No Structure [M + H]+ RT Method R-005

459 2.28 1 R-006

585 2.24 1 R-007

440 2.3 1 R-008

412 2.21 1 R-009

552 2.11 1 R-010

553 2.05 1

TABLE 59 Compound No Structure [M + H]+ RT Method R-011

523 2.61 1 R-012

542 2.47 1 R-013

557 2.37 1 R-014

543 2.12 1 R-015

556 2.7 1

TABLE 60 Compound No Structure [M + H]+ RT Method R-016

528 2.27 1 R-017

523 2.12 1 R-018

527 2.23 1 R-019

509 1.86 1 R-020

523 1.94 1

TABLE 61 Compound No Structure [M + H]+ RT Method R-021

519 2.31 1 R-022

519 2.26 1 R-023

509 2.32 1 R-024

509 2.27 1 R-025

571 2.48 1

TABLE 62 Compound No Structure [M + H]+ RT Method R-026

588 2.39 1 R-027

557 2.19 1 R-028

591 2.32 1 R-029

605 2.42 1 R-030

577 2.08 1

TABLE 63 Compound No Structure [M + H ]+ RT Method R-031

591 2.15 1 R-032

538 2 1 R-033

541 2.17 1 R-034

555 2.27 1 R-035

591 2.46 1

TABLE 64 Compound No Structure [M + H]+ RT Method R-036

605 2.56 1 R-037

527 1.93 1 R-038

543 2.01 1 R-039

577 2.22 1 R-040

558 2.47 1

TABLE 65 Compound No Structure [M + H]+ RT Method R-041

572 2.57 1 R-042

537 2.03 1 R-043

551 2.15 1 R-044

523 1.78 1 R-045

537 1.87 1

TABLE 66 Compound No Structure [M + H]+ RT Method R-046

557 2.32 1 R-047

571 2.42 1 R-048

541 2.27 1 R-049

555 2.37 1 R-050

539 2.02 1

TABLE 67 Compound No Structure [M + H]+ RT Method R-051

556 2.49 1 R-052

528 2.08 1 R-053

556 2.61 1 R-054

528 2.19 1 R-055

527 2.01 1

TABLE 68 Compound No Structure [M + H]+ RT Method R-056

541 2.1 1 R-057

544 2.21 1 R-058

556 2.27 1 R-059

523 2.03 1 R-060

523 1.86 1

TABLE 69 Compound No Structure [M + H]+ RT Method R-061

539 1.94 1 R-062

499 2.28 1 R-063

471 1.87 1 R-064

542 2.41 1 R-065

542 2.4 1

TABLE 70 Compound No Structure [M + H]+ RT Method R-066

528 2.11 1 R-067

528 2.12 1 R-068

510 2.25 1 R-069

524 2.36 1 R-070

558 2.29 1

TABLE 71 Compound No Structure [M + H]+ RT Method R-071

570 2.35 1 R-072

517 2.45 1 R-073

531 2.55 1 R-074

496 2 1 R-075

510 2.09 1

TABLE 72 Compound No Structure [M + H]+ RT Method R-076

503 2.19 1 R-077

517 2.27 1 R-078

509 1.77 1 R-079

556 2.37 1 R-080

570 2.48 1

TABLE 73 Compound No Structure [M + H]+ RT Method R-081

542 2.17 1 R-082

556 2.2 1 R-083

540 1.98 1 R-084

540 1.97 1 R-085

539 1.93 1

TABLE 74 Compound No Structure [M + H]+ RT Method R-086

556 2.38 1 R-087

570 2.47 1 R-088

542 2.09 1 R-089

556 2.17 1 R-090

559 2.55 1

TABLE 75 Compound No Structure [M + H]+ RT Method R-091

573 2.58 1 R-092

557 2.15 1 R-093

545 2.26 1 R-094

639 2.46 1 R-095

559 2.33 1

TABLE 76 Compound No Structure [M + H]+ RT Method R-096

653 2.51 1 R-097

555 2.49 1 R-098

541 2.25 1 R-099

547 2.25 1 R-100

561 2.36 1

TABLE 77 Compound No Structure [M + H]+ RT Method R-101

528 2.2 1 R-102

542 2.32 1 R-103

514 1.91 1 R-104

528 2 1 R-105

580 1.94 1

TABLE 78 Compound No Structure [M + H]+ RT Method R-106

532 2.14 1 R-107

546 2.26 1 R-108

547 2.18 1 R-109

518 1.88 1 R-110

532 1.97 1

TABLE 79 Compound No Structure [M + H]+ RT Method R-111

537 2.22 1 R-112

527 2.15 1 R-113

541 2.27 1 R-114

513 1.9 1 R-115

527 1.99 1

TABLE 80 Compound No Structure [M + H]+ RT Method R-116

540 2.08 1 R-117

544 2.12 1 R-118

554 2.16 1 R-119

523 2.01 1 R-120

509 1.77 1

TABLE 81 Compound No Structure [M + H]+ RT Method R-121

558 2.2 1 R-122

555 2.42 1 R-123

533 2 1 R-124

543 2.07 1 R-125

541 2.13 1

TABLE 82 Compond No Structure [M+H]+ RT Method R-126

556 1.99 1 R-127

524 2.39 1 R-128

510 2.1 1 R-129

551 2.33 1 R-130

523 1.97 1

TABLE 83 Compound No Structure [M+H]⁺ RT Method R-131

537 2.06 1 R-132

542 2.38 1 R-133

528 2.13 1 R-134

529 2.2 1 R-135

543 2.27 1

TABLE 84 Compound No Structure [M+H]+ RT Method R-136

543 2.31 1 R-137

557 2.38 1 R-138

526 1.98 1 R-139

540 2.12 1 R-140

530 2.43 1

TABLE 85 Compound No Structure [M+H]+ RT Method R-141

544 2.54 1 R-142

512 2.17 1 R-143

526 1.77 1 R-144

548 2.26 1 R-145

583 2.8 1

TABLE 86 Compound No Structure [M+H]+ RT Method R-146

516 2.14 1 R-147

530 2.23 2 R-148

537 2.12 1 R-149

556 2.49 1 R-150

570 2.49 1

TABLE 87 Compound No Structure [M+H]+ RT Method R-151

523 1.87 1 R-152

552 1.8 1 R-153

542 2.22 1 R-154

556 2.21 1 R-155

538 1.55 1

TABLE 88 Compound No Structure [M+H]+ RT Method R-156

572 2.6 1 R-157

558 2.33 1 R-158

551 2.38 1 R-159

571 2.5 1 R-160

529 2.02 1

TABLE 89 Compound No Structure [M+H]+ RT Method R-161

537 2.08 1 R-162

557 2.23 1 R-163

529 2.03 1 R-164

527 1.93 1 R-165

541 2.01 1

TABLE 90 Compound No Structure [M+H]+ RT Method R-166

509 2.42 1 R-167

537 2.27 1 R-168

523 1.97 1 R-169

528 2.05 1 R-170

440 2.02 1

TABLE 91 Compound No Structure [M+H]+ RT Method R-171

551 2.35 1 R-172

541 2.35 1 R-173

411 2.23 1 R-174

555 2.24 1 R-175

569 2.34 1

TABLE 92 Compound No Structure [M+H]+ RT Method R-176

591 2.3 1 R-177

570 2.4 1 R-178

513 2.06 1 R-179

523 2.05 1 R-180

541 1.99 1

TABLE 93 Compound No Structure [M+H]+ RT Method R-181

555 2.08 1 R-182

556 2.53 1 R-183

542 2.25 1 R-184

536 1.92 1 R-185

522 1.66 1

TABLE 94 Compound No Structure [M+H]+ RT Method R-186

568 2.51 1 R-187

572 2.54 1 R-188

554 2.21 1 R-189

558 2.25 1 R-190

553 2.02 1

TABLE 95 Compound No Structure [M + H]+ RT Method R-191

553 2.04 1 R-192

564 2.37 1 R-193

550 2.04 1 R-194

536 1.75 1 R-195

515 1.95 1

TABLE 96 Compound No Structure [M + H]+ RT Method R-196

527 1.88 1 R-197

543 1.96 1 R-198

527 2 1 R-199

552 2.11 1 R-200

566 2.22 1

TABLE 97 Compound No Structure [M + H]+ RT Method R-201

538 1.85 1 R-202

552 1.94 1 R-203

581 2.12 1 R-204

549 1.97 1 R-205

522 1.94 1

TABLE 98 Compound No Structure [M + H]+ RT Method R-206

552 1.5 1 R-207

508 1.69 1 R-208

508 1.39 1 R-209

519 1.7 1 R-210

505 1.51 1

TABLE 99 Compound No Structure [M + H]+ RT Method R-211

543 2.1 1 R-212

547 2.11 1 R-213

536 2.44 1 R-214

522 2.3 1 R-215

536 2.4 1

TABLE 100 Compound No Structure [M + H]+ RT Method R-216

568 2.16 1 R-217

522 2.16 1 R-218

508 2.05 1 R-219

522 2.13 1 R-220

491 2.44 1

TABLE 101 Compound No Structure [M + H]+ RT Method R-221

520 2.21 1 R-222

477 2.19 1 R-223

506 1.95 1 R-224

548 2.1 1 R-225

508 2.19 1

TABLE 102 Compound No Structure [M + H]+ RT Method R-226

488 2.1 1 R-227

508 1.88 1 R-228

494 1.66 1 R-229

493 1.82 1 R-230

507 1.88 1

TABLE 103 Compound No Structure [M + H]+ RT Method R-231

548 1.52 1 R-232

461 1.9 1 R-233

521 2.07 1 R-234

536 2.32 1 R-235

496 1.8 1

TABLE 104 Compound No Structure [M + H]+ RT Method R-236

564 2.43 1 R-237

523 1.98 1 R-238

494 2.13 1 R-239

480 1.93 1 R-240

479 1.8 1

TABLE 105 Compound No Structure [M + H]+ RT Method R-241

493 1.87 1 R-242

523 1.75 1 R-243

561 2.12 1 R-244

524 1.94 1 R-245

550 2.3 1

TABLE 106 Compound No Structure [M + H]+ RT Method R-246

534 2.02 1 R-247

536 2.33 1 R-248

564 2.5 1 R-249

548 2.13 1 R-250

496 1.8 1

TABLE 107 Compound No Structure [M + H]+ RT Method R-251

480 1.97 1 R-252

536 2.35 1 R-253

516 2.25 1 R-254

492 2.02 1 R-255

526 1.77 1

TABLE 108 Compound No Structure [M + H]+ RT Method R-256

522 1.86 1 R-257

466 1.93 1 R-258

522 2.05 1 R-259

506 1.96 1 R-260

492 1.75 1

TABLE 109 Compound No Structure [M + H]+ RT Method R-261

524 2.03 1 R-262

502 1.96 1 R-263

510 1.81 1 R-264

516 2.26 1 R-265

536 2.36 1

TABLE 110 Compound No Structure [M + H]+ RT Method R-266

473 2.04 1 R-267

488 1.9  1 R-268

492 1.85 1 R-269

508 1.99 1 R-270

472 1.73 1

TABLE 111 Compound No Structure [M + H]+ RT Method R-271

414 1.77 1 R-272

548 2.25 1 R-273

458 1.5  1 R-274

523 2.04 1

TABLE 112 Compound No Structure [M + H]+ RT Method R-275

510 1.84 1 R-276

510 1.83 1 R-277

506 1.98 1 R-278

506 1.99 1 R-279

506 2.02 1

TABLE 113 Compound No Structure [M + H]+ RT Method R-280

492 2.06 1 R-281

512 2.12 1 R-282

488 1.98 1 R-283

508 2.07 1 R-284

528 2.19 1

TABLE 114 Compound No Structure [M + H]+ RT Method R-285

508 2.11 1 R-286

524 2.05 1 R-287

542 2.38 1 R-288

524 2.03 1 R-289

522 2.3  1

TABLE 115 Compound No Structure [M + H]+ RT Method R-290

502 2.23 1 R-291

522 2.33 1 R-292

506 2.29 1 R-293

526 2.37 1 R-294

534 2.35 1

TABLE 116 Compound No Structure [M + H]+ RT Method R-295

534 2.34 1 R-296

534 2.36 1 R-297

528 2.22 1 R-298

508 2.14 1 R-299

536 1.98 1

TABLE 117 Compound No Structure [M + H]+ RT Method R-300

542 2.46 1 R-301

522 2.38 1 R-302

550 2.22 1 R-303

550 2.17 1 R-304

552 2   1

TABLE 118 Compound No Structure [M + H]+ RT Method R-305

536 1.93 1 R-306

538 1.79 1 R-307

492 2.11 1 R-308

464 1.78 1 R-309

526 2.29 1

TABLE 119 Compound No Structure [M + H]+ RT Method R-310

542 2.44 1 R-311

498 1.96 1 R-312

514 2.1  1 R-313

533 2.23 1 R-314

505 1.91 1

The following compounds of the invention can be synthesized in a similar manner to those described in the above general procedures for the synthesis of the compound of the invention and Examples, with reference to the contents described in WO2010/092966 and WO2012/020749 as needed.

TABLE 120 R³ R^(C) (R^(2′))m 4-(2-Pyridyl)O—Ph CH₂CHMeCOOH 4-CHF₂ 4-(2-Pyridyl)O—Ph CH(Me)CH(Me)COOHR 4-Me 4-(3-F-2-Pyridyl)O—Ph (CH₂)₃COOH 4-Me 4-(5-F-2-Pyridyl)O—Ph (CH₂)₃COOH 4-Me 4-(6-F-2-Pyridyl)O—Ph (CH₂)₃COOH 4-Me 4-(5-F-3-Pyridyl)O—Ph CH₂CHMeCOOH 4-Me 4-(2-F-4-Pyridyl)O—Ph CH₂C(Me)₂COOH 4-Me 4-(2-F-4-Pyridyl)O—Ph CH(Me)CH(Me)COOH 4-Me 4-(5-Cl-2-Pyridyl)O—Ph (CH₂)₂COOH 4-Cl 4-(5-Cl-2-Pyridyl)O—Ph (CH₂)₂COOH 4-Me 4-(5-Cl-3-Pyridyl)O—Ph CH(Me)CH(Me)COOH 4-Cl 4-(2-Cl-4-Pyridyl)O—Ph CH₂CHMeCOOH 4-Me 4-(3-MeO-2-Pyridyl)O—Ph CH₂CHMeCOOH 4-Me 4-(5-MeO-2-Pyridyl)O—Ph CH₂CHMeCOOH 4-Me 4-(6-MeO-2-Pyridyl)O—Ph CH₂CHMeCOOH 4-Me 4-(5-MeO-3-Pyridyl)O—Ph CH(Me)CH(Me)COOH 4-Cl 4-(2-MeO-4-Pyridyl)O—Ph CH₂CHMeCOOH 4-Me 4-(2-MeO-4-Pyridyl)O—Ph CH₂C(Me)₂COOH 4-Cl 4-(5-HOCO-2-thiazolyl)O—Ph Et 4-CH₂F 4-(5-HOCO-2-Pyridyl)O—Ph Et 4-CH₂F 4-(5-HOCO-2-Pyridyl)O-3-Me—Ph Et 4-CH₂F 4-(5-HOCO-3-Pyridyl)O—Ph Et 4-CH₂F 4-(2-HOCO-4-Pyridyl)O—Ph Et 4-CH₂F 4-(6-HOCO-3-Pyridazinyl)O—Ph Et 4-CH₂F 4-(6-H₂NCO-3-Pyridazinyl)O—Ph Et 4-CH₂F 4-(2-Pyrimidyl)O—Ph CH(Me)CH(Me)COOH 4-Cl 4-(2-Pyrimidyl)O-3-F—Ph CH(Me)CH(Me)COOH 4-Cl 4-(6-Cl-4-Pyrimidyl)O—Ph CH(Me)CH(Me)COOH 4-Cl 4-(6-F-4-Pyrimidyl)O—Ph CH₂C(Me)₂COOH 4-Cl 4-(6-F-4-Pyrimidyl)O—Ph CH(Me)CH(Me)COOH 4-Cl 4-(2-Me-4-Pyrimidyl)O—Ph CH(Me)CH(Me)COOH 4-Cl 4-(2-CN-5-Pyrimidyl)O—Ph CH₂C(Me)₂COOH 4-Cl 4-(5-Cl-2-Pyrazinyl)O—Ph CH₂C(Me)₂COOH 4-Me 4-(5-Cl-2-Pyrazinyl)O—Ph CH(Me)CH(Me)COOH 4-Me 4-(5-CF₃-2-Pyrazinyl)O—Ph CH(Me)CH(Me)COOH 4-Cl 4-(3-Pyridazinyl)O—Ph CH₂CHMeCOOH 4-Me 4-(3-Pyridazinyl)O—Ph CH(Me)CH(Me)COOH 4-Cl 4-(3-Pyridazinyl)O-3-F—Ph CH(Me)CH(Me)COOH 4-Cl 4-(6-Me-3-Pyridazinyl)O-3-F—Ph CH(Me)CH(Me)COOH 4-Cl 4-(6-MeO-3-Pyridazinyl)O—Ph CH₂CHMeCOOH 4-Me 4-(6-CF₃3-Pyridazinyl)O—Ph CH(Me)CH(Me)COOH 4-Cl 4-(4-Pyridazinyl)O-3-F—Ph CH₂CHMeCOOH 4-Cl 4-(4-Pyridazinyl)O-3-F—Ph CH₂C(Me)₂COOH 4-Cl 4-(4-Pyridazinyl)O-3-F—Ph CH(Me)CH(Me)COOH 4-Cl

TABLE 121 R³ R^(C) (R^(2′))m 4-(2-oxazolyl)O—Ph CH₂CHMeCOOH 4-Cl 4-(2-oxazolyl)O—Ph CH₂CHMeCOOH 4-Me 4-(2-oxazolyl)O—Ph CH₂C(Me)₂COOH 4-Cl 4-(2-oxazolyl)O—Ph CH(Me)CH(Me)COOH 4-Cl 4-(1,2,4-oxadiazol-2-yl)O—Ph CH₂CHMeCOOH 4-Cl 4-(1,2,4-oxadiazol-2-yl)O—Ph CH₂CHMeCOOH 4-Me 4-(1,2,4-oxadiazol-2-yl)O—Ph CH₂C(Me)₂COOH 4-Cl 4-(1,2,4-oxadiazol-2-yl)O—Ph CH(Me)CH(Me)COOH 4-Cl 4-(1,3,4-oxadiazol-2-yl)O—Ph CH₂CHMeCOOH 4-Cl 4-(1,3,4-oxadiazol-2-yl)O—Ph CH₂CHMeCOOH 4-Me 4-(1,3,4-oxadiazol-2-yl)O—Ph CH₂C(Me)₂COOH 4-Cl 4-(1,3,4-oxadiazol-2-yl)O—Ph CH(Me)CH(Me)COOH 4-Cl 4-(3-isothiazolyl)O—Ph CH₂CHMeCOOH 4-Cl 4-(3-isothiazolyl)O—Ph CH₂CHMeCOOH 4-Me 4-(3-isothiazolyl)O—Ph CH₂C(Me)₂COOH 4-Cl 4-(3-isothiazolyl)O—Ph CH(Me)CH(Me)COOH 4-Cl 4-(2-thiazolyl)O—Ph CH₂CHMeCOOH 4-Me 4-(1,2,4-thiadiazol-5-yl)O—Ph CH₂CHMeCOOH 4-Me 4-(1,2,4-thiadiazol-5-yl)O—Ph CH(Me)CH(Me)COOH 4-Cl 4-(3-Me-1,2,4-thiadiazol-5-yl)O—Ph CH₂CHMeCOOH 4-Me 4-(3-Me-1,2,4-thiadiazol-5-yl)O—Ph CH₂CHMeCOOH 4-Cl 4-(3-Me-1,2,4-thiadiazol-5-yl)O—Ph CH(Me)CH(Me)COOH 4-Cl 4-(1,2,5-thiadiazol-3-yl)O—Ph CH₂CHMeCOOH 4-Cl 4-(1,2,5-thiadiazol-3-yl)O—Ph CH₂CHMeCOOH 4-Me 4-(1,2,5-thiadiazol-3-yl)O—Ph CH₂C(Me)₂COOH 4-Cl 4-(1,2,5-thiadiazol-3-yl)O—Ph CH(Me)CH(Me)COOH 4-Cl 4-(2-Pyridyl)O-3-F—Ph (CH₂)₂COOH 4-Cl 4-(2-Pyridyl)O-3-F—Ph (CH₂)₂COOH 4-Me 4-(2-Pyridyl)O-3-F—Ph CH₂CHMeCOOH 4-Cl 4-(2-Pyridyl)O-3-F—Ph CH₂CHMeCOOH 4-Me 4-(2-Pyridyl)O-3-F—Ph CH₂C(Me)₂COOH 4-Cl 4-(2-Pyridyl)O-3-F—Ph CH(Me)CH(Me)COOH 4-Cl 4-(2-Pyridyl)O-3-Me—Ph (CH₂)₂COOH 4-Cl 4-(2-Pyridyl)O-3-Me—Ph (CH₂)₂COOH 4-Me 4-(2-Pyridyl)O-3-Me—Ph CH₂CHMeCOOH 4-Cl 4-(2-Pyridyl)O-3-Me—Ph CH₂CHMeCOOH 4-Me 4-(2-Pyridyl)O-3-Me—Ph CH₂C(Me)₂COOH 4-Cl 4-(2-Pyridyl)O-3-Me—Ph CH(Me)CH(Me)COOH 4-Cl 4-(5-Et-2-Pyridyl)O—Ph CH₂CHMeCOOH 4-Cl 4-(5-Et-2-Pyridyl)O—Ph CH₂CHMeCOOH 4-Me 4-(5-Et-2-Pyridyl)O—Ph CH₂C(Me)₂COOH 4-Cl 4-(5-Et-2-Pyridyl)O—Ph CH(Me)CH(Me)COOH 4-Cl 4-(6-Et-2-Pyridyl)O—Ph CH₂CHMeCOOH 4-Cl 4-(6-Et-2-Pyridyl)O—Ph CH₂CHMeCOOH 4-Me

TABLE 122 R³ R^(C) (R^(2′))m 4-(6-Et-2-Pyridyl)O—Ph CH₂C(Me)₂COOH 4-Cl 4-(6-Et-2-Pyridyl)O—Ph CH(Me)CH(Me)COOH 4-Cl 4-(2-Pyridyl)O—Ph CH₂CHMeCOOH 4-CH₂F 4-(3-F-2-Pyridyl)O—Ph CH₂CHMeCOOH 4-CH₂F 4-(5-F-2-Pyridyl)O—Ph CH₂CHMeCOOH 4-CH₂F 4-(6-F-2-Pyridyl)O—Ph CH₂CHMeCOOH 4-CH₂F 4-(5-F-3-Pyridyl)O—Ph CH₂CHMeCOOH 4-CH₂F 4-(Benzoxazol-2-yl)O—Ph CH₂CHMeCOOH 4-Me 4-(4-Azabenzoxazol-2-yl)O—Ph CH₂CHMeCOOH 4-Me 4-(Benzothiazol-2-yl)O—Ph CH₂CHMeCOOH 4-Me 4-(3-Me-1,2-Benzizoxazol-6- CH₂CHMeCOOH 4-Cl yl)O—Ph 4-(3-Me-1,2-Benzizoxazol-6- CH₂CHMeCOOH 4-Me yl)O—Ph 4-(5-Benzoimidazolyl)O—Ph CH₂CHMeCOOH 4-Cl 4-(5-Benzoimidazolyl)O—Ph CH₂CHMeCCCH 4-Me 4-(Imidazopyridaziin-3-yl)O—Ph CH₂CHMeCOOH 4-Me 4-(Imidazopyridaziin-3-yl)O—Ph CH₂C(Me)₂COOH 4-Cl 4-(Imidazopyridaziin-3-yl)O—Ph CH(Me)CH(Me)COOH 4-Cl 4-(Imidazopyridaziin-3-yl)O—Ph (CH₂)₂OH 4-Cl 4-(Imidazopyridaziin-3-yl)O—Ph (CH₂)₃OH 4-Cl 4-(Imidazopyridaziin-3-yl)O—Ph CH₂CH(OH)CH₂OH 4-Cl 4-(Imidazopyridaziin-3-yl)O—Ph CH₂CH(CH₂OH)₂ 4-Cl 4-(Imidazopyridaziin-3-yl)O—Ph CH₂CMe(CH₂OH)₂ 4-Cl 4-(Imidazopyridaziin-3-yl)O—Ph CH₂COH(CH₂OH)₂ 4-Cl

TABLE 123 R³ R^(C) (R^(2′))m 4-(2-Pyridyl)O—Ph (CH₂)₂COOH 4-Me 4-(2-Pyridyl)O—Ph (CH₂)₂COOH 4,4-(CH₂)₂ 4-(2-Pyridyl)O—Ph CH₂CHMeCOOH 4,4-(CH₂)₂ 4-(2-Pyridyl)O-3-F—Ph (CH₂)₂COOH 4-Me 4-(2-Pyridyl)O-3-F—Ph CH₂CHMeCOOH 4-Me 4-(2-Pyridyl)O-3-F—Ph (CH₂)₂COOH 4,4-(CH₂)₂ 4-(2-Pyridyl)O-3-F—Ph CH₂CHMeCOOH 4,4-(CH₂)₂ 4-(2-Pyridyl)O-3-Me—Ph (CH₂)₂COOH 4-Me 4-(2-Pyridyl)O-3-Me—Ph CH₂CHMeCOOH 4-Me 4-(2-Pyridyl)O-3-Me—Ph (CH₂)₂COOH 4,4-(CH₂)₂ 4-(2-Pyridyl)O-3-Me—Ph CH₂CHMeCOOH 4,4-(CH₂)₂ 4-(3-F-2-Pyridyl)O—Ph CH₂CHMeCOOH 4,4-(CH₂)₂ 4-(5-F-2-Pyridyl)O—Ph CH₂CHMeCOOH 4,4-(CH₂)₂ 4-(6-F-2-Pyridyl)O—Ph CH₂CHMeCOOH 4,4-(CH₂)₂ 4-(5-F-3-Pyridyl)O—Ph CH₂CHMeCOOH 4,4-(CH₂)₂ 4-(4-HOCO-2-Pyridyl)O—Ph Et 4,4-(CH₂)₂ 4-(5-HOCO-2-Pyridyl)O—Ph Et 4,4-(CH₂)₂ 4-(6-HOCO-2-Pyridyl)O—Ph Et 4,4-(CH₂)₂ 4-(5-HOCO-2-Pyridyl)O-3-Me—Ph Et 4,4-(CH₂)₂ 4-(6-HOCO-2-Pyridyl)O-3-Me—Ph Et 4,4-(CH₂)₂ 4-(5-HOCO-2-Pyridyl)O-3-F—Ph Et 4,4-(CH₂)₂ 4-(6-HOCO-2-Pyridyl)O-3-F—Ph Et 4,4-(CH₂)₂

Biological test examples for compounds of the present invention were described below.

TEST EXAMPLES TEST EXAMPLE 1 Evaluation of Human P2X₃ Receptor Inhibitory Activity

Stably expressing cell line (C6BU-1 cell transfected with human P2X₃ receptor gene (GenBank accession number Y07683) was used. The cells were seeded in a 384-well PDL-coated microtiter plate at a concentration of 3000 cells/well and cultured in the medium (8.3% fetal bovine serum, 8.3% horse serum, and 1% antibiotic and antifungal in DMEM) for one day at 37° C. under 5% carbon dioxide atmosphere. The medium was replaced with 4 μM Fluo-3-AM solution (20 mM HEPES, 137 mM NaCl, 2.7 mM KCl, 0.9 mM MgCl₂, 5.0 mM CaCl₂, 5.6 mM D-glucose, 2.5 mM probenecid, 0.5% BSA, and 0.04% Pluronic P-127, pH 7.5) and incubated at 37° C. under 5% dioxide carbon atmosphere for one hour. The plate was washed with washing buffer (20 mM HEPES, 137 mM NaCl, 2.7 mM KCl, 0.9 mM MgCl₂, 5.0 mM CaCl₂, 5.6 mM D-glucose, 2.5 mM probenecid, pH 7.5), and each well was added with 20 μL of the washing buffer. The plate was placed in High-Throughput Screening System FLIPR 384 (Molecular Device Co.). Measurement of fluorescence intensity by FLIPR 884 was started, and 20 μL of DMSO solutions containing different concentrations of the test compound as prepared by dilution with dilution buffer (20 mM HEPES, 137 mM NaCl, 2.7 mM KCl, 0.9 mM MgCl₂, 5.0 mM CaCl₂, 5.6 mM D-glucose, 2.5 mM probenecid, 0.1% Pluronic F-127, pH 7.5) were dispensed to each well through the built-in automatic dispenser. Five minutes after, 150 nM ATP solution (25 μL) prepared by dilution with the dilution buffer was dispensed through the built-in automatic dispenser, and the measurement of fluorescence intensity was continued for 4 min. For each well, the specific maximum fluorescence intensity was calculated as the ratio of the maximum fluorescence intensity after addition of the ATP solution to the fluorescence intensity at the starting of the measurement. The 50% inhibitory concentration (IC₅₀) was calculated under the assumption that the specific maximum fluorescence intensity without test compound is 0% inhibition and that the specific maximum fluorescence intensity when the dilution buffer was added in place of ATP solution is 100% inhibition, to evaluate the inhibitory activity of the test compound. The specific maximum fluorescence intensify and IC₅₀ were calculated using Spotfire (Science & Technology Systems. Inc.)

The data of the compounds of the present invention are as shown in the following Tables.

TABLE 124 Compound P2X3 No. IC50 (μM) I-001 0.044 I-002 0.005 I-003 0.007 I-004 0.014 I-005 0.008 I-006 0.005 I-007 0.009 I-008 0.007 I-009 0.007 I-010 0.005 I-011 0.018 I-012 0.025 I-013 0.058 I-014 0.007 I-015 0.009 I-016 0.008 I-017 0.006 I-018 0.012 I-019 0.007 I-020 0.009 I-021 0.025 I-022 0.004 I-023 0.007 I-024 0.034 I-025 0.023 I-026 0.017 I-027 0.039 I-028 0.02 I-029 0.014 I-030 0.176 I-031 0.199 I-032 0.011 I-033 0.023 I-034 0.009 I-035 0.012 I-036 0.005 I-037 0.006 I-038 0.005 I-039 0.008 I-040 0.006 I-041 0.009 I-042 0.004 I-043 0.117 I-044 0.026 I-045 0.019 I-046 0.019 I-047 0.022 I-048 0.03 I-049 0.015 I-050 0.028 I-051 0.006 I-052 0.006 I-053 0.006 I-054 0.005 I-055 0.009 I-056 0.007 I-057 0.005 I-058 0.006 I-059 0.016 I-060 0.024 I-061 0.062 I-062 0.031 I-063 0.009 I-064 0.01 I-065 0.008 I-066 0.015 I-067 0.011 I-068 0.005 I-069 0.007 I-070 0.005 I-071 0.038 I-072 0.006 I-073 0.015 I-074 0.005 I-075 0.021 I-076 0.022 I-077 0.01 I-078 0.019 I-079 0.005 I-080 0.01 I-081 0.038 I-082 0.112 I-083 0.006 I-084 0.008 I-085 0.225 I-086 0.033 I-087 0.107 I-088 0.015 I-089 0.008 I-090 0.072 I-091 0.01 I-092 0.068 I-093 0.016 I-094 0.011 I-095 0.009 I-096 0.008 I-097 0.005 I-098 0.007 I-099 0.006 I-100 0.004 I-101 0.005 I-102 0.005 I-103 0.007 I-104 0.005 I-105 0.007 I-106 0.006 I-107 0.031 I-108 0.004 I-109 0.006 I-110 0.004 I-111 0.009 I-112 0.004 I-113 0.005 I-114 0.006 I-115 0.006 I-116 0.007 I-117 0.005 I-118 0.009 I-119 0.006 I-120 0.009 I-121 0.006 I-122 0.004 I-123 0.005 I-124 0.005 I-125 0.005 I-126 0.005 I-127 0.004 I-128 0.008 I-129 0.004 I-130 0.006 I-131 0.008 I-132 0.008 I-133 0.008 I-134 0.007 I-135 0.004 I-136 0.007 I-137 0.014 I-138 0.007 I-139 0.01 I-140 0.003 I-141 0.014 I-142 0.007 I-143 0.005 I-144 0.009 I-145 0.006 I-146 0.005 I-147 0.007 I-148 0.009 I-149 0.005 I-150 0.004

TABLE 125 Compound P2X3 No. IC50 (μM) I-151 0.01 I-152 0.006 I-153 0.013 I-154 0.008 I-155 0.008 I-156 0.012 I-157 0.005 I-158 0.006 I-159 0.009 I-160 0.005 I-161 0.01 I-162 0.007 I-163 0.008 I-164 0.029 I-165 0.015 I-166 0.013 I-167 0.019 I-168 0.012 I-169 0.021 I-170 0.015 I-171 0.009 I-172 0.026 I-173 0.008 I-174 0.006 I-175 0.009 I-176 0.007 I-177 0.006 I-178 0.005 I-179 0.006 I-180 0.005 I-181 0.005 I-182 0.008 I-183 0.012 I-184 0.006 I-185 0.009 I-186 0.005 I-187 0.008 I-188 0.007 I-189 0.012 I-190 0.005 I-191 0.011 I-192 0.005 I-193 0.008 I-194 0.012 I-195 0.007 R-001 0.007 R-002 0.363 R-003 0.004 R-004 0.123 R-005 0.608 R-006 0.004 R-007 0.301 R-009 0.007 R-010 0.01 R-011 0.049 R-012 0.005 R-013 0.006 R-014 0.005 R-015 0.104 R-016 0.006 R-017 0.006 R-018 0.005 R-019 0.006 R-020 0.013 R-021 0.015 R-022 0.012 R-023 0.021 R-024 0.018 R-025 0.005 R-026 0.008 R-027 0.006 R-028 0.007 R-029 0.007 R-030 0.008 R-031 0.012 R-032 0.004 R-033 0.006 R-034 0.005 R-035 0.008 R-036 0.011 R-037 0.007 R-038 0.007 R-039 0.006 R-040 0.007 R-041 0.011 R-042 0.005 R-043 0.005 R-044 0.01 R-045 0.014 R-046 0.006 R-047 0.009 R-048 0.006 R-049 0.008 R-050 0.014 R-053 0.052 R-054 0.026 R-055 0.007 R-056 0.01 R-057 0.006 R-058 0.004 R-059 0.005 R-060 0.016 R-061 0.007 R-062 0.318 R-063 0.456 R-064 0.012 R-066 0.058 R-068 0.04 R-069 0.051 R-070 0.007 R-071 0.006 R-072 0.016 R-073 0.031 R-074 0.013 R-075 0.013 R-076 0.013 R-077 0.024 R-078 0.01 R-079 0.011 R-080 0.013 R-081 0.005 R-082 0.007 R-083 0.007 R-084 0.006 R-085 0.006 R-086 0.007 R-087 0.012 R-088 0.006 R-089 0.007 R-090 0.07 R-091 0.108 R-092 0.01 R-093 0.013 R-094 0.029 R-095 0.045 R-096 0.156 R-097 0.212 R-098 0.08 R-099 0.004 R-100 0.006 R-101 0.201 R-102 0.1 R-105 0.007 R-106 0.379 R-107 0.217

TABLE 126 Compound P2X3 No. IC50 (μM) R-108 0.008 R-111 0.005 R-112 0.017 R-113 0.013 R-114 0.039 R-115 0.065 R-116 0.005 R-117 0.006 R-118 0.005 R-119 0.005 R-120 0.008 R-121 0.005 R-122 0.013 R-123 0.005 R-124 0.009 R-125 0.007 R-126 0.01 R-127 0.09 R-128 0.011 R-129 0.007 R-130 0.009 R-131 0.009 R-132 0.01 R-133 0.006 R-134 0.005 R-135 0.005 R-136 0.006 R-137 0.006 R-138 0.078 R-139 0.119 R-140 0.037 R-141 0.047 R-142 0.069 R-143 0.097 R-144 0.005 R-145 0.011 R-146 0.033 R-147 0.051 R-148 0.005 R-149 0.012 R-150 0.018 R-151 0.011 R-152 0.005 R-153 0.008 R-154 0.008 R-155 0.01 R-156 0.035 R-157 0.006 R-158 0.012 R-159 0.018 R-160 0.008 R-161 0.01 R-162 0.006 R-163 0.014 R-164 0.01 R-165 0.014 R-166 0.048 R-167 0.011 R-168 0.017 R-169 0.304 R-170 0.193 R-171 0.033 R-172 0.033 R-173 0.376 R-174 0.01 R-175 0.019 R-176 0.007 R-177 0.005 R-178 0.045 R-179 0.056 R-180 0.007 R-181 0.007 R-182 0.026 R-183 0.007 R-184 0.01 R-185 0.012 R-186 0.026 R-187 0.021 R-188 0.009 R-189 0.008 R-190 0.009 R-191 0.012 R-192 0.004 R-193 0.011 R-194 0.013 R-195 0.009 R-196 0.011 R-197 0.007 R-198 0.009 R-199 0.007 R-200 0.008 R-201 0.008 R-202 0.012 R-203 0.006 R-204 0.008 R-205 0.008 R-206 0.005 R-207 0.009 R-208 0.005 R-209 0.005 R-210 0.006 R-211 0.007 R-212 0.008 R-213 0.012 R-214 0.006 R-215 0.006 R-216 0.007 R-217 0.008 R-218 0.008 R-219 0.011 R-220 0.022 R-221 0.005 R-222 0.009 R-223 0.007 R-224 0.012 R-225 0.004 R-226 0.003 R-227 0.035 R-229 0.007 R-230 0.005 R-231 0.005 R-232 0.061 R-233 0.318 R-234 0.003 R-235 0.01 R-236 0.004 R-237 0.009 R-238 0.007 R-239 0.399 R-240 0.011 R-241 0.009 R-242 0.005 R-243 0.004 R-244 0.004 R-245 0.004 R-246 0.006 R-247 0.005 R-248 0.005 R-249 0.006 R-250 0.009 R-251 0.005 R-254 0.003 R-255 0.005 R-256 0.002 R-257 0.01

TABLE 127 Compound P2X3 No. IC50 (μM) I-200 0.042 I-201 0.013 I-202 0.008 I-203 0.003 I-204 0.004 I-205 0.012 I-206 0.010 I-207 0.012 I-208 0.012 I-209 0.008 I-210 0.007 I-211 0.007 I-212 0.010 I-213 0.012 I-214 0.011 I-215 0.016 I-216 0.017 I-217 0.011 I-218 0.010 I-219 0.012 I-220 0.010 I-221 0.011 I-222 0.004 I-223 0.011 I-224 0.006 I-225 0.014 I-226 0.038 I-227 0.031 I-228 0.021 I-229 0.006 I-230 0.011 I-231 0.007 I-232 0.005 I-233 0.006 I-234 0.007 I-235 0.009 I-236 0.016 I-237 0.014 I-238 0.005 I-239 0.006 I-240 0.022 I-241 0.008 I-242 0.008 I-243 0.007 I-244 0.008 I-245 0.014 I-246 0.014 I-247 0.006 I-248 0.005 I-249 0.036 I-250 0.031 I-251 0.008 I-252 0.014 I-253 0.009 I-254 0.006 I-255 0.018 I-256 0.029 I-257 0.016 I-258 0.004 I-259 0.005 I-260 0.005 I-261 0.008 I-262 0.007 I-263 0.005 I-264 0.005 I-265 0.010 I-266 0.008 I-267 0.003 I-268 0.003 I-269 0.004 I-270 0.004 I-271 0.010 I-272 0.008 I-273 0.005 I-274 0.005 I-275 0.004 I-276 0.019 I-277 0.004 I-278 0.006 R-275 0.023 R-276 0.042 R-277 0.014 R-278 0.015 R-279 0.007 R-280 0.009 R-281 0.007 R-282 0.023 R-283 0.028 R-284 0.005 R-285 0.006 R-286 0.006 R-287 0.006 R-288 0.012 R-289 0.005 R-290 0.006 R-291 0.006 R-292 0.004 R-293 0.004 R-294 0.006 R-295 0.006 R-296 0.005 R-297 0.008 R-298 0.009 R-299 0.020 R-300 0.008 R-301 0.005 R-302 0.006 R-303 0.003 R-304 0.004 R-305 0.007 R-306 0.014 R-307 0.013 R-309 0.004 R-310 0.004 R-311 0.428 R-312 0.350 R-313 0.003 R-314 0.048

TEST EXAMPLE 2 Evaluation of Human P2X₃ Receptor Inhibitory Activity in the Presence of Human Serum Albumin (HSA)

Stably expressing cell line (C6BU-1 cell transfected with human P₂X₃ receptor gene (GenBank accession number Y07683; was used. The cells were seeded in a 96-well microtiter plate at a concentration of 8000 cells/well and cultured in the medium (7.0% fetal bovine serum, 7.0% horse serum, 1% antibiotic and antifungal, and 2.0% glutamine in DMEM) for one day at 37° C. under 5% carbon dioxide atmosphere. The medium was replaced with 4 μM Fluo-3-AM solution (20 mM HEPES, 137 mM NaCl, 5.37 mM KCl, 0.9 mM MgCl₂, 1.26 mM CaCl₂, 5.6 mM D-glucose, 2.5 mM probenecid, 0.5% BSA, and 0.04% Pluronic F-127, pH 7.5) and incubated at 37° C. under 5% dioxide carbon atmosphere for one hour. The plate was washed with washing buffer (20 mM HEPES, 137 mM NaCl, 5.27 mM KCl, 0.9 mM MgCl₂, 1.26 mM CaCl₂, 5.6 mM D-glucose, 2.5 mM probenecid, pH 7.5), and each well was added with 40 μL of this buffer. The plate was placed in High-Throughput Screening System FDSS 3000 (Hamamatsu Photonics K.K.). Measurement of fluorescence intensity by FDSS 3000 was started, and 40 μL of DMSO solutions containing 1% HSA (final concentrations) different concentrations of the test compound as prepared by dilution with dilution buffer (20 mM HEPES, 137 mM NaCl, 5.27 mM KCl, 0.9 mM MgCl₂, 1.26 mM CaCl₂, 5.6 mM D-glucose, 2.5 mM probenecid, 0.1% Pluronic F-127, pH 7.5) were dispensed to each well through the built-in automatic dispenser. Five minutes after, 50 nM ATP solution (50 μL) prepared by dilution with the dilution buffer was dispensed through the built-in automatic dispenser, and the measurement of fluorescence intensity was continued for 4 min. For each well, the specific maximum fluorescence intensity was calculated as the ratio of the maximum fluorescence intensity after addition of the ATP solution to the fluorescence intensity at the starting of the measurement. The 50% inhibitory concentration (IC₅₀) was calculated under the assumption that the specific maximum fluorescence intensity without test compound is 0% inhibition and that the specific maximum fluorescence intensity when the dilution buffer was added in place of ATP solution is 100% inhibition, to evaluate the inhibitory activity of the test compound. FDSS software (Hamamatsu Photonics K.K.) was used for calculation of the specific maximum fluorescence intensity. IC₅₀ was calculated using Microsoft Excel (Microsoft Corporation) and XLfit (idbs Ltd.)

The data of the compounds of the present invention are as shown in the following Tables.

TABLE 128 Compound P2X3 + HSA No. IC50 (μM) I-019 0.068 I-040 0.018 I-056 0.023 I-070 0.037 I-079 0.037 R-123 0.018

TEST EXAMPLE 3 Evaluation of Rat P2X₃ Receptor Inhibitory Activity

Rat P2X₃ receptor gene (GenBank accession number NM_031075) was expressed in C6BU-1 cell. The C6BU-1 cells were seeded in a 96-well microtiter plate at a concentration of 2500 cells/well and cultured in the medium (7.0% fetal bovine serum, 7.0% horse serum, and 1% antibiotic and antifungal in DMEM) for one day at 37° C. under 5% carbon dioxide atmosphere. The plasmid was transfected into the cells using transfection reagent FuGENE6 (Promega). The transfected cells were cultured in the medium for one day at 37° C. under 5% carbon dioxide atmosphere. The medium was replaced with 4 μM Fluo-3-AM solution (pH 7.5) containing 20 mM HEPES, 137 mM NaCl, 5.27 mM KCl, 0.9 mM MgCl₂, 1.26 mM CaCl₂, 5.6 mM D-glucose, 2.5 mM probenecid, 1% BSA, and 0.08% Pluronic F-127, and incubated at 37° C. under 5% dioxide carbon atmosphere for one hour. The plate was washed with washing buffer (20 mM HEPES, 137 mM NaCl, 5.27 mM KCl, 0.9 mM MgCl₂, 1.26 mM CaCl₂, 5.6 mM D-glucose, 2.5 mM probenecid, pH 7.5), and each well was added with 40 μL of this buffer. The plate was placed in High-Throughput Screening System FDSS 3000 (Hamamatsu Photonics K.K.). Measurement of fluorescence intensity by FDSS 3000 was started, and 40 μL of DMSO solutions containing different concentrations of the test compound as prepared by dilution with dilution buffer (20 mM HEPES, 137 mM 137 NaCl, 5.27 mM KCl, 0.9 mM MgCl₂, 1.26 mM CaCl₂, 5.6 mM D-glucose, 2.5 mM probenecid, 0.1% Pluronic F-127, pH 7.5) were dispensed to each well through the built-in automatic dispenser. Five minutes after, 50 nM ATP solution (50 μL) prepared by dilution with the dilution buffer was dispensed through the built-in automatic dispenser, and the measurement of fluorescence intensity was continued for 4 min. For each well, the specific maximum fluorescence intensity was calculated as the ratio of the maximum fluorescence intensity after addition of the ATP solution to the fluorescence intensity at the starting of the measurement. The 50% inhibitory concentration (IC₅₀) was calculated under the assumption that the specific maximum fluorescence intensity without test compound is 0% inhibition and that the specific maximum fluorescence intensity when the dilution buffer was added in place of ATP solution is 100% inhibition, to evaluate the inhibitory activity of the test compound. FDSS software (Hamamatsu Photonics K.K.) was used for calculation of the specific maximum fluorescence intensity. IC₅₀ was calculated using Microsoft Excel (Microsoft Corporation) and XLfit (idbs Ltd.).

The data of the compounds of the present invention are as shown in the following Table.

TABLE 129 Compound ratP2X3 No. IC50 (μM) I-002 0.006 R-009 0.004

TEST EXAMPLE 4 Evaluation of Rat P2X₃ Receptor Inhibitory Activity in the presence of Rat Serum Albumin (RSA)

Rat P2X₃ receptor gene (GenBank accession number NM_031075) was expressed in C6BU-1 cell. The C6BU-1 cells were seeded in a 96-well micro titer plate at a concentration of 2500 cells/well and cultured in the medium (7.0% fetal bovine serum, 7.0% horse serum, and 1% antibiotic and antifungal in DMEM) for one day at 37° C. under 5% carbon dioxide atmosphere. The plasmid was transfected into the cells using transfection reagent FuGENE6 (Promega). The transfected cells were cultured in the medium for one day at 37° C. under 5% carbon dioxide atmosphere. The medium was replaced with 4 μM Fluo-4-AM solution (pH 7.5) containing 20 mM HEPES, 137 mM NaCl, 5.27 mM KCl, 0.9 mM MgCl₂, 1.26 mM CaCl₂, 5.6 mM D-glucose, 2.5 mM probenecid, 10% RSA, and 0.08% Pluronic F-127, and incubated at 37° C. under 5% dioxide carbon atmosphere for one hour. The plate was washed with washing buffer (20 mM HEPES, 137 mM NaCl, 5.27 mM KCl, 0.9 mM MgCl₂, 1.26 mM CaCl₂, 5.6 mM D-glucose, 2.5 mM probenecid, pH 7.5), and each well was added with 40 μL of this buffer. The plate was placed in High-Throughput Screening System FDSS 3000 (Hamamatsu Photonics K.K.). Measurement of fluorescence intensity by FDSS 3000 was started, and 40 μL of DMSO solutions containing 1% RSA (final concentrations) and different concentrations of the test compound as prepared by dilution with dilution buffer (20 mM HEPES, 137 mM NaCl, 5.27 mM KCl, 0.9 mM MgCl₂, 1.26 mM CaCl₂, 5.6 mM D-glucose, 2.5 mM probenecid, 0.1% Pluronic F-127, pH 7.5) were dispensed to each well through the built-in automatic dispenser. Five minutes after, 50 nM ATP solution (50 μL) prepared by dilution with the dilution buffer was dispensed through the built-in automatic dispenser, and the measurement of fluorescence intensity was continued for 4 min. For each well, the specific maximum fluorescence intensity was calculated as the ratio of the maximum fluorescence intensity after addition of the ATP solution to the fluorescence intensity at the starting of the measurement. The 50% inhibitory concentration (IC₅₀) was calculated under the assumption that the specific maximum fluorescence intensity without test compound is 0% inhibition and that the specific maximum fluorescence intensity when the dilution buffer was added in place of ATP solution is 100% inhibition, to evaluate the inhibitory activity of the test compound. FDSS software (Hamamatsu Photonics K.K.) was used for calculation of the specific maximum fluorescence intensity. IC₅₀ was calculated using Microsoft Excel (Microsoft Corporation) and XLfit (idbs Ltd.).

The data of the compounds of the present invention are as shown in the following Table.

TABLE 130 Compound ratP2X3 + RSA No. IC50 (μM) I-019 0.011 I-022 0.011 I-040 0.009 I-100 0.009 I-113 0.010 R-014 0.006 R-019 0.008 R-037 0.008

As shown, the compounds described in the present specification showed inhibiting activity on P2X₃ receptor. Furthermore, as the compounds of the invention are effective on P2X₃ subtype, the compounds are also considered to have inhibiting activity on P2X_(2/3) receptor, which comprises P2X₂ subtype.

TEST EXAMPLE 5 Evaluation of the Urinary Function in a Rat Model of Cystitis Surgery for Cystometry

A rat is fixed in the supine position after being given anesthesia through the inhalation of 2% isoflurane (Anesthetic background: Nitrous oxide:Oxygen=7:3). A midline incision is made in its abdomen to expose the bladder. A cannula (made by processing a polyethylene tube (PE-50: Becton Dickinson).) is inserted through a small incision on top of the bladder and fixed to create a bladder fistula. The other end of the cannula is led through the hypodermal tissue to the back, and the muscular coat and skin are sutured. The cannula, which is led to the back, is protected with a stainless spring in the middle and connected to the cannula swivel.

Acetic Acid Infusion

Two days after the surgery, 0.3% acetic acid is infused into the bladder through the indwelled cannula at a rate of 4 mL/hr for 30 minutes to induce cystitis. The animals, where acetic acid is not infused, are used as normal animals.

Cystometry Measurement

Two or three days after the acetic acid infusion, the other end of the cannula inserted into the bladder is connected to a T shape stopcock and then the intravesical pressure is recorded continuously using a pressure amplifier while infusing warmed normal saline solution at a rate of 3.0 mL/hr from one side and through a pressure transducer on the other side. The baseline of the intravesical pressure is measured (for approximately 40 minutes) after a measurement for stable duration (for approximately 20 minutes). After that, a vehicle, positive control compound or test compound, are administered, and the value after administration is measured for approximately 120 minutes. A compound of the present invention is crushed with a mortar and pestle so as to be 0.1-2 mg/mL/kg solution or suspension using 0.5% methylcellulose solution, and administered to an animal orally with an oral sonde. At the same time, the voided urine is received on scales under the cage to measure the variation in weight simultaneously.

Data Adoption Criteria

Based on the voiding interval, normal animals whose voiding interval is 10 minutes or longer were adopted and those whose voiding interval is shorter than that were excluded. In the case of the animals into which acetic acid is infused, those whose voiding interval is less than half the average value of the normal animals are adopted as animals with cystitis and those whose voiding interval is longer than that were excluded.

Collection of Residual Urine

After the completion of the measurement, the infusion of normal saline solution is stopped immediately after urination to collect the residual urine under pentobarbital sodium anesthesia. The collected residual urine is transferred to the voided urine receiver and recorded on the chart.

Analysis Items

Intravesical pressure one to two hours after the start of the measurement (pressure during rest and pressure during urination), voiding interval, voided volume per urination, and residual urine volume

The following value is used as an indicator of the effect on the voiding interval: Improvement rate of the urinary function=(Voiding interval of an animal with cystitis after drug treatment−Voiding interval of an animal with cystitis before drug treatment)/(Mean voiding interval of normal animals before drug treatment−Voiding interval of an animal with cystitis before drug treatment)×100

The following value is used as an indicator of the effect on the voided volume per urination: Improvement rate of the voided volume per urination=(Voided volume per urination of a rat with cystitis after drug treatment−Voided volume per urination of an animal with cystitis before drug treatment)/(Mean voided volume per urination of normal animals before drug treatment−Voided volume per urination of an animal with cystitis before drug treatment)×100

TEST EXAMPLE 6 Analgesic Effect in a Seltzer Model

Preparation of Partial Sciatic Nerve Ligation Model in Rats

Rats were anaesthetized using isoflurane/O2 inhalation anaesthesia. After induction of anesthesia, the left thigh was shaved. An incision was made in the skin just below the hip bone. The muscle was bluntly dissected to expose the sciatic nerve. One third (⅓) to one half (½) of the sciatic nerve thickness was tightly ligated and the wound was closed. The right thigh is used as a sham-operated control. The right thigh undergoes an identical procedure with the left hind limb, however, the sciatic nerve is not manipulated or ligated.

Evaluation (1)

Two weeks after nerve ligation, the effect on mechanical allodynia was assessed using a series of von Frey filaments. For habituation, the rats were placed into a plastic cage on a wire mesh bottom. The mechanical sensitivity (mechanical threshold) of the hind paws was estimated with a series of von Frey filaments (0.4-26 g). The measurement of mechanical sensitivity of the right and left hind paws was performed to obtain predose mechanical sensitivity. The rats showing the threshold change from 0.6 to 2 g (in nerve ligated side) and 8 to 15 g (in sham operated side) were used in the experiments. On the day before the experiment, the rats were evaluated with a series of von Frey filaments to familiarize them with the test procedure. The adopted animal was administrated with the test compounds. The test compounds were homogenized with mortar and pestle and suspended or diluted in 0.5% Methyl Cellulose to prepare 0.1-2.0 mg/mL/kg suspension and orally administered to rat using a syringe attached with a sonde. Post-dose mechanical sensitivities of the right and left hind paws were measured at approximately 1 to 5 hours after drug administration. Percent reversal of mechanical allodynia for each rat was calculated using the following formula.

The analgesic effects of the compounds were compared.

${\%\mspace{14mu}{Reversal}} = \frac{\begin{matrix} {{{Log}_{10}\left( {{Postdose}\mspace{14mu}{mechanical}\mspace{14mu}{sensitivity}\mspace{14mu}{in}\mspace{14mu}{nerve}\mspace{14mu}{ligated}\mspace{14mu}{side}} \right)} -} \\ {{Log}_{10}\left( {{Predose}\mspace{14mu}{mechanical}\mspace{14mu}{sensitivity}\mspace{14mu}{in}\mspace{14mu}{nerve}\mspace{14mu}{ligated}\mspace{14mu}{side}} \right)} \end{matrix}}{\begin{matrix} {{{Log}_{10}\left( {{Predose}\mspace{14mu}{mechanical}\mspace{14mu}{sensitivity}\mspace{14mu}{in}\mspace{14mu}{sham}\mspace{14mu}{operated}\mspace{14mu}{side}} \right)} -} \\ {{Log}_{10}\left( {{Predose}\mspace{14mu}{mechanical}\mspace{14mu}{sensitivity}\mspace{14mu}{in}\mspace{14mu}{nerve}\mspace{14mu}{ligated}\mspace{14mu}{side}} \right)} \end{matrix}}$

The analgesic effects of the compounds of the present invention after single administration of 1 mg/kg at 3 hours are as shown in the following Table.

TABLE 131 Compound No. % reversal I-019 27.9 I-057 21.4 Evaluation (2)

Mechanical hyperalgesia is evaluated using an analgesy meter. Two weeks after nerve ligation, the paw pressure test is performed using an analgesy meter (stimulus pressure increased 16 g per second) to obtain paw withdrawal thresholds (PWT). Measurements are made on both sides of the hind paw and to obtain pre-dose PWT. The rats showing the threshold change from 60 to 90 g (in nerve ligated side) and 100 to 175 g (in sham operated side) are used in the experiments. On the day before the experiment, the rats have their hind paws set on the apparatus to familiarize them with the test procedure. The adopted animal is administrated with the test compounds. The test compounds are homogenized with mortar and pestle and suspended or diluted in 0.5% Methyl Cellulose to prepare 0.03-100 mg/2 mL/kg suspension and orally administered to rat using a syringe attached with a sonde. Post-dose PWT of the right and left hind paws are measured at approximately 1 to 5 hours after drug administration. Percent reversal of mechanical hyperalgesia for each rat is calculated using the following formula. The analgesic effects of the compounds are compared.

${\%\mspace{14mu}{Reversal}} = \frac{\begin{matrix} {{{Postdose}\mspace{14mu}{PWT}\mspace{14mu}{in}\mspace{14mu}{nerve}\mspace{14mu}{ligated}\mspace{14mu}{side}} -} \\ {{Predose}\mspace{14mu}{PWT}\mspace{14mu}{in}\mspace{14mu}{nerve}\mspace{14mu}{ligated}\mspace{14mu}{side}} \end{matrix}}{\begin{matrix} {{{Predose}\mspace{14mu}{PWT}\mspace{14mu}{in}\mspace{14mu}{sham}\mspace{14mu}{operated}\mspace{14mu}{side}} -} \\ {{Predose}\mspace{14mu}{PWT}\mspace{14mu}{in}\mspace{14mu}{nerve}\mspace{14mu}{ligated}\mspace{14mu}{side}} \end{matrix}}$

TEST EXAMPLE 7 CYP3A4 Fluorescent MBI Test

The CYP3A4 fluorescent MBI test is a test of investigating enhancement of CYP3A4 inhibition of a compound by a metabolism reaction, and the test was performed using, as CYP3A4 enzyme expressed in Escherichia coli and employing, as an index, a reaction in which 7-benzyloxytrifluoromethylchmarin (BFC) is debenzylated by the CYP3A4 enzyme to produce a metabolite, 7-hydroxytrifluoromethylchmarin (HFC) emitting fluorescent light.

The reaction conditions were as follows: substrate, 5.6 μmol/L 7-BFC; pre-reaction time, 0 or 30 minutes; reaction time, 15 minutes; reaction temperature, 25° C. (room temperature); CYP3A4 content (expressed in Escherichia coli), at pre-reaction 62.5 pmol/mL, at reaction 6.25 pmol/mL (at 10-fold dilution); test drug concentration, 1.56, 3.125, 6.25, 12.5, 25, 50 μmol/L (six points).

An enzyme in a K-Pi buffer (pH 7.4) and a test drug solution as a pre-reaction solution were added to a 96-well plate at the composition of the pre-reaction, a part of it was transferred to another 96-well plate so that it was 1/10 diluted by a substrate in a K-Pi buffer, NADPH as a co-factor was added to initiate a reaction as an index (without preincubation) and, after a predetermined time of a reaction, acetonitrile: 0.5 mol/L Tris (trishydroxyaminomethane)=4:1 was added to stop the reaction. In addition, NADPH was added to a remaining preincubation solution to initiate a preincubation (with preincubation) and, after a predetermined time of a preincubation, a part was transferred to another plate so that it was 1/10 diluted with a substrate and a K-Pi buffer to initiate a reaction as an index. After a predetermined time of a reaction, acetonitrile: 0.5 mol/L Tris (trishydroxyaminomethane)=4:1 was added to stop the reaction. For the plate on which each index reaction had been performed, a fluorescent value of 7-HFC which is a metabolite was measured with a fluorescent plate reader. (Ex=420 nm, Em=535 nm).

Addition of only DMSO which is a solvent dissolving a drug to a reaction system was adopted as a control (100%), remaining activity (%) was calculated at each concentration of a test drug added as the solution, and IC₅₀ was calculated by reverse-presumption by a logistic model using a concentration and an inhibition rate. When a difference between IC₅₀ values is 5 μM or more, this was defined as (+) and, when the difference is 3 μM or less, this was defined as (−).

The results of the compounds of the present invention are as shown in the following Table.

TABLE 132 Compound No. MBI I-041 (—) I-057 (—) I-063 (—) I-069 (—) I-106 (—) R-010 (—) R-014 (—) R-027 (—) R-058 (—)

Test Example 8 GYP Inhibition Test

Using commercially available pooled human hepatic microsome, and employing, as markers, 7-ethoxyresorufin-O-deethylation (CYP1A2), tolbutamide methyl-hydroxylation (CYP2C9), mephenytoin 4′-hydroxylation (CYP2C19), dextromethorphan O-demethylation (CYP2D6), and terfenedine hydroxylation as typical substrate metabolism reactions of human main five CYP enzyme forms (CYP1A2, 2C9, 2C19, 2D6, 3A4), an inhibitory degree of each metabolite production amount by a test compound was assessed.

The reaction conditions were as follows: substrate, 0.5 μmol/L ethoxyresorufin (CYP1A2), 100 μmol/L tolbutamide (CYP2C9), 50 μmol/L S-mephenitoin (CYP2C19), 5 μmol/L dextromethorphan (CYP2D6), 1 μmol/L terfenedine (CYP3A4); reaction time, 15 minutes; reaction temperature, 37° C. enzyme, pooled human hepatic microsome 0.2 mg protein/mL; test, drug concentration, 1.0, 5.0, 10, 20 μmol/L (four points).

Each five kinds of substrates, human hepatic microsome, or a test drug in 50 mmol/L Hepes buffer as a reaction solution was added to a 98-well plate at the composition as described above, NADPH, as a cofactor was added to initiate metabolism reactions as markers and, after the incubation at 37° C. for 15 minutes, a methanol/acetonitrile=1/1 (v/v) solution was added to stop the reaction. After the centrifugation at 3000 rpm for 15 minutes, resorufin (CYP1A2 metabolite) in the supernatant was quantified by a fluorescent multilabel counter and tributamide hydroxide (CYP2CP metabolite), mephenytoin 4′hydroxide (CYP2C19 metabolite), dextromethorphan (CYP2D6 metabolite), and terfenadine alcohol (CYP3A4 metabolite) were quantified by LC/MS/MS.

Addition of only DMSO being a solvent dissolving a drug to a reaction system was adopted as a control (100%), remaining activity (%) was calculated at each concentration of a test drug added as the solution and IC₅₀ was calculated by reverse presumption by a logistic model using a concentration and an inhibition rate.

The data of the compounds of the present invention are as shown in the following Table.

TABLE 133 Compound CYP1A2 CYP2C9 CYP2C19 CYP2D6 CYP3A4 No. (μmol/L) (μmol/L) (μmol/L) (μmol/L) (μmol/L) I-041 >20 >20 >20 >20 >20 I-057 >20 >20 >20 >20 >20 I-063 >20 >20 >20 >20 >20 I-069 >20 >20 >20 >20 >20 I-106 >20 >20 >20 >20 >20 R-010 >20 >20 >20 >20 >20 R-014 >20 >20 >20 >20 >20 R-027 >20 >20 >20 >20 >20 R-058 >20 >20 >20 >20 >20

Test Example 9 Fluctuation Ames Test

Mutagenicity of compounds of the present invention was evaluated.

20 μL of freezing-stored rat typhoid bacillus (Salmonella typhimurium TA98 strain, TA100 strain) was inoculated on 10 mL of a liquid nutrient medium (2.5% Oxoid nutrient broth No. 2), and this was cultured before shaking at 3° C. for 10 hours. 7.70 mL of a bacterial solution of the TA98 strain was centrifuged (2000×g, 10 minutes) to remove a culturing solution. The bacteria was suspended in 7.70 mL of a Micro F buffer (K₂HPO₄: 3.5 g/L, KH₂PO₄: 1 g/L, (NH₄)₂SO₄: 1 g/L, trisodium citrate dehydrate: 0.25 g/L, MgSO₄.7H₂O: 0.1 g/L), the suspension was added to 110 mL of an Exposure medium (Micro F buffer containing Biotin: 8 μg/mL, histidine: 0.2 μg/mL, glucose: 8 mg/mL). The TA100 strain was added to 120 mL of the Exposure medium relative to 3.42 mL of the bacterial solution to prepare a test bacterial solution. Each 12 μL of DMSO solution of a compound of the present invention (several stage dilution from maximum dose 50 mg/mL at 2 to 3 fold ratio), DMSO as a negative control, and 50 μg/mL of 4-nitroquinoline-1-oxide DMSO solution for the TA98 strain, 0.25 μg/mL of 2-(2-furyl)-3-(5-nitro-2-furyl)acrylamide DMSO solution for the TA100 strain under the non-metabolism activating condition, 40 μg/mL of 2-aminoanthracene DMSO solution for the TA98 strain, 20 μg/mL of 2-amino anthracene DMSO solution for the TA100 strain under the metabolism activating condition as a positive control, and 588 μL of the test bacterial solution (a mixed solution of 498 μl of the test bacterial solution and 90 μL of S9 mix under the metabolism activating condition) were mixed, and this was shaking-cultured at 37° C. for 90 minutes. 460 μL of the bacterial solution exposed to a compound of the present invention was mixed with 2300 μL of an Indicator medium (Micro F buffer containing biotin: 8 μg/mL, histidine: 0.2 μg/mL, glucose: 8 mg/mL, Bromo Cresol Purple: 37.5 μg/mL), each 50 μL was dispensed, into microplate 48 wells/dose, and this was subjected to stationary culturing at 37° C. for 3 days. Since a well containing a bacterium which has obtained the proliferation ability by mutation of an amino acid (histidine) synthesizing enzyme gene turns from purple to yellow due to a pH change, the bacterium proliferation well which has turned to yellow in 48 wells per dose is counted, and was assessed by comparing with a negative control group. (−) means that mutagenicity is negative and (+) is positive.

The data of the compounds of the present invention are as shown in the following Table.

TABLE 134 Compound No. FAT I-002 (−) I-019 (−) I-040 (−) I-057 (−) I-070 (−)

Test Example 10 Solubility Test

The solubility of a compound was determined under a condition in which 1% DMSO was added. 10 mmol/L compound solution was prepared using DMSO, and then 2 μL of the compound solution was added to 198 μL of artificial intestinal juice in pH 6.8 (to 250 mL of 0.2 mol/L potassium dihydrogen phosphate reagent solution was added 118 mL of 0.2 mol/L NaOH reagent solution and water to provide a final volume of 1000 mL). After standing at 25 degrees Celsius for 18 hours, the mixed solution was filtrated with suction. The filtrate was diluted twice with methanol/water (1/1), and then a concentration in the filtration was measured with HPLC or LC/MS/MS by the absolute calibration method.

The results of the compounds of the present invention are as shown in the following Table.

TABLE 135 Compound No. Solubulity (μmol/L) I-002 >50 I-019 >50 I-038 >50 I-039 >50 I-040 >50 I-041 >50 I-057 >50 I-063 >50

Test Example 11 Metabolism Stability Test

Using commercially available pooled human hepatic microsomes, a test compound is reacted for a constant time, a remaining rate is calculated by comparing a reacted sample and an unreacted sample, thereby, a degree of metabolism in liver is assessed.

A reaction was performed (oxidative reaction) at 37° C. for 0 minute or 30 minutes in the presence of 1 mmol/L NADPH in 0.2 mL of a buffer (50 mmol/L tris-HCl pH 7.4, 150 mmol/L potassium chloride, 10 mmol/L magnesium chloride) containing 0.5 mg protein/mL of human liver microsomes. After the reaction, 50 μL of the reaction solution was added to 100 μL of a methanol/acetonitrile=1/1 (v/v) mixed and centrifuged at 3000 rpm for 15 minutes. The test compound in the supernatant was quantified by LC/MS/MS, and a remaining amount of the test compound after the reaction was calculated, letting a compound amount at 0 minute reaction time to be 100%.

The data of the compounds of the present invention are as shown in the following Table. The remaining rate at the compound concentration 0.5 μmol/L are shown below.

TABLE 136 Compound No. Metabolism Stability (%) I-002 99 I-019 96 I-029 100 I-057 91 I-063 97 I-070 103

Test Example 12 Metabolism Stability Test

The test compound is reacted for a given period of time using cryopreserved rat hepatocytes that are prepared and the residual ratio is calculated based on the comparison between reacted and unreacted samples to evaluate the degree of hepatic metabolism.

The compound is reacted in the Williams E medium containing 1.0×10⁶ cells/mL of cryopreserved rat hepatocytes at a temperature of 3° C. for 0, 1 or 2 hours. After reaction, 50 μL of reaction solution is added to and mixed with 100 μL of a solution containing methanol and acetonitrile in the proportion of one to one (v/v) and the mixture is centrifuged at 3000 rpm for 15 minutes. The test compound contained in the centrifugal supernatant is quantitated using a LC/MS/MS system and the residual ratio of the test compound after reaction is calculated regarding the amount of compound after the reaction for 0 minute as 100%.

Test Example 13 hERG Test

For the purpose of assessing risk of an electrocardiogram QT interval prolongation of the compound of the present invention, effects of the compound of the present invention on delayed rectifier K+ current (I_(Kr)), which plays an important role in the ventricular repolarization process, was studied using CHO cells expressing human ether-a-go-go related gene (hERG) channel.

After a cell was retained at a membrane potential of −80 mV by whole cell patch clamp method using an automated patch clamp system (QPatch: Sophion Bioscience A/S) and gave a leak potential of −50 mV, I_(Kr) induced by depolarization pulse stimulation at +20 mV for 2 seconds and, further, repolarization pulse stimulation at −50 mV for 2 seconds, was recorded. After the generated current was stabilized, extracellular solution (NaCl: 145 mmol/L, KCl: 4 mmol/L, CaCl₂: 2 mmol/L, MgCl₂: 1 mmol/L, glucose: 10 mmol/L, HEPES (4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid): 10 mmol/L, pH=7.4), in which the compound of the present invention had been dissolved at an objective concentration, was applied to the cell at room temperature for 10 minutes. From the recording I_(Kr), an absolute value of the tail peak current was measured based on the current value at the resting membrane potential using analysis software (Falster Patch; Sophion Bioscience A/S). Further, the % inhibition relative to the tail peak current before application of the compound of the present invention was calculated, and compared with the vehicle-applied group (0.1% dimethyl sulfoxide solution) to assess influence of the compound of the present invention on I_(Kr).

The data of the compounds of the present invention are as shown in the following Table.

TABLE 137 Compound No. hERG Inhibition (%) I-002 7.3 I-006 5.3

Test Example 14 Protein Binding Test

The unbound fraction of the present compound in serum was measured using serum of various species.

The reactive conditions are as follows: Evaluation method, Equilibrium dialysis; Reaction time, 24 hours; Reaction temperature, 37° C.; Concentration of the present compound, 2 μg/mL

The test solution was added to each serum and the mixture was agitated to prepare the serum samples at the concentration mentioned above. Each serum sample was added into one side of the cell and phosphate buffered saline (PBS) was added into the other side to perform equilibrium dialysis at 37° C. for 24 hours. Then, the concentration of the compounds in the samples that were obtained from both sides was measured by LC/MS/MS.

The data of the compounds of the present invention are as shown in the following Table. The ratio of PBS concentration to serum concentration is expressed as unbound fraction (fu),

TABLE 138 Compound No. fu (%) I-019 1 I-029 1.7 I-040 3.5 I-056 1.8 I-057 1.7 R-019  1.8

Test Example 15 Pharmacokinetic test Materials and Methods

-   (1) Animals: SD rats were used -   (2) Breeding conditions: SD rats were allowed to freely take solid     food and sterilized tap water. -   (3) Dose and grouping: orally or intravenously administered at a     predetermined dose; grouping was as follows (Dose depends on the     compound)

Oral administration: 1 mg/kg (n=2)

Intravenous administration: 0.5 mg/kg (n=2)

-   (4) Preparation of dosing solution: for oral administration, in a     solution or a suspension state; for intravenous administration, in a     solubilized state -   (5) Administration method: in oral administration, forcedly     administer into ventriculus with oral probe; in intravenous     administration, administer from caudal vein with a needle-equipped     syringe -   (6) Evaluation items: blood was collected over time, and the plasma     concentration of drug was measured by LC/MS/MS -   (7) Statistical analysis: regarding the transition of the plasma     concentration of the present compound, the area under the plasma     concentration-time curve (AUC) was calculated by non-linear least     squares program WinNonlin (Registered trade name), and the     bioavailability (BA) was calculated from the AUCs of the oral     administration group and intravenous administration group. The total     body clearance (CLtot) was calculated by dividing the dose by the     AUC of the intravenous administration group.

The data of the compounds of the present invention are as shown in the following Table.

TABLE 139 AUC (po) AUC (iv) BA CLtot Compound No. (ng · hr/mL) (ng · hr/mL) (%) (mL/min/kg) I-014 4890 2300 106.2 4 I-017 6110 3790 80.7 2.3 I-040 410 291 70.3 28.6 I-057 487 367 66.4 22.9 I-058 2030 1510 67.2 5.8 I-127 2460 2330 52.8 3.8

Test Example 16 Powder Solubility Test

Appropriate quantity of the compound of the present invention is put in a suitable container and 200 μL of JP-1 solution (water was added to 2.0 g of sodium chloride and 7.0 mL of hydrochloric acid to reach 1000 mL), JP-2 solution (500 mL of water is added to 500 mL of phosphate buffer with a pH of 6.8) or 20 mmol/L sodium taurocholate (TCA)/JP-2 solution (JP-2 solution was added to 1.08 g of TCA to reach 100 mL) is independently added to each container. When total amount is dissolved after adding the test reagent, the compound of the present invention is added appropriately. After sealing and shaking at 37° C. for 1 hour, solution is filtrated and 100 μL of methanol was added to 100 μL of each filtrate to dilute two-fold. The dilution rate is changed as necessary. After checking that there is no bubble and deposit, the container is sealed and shaken. The compound of the present invention is measured using HPLC by absolute calibration curve method.

Preparation Example

The following Formulation Examples are only exemplified and not intended to limit the scope of the invention.

Formulation Example 1 Tablet

Compound of the present invention 15 mg Lactose 15 mg Calcium Stearate  3 mg

The above ingredients other than Calcium Stearate are uniformly mixed, crushed, granule, dried to prepare granules of suitable size. After addition of Calcium Stearate, the mixture is compressed to prepare tables.

Formulation Example 2 Capsules

Compound of the present invention 10 mg Magnecium Stearate 10 mg Lactose 80 mg

The above ingredients are uniformly mixed to prepare powdered medicine as powder or fine particles, which are put into capsule containers to prepare capsules.

Formulation Example 3 Granules

Compound of the present invention  30 g Lactose 265 g Magnecium Stearate  5 g

The above ingredients are fully mixed, compressed, crushed, selected the size to prepare granules of suitable size.

Formulation Example 4 Orally Dispersing Tablets

The compounds of the present invention and crystalline cellulose are mixed, granulated and tablets are made to give orally dispersing tablets.

Formulation Example 5 Dry Syrups

The compounds of the present invention and lactose are mixed, crushed, granulated and sieved to give suitable sizes of dry syrups.

Formulation Example 8 Injections

The compounds of the present invention and phosphate buffer are mixed to give injection.

Formulation Example 7 Infusions

The compounds of the present invention and phosphate buffer are mixed to give injection.

Formulation Example 8 Inhalations

The compound of the present invention and lactose are mixed and crushed finely to give inhalations.

Formulation Example 9 Ointments

The compounds of the present invention and petrolatum are mixed to give ointments.

Formulation Example 10 Patches

The compounds of the present invention and base such as adhesive plaster or the like are mixed to give patches.

INDUSTRIAL APPLICABILITY

The compounds represented by Formula (I) have an antagonistic activity on P2X₃ and/or P2X_(2/3) receptor and are useful in the treatment of diseases or conditions associated with a P2X₃ and/or P2X_(2/3) receptor, such as chronic pain, urination disorder, respiratory disease, and the like. 

The invention claimed is:
 1. A compound of formula:

or its pharmaceutically acceptable salt.
 2. A pharmaceutical composition comprising the compound according to claim 1, or its pharmaceutically acceptable salt, and further comprising a pharmaceutical additive.
 3. The pharmaceutical composition according to claim 2, wherein the composition has a P2X₃ and/or P2X_(2/3) receptor antagonistic activity.
 4. The compound according to claim 1, chosen from a compound of the following formula:

or its pharmaceutically acceptable salt.
 5. The compound according to claim 1, chosen from a compound of the following formula:

or its pharmaceutically acceptable salt.
 6. The compound according to claim 1, chosen from a compound of the following formula:

or its pharmaceutically acceptable salt.
 7. A pharmaceutical composition comprising the compound according to any one of claims 4, 5 and 6, or its pharmaceutically acceptable salt, and further comprising a pharmaceutical additive.
 8. The pharmaceutical composition according to claim 7, wherein the composition has a P2X₃ and/or P2X_(2/3) receptor antagonistic activity. 